<nodes>
	<node>
		<Fname>
404: File Not Found ./id/custom403.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/custom403.html</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
404: File Not Found ./id/custom404.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/custom404.html</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
404: File Not Found ./id/custom404.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/custom404.html~</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/i2.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/i2.html</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;




						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;


			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/i2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/i2.html~</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;




						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;


			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
i3.html ./id/i3.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/i3.html</Path>
		<FileBody>



			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home1.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home2.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home3.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home4.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home5.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home6.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home7.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;




			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 3000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;div class=&quot;news mod&quot;&gt;
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;



			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Our Mission&lt;/h4&gt;
			&lt;p style=&quot;margin&#45;top:10px;padding&#45;right:60px;font&#45;weight:bold;&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;
			&lt;/div&gt;


			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;
			&lt;h4&gt;Calendar&lt;/h4&gt;

			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
i3.html~ ./id/i3.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/i3.html~</Path>
		<FileBody>



			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home1.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home2.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home3.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home4.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home5.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home6.jpg&quot; &gt;
			     &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home7.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;




			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 3000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;div class=&quot;news mod&quot;&gt;
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;



			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Our Mission&lt;/h4&gt;
			&lt;p style=&quot;margin&#45;top:10px;padding&#45;right:60px;font&#45;weight:bold;&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;
			&lt;/div&gt;


			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;
			&lt;h4&gt;Calendar&lt;/h4&gt;

			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/index.html</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;




						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;


			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/index.html~</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;




						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;


			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/new.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/new.html</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;






						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
					&lt;!&#45;&#45;&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;


					&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;


			&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;






			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Division of Infectious Diseases ./id/new.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/new.html~</Path>
		<FileBody>




			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;


			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;






						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
					&lt;!&#45;&#45;&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;


					&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;


			&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;






			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;

										&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
skp.html~ ./id/skp.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/skp.html~</Path>
		<FileBody>
			&lt;html lang=&quot;en&quot;&gt;
			&lt;head&gt;
			  &lt;meta charset=&quot;utf&#45;8&quot;&gt;
			  &lt;meta http&#45;equiv=&quot;X&#45;UA&#45;Compatible&quot; content=&quot;IE=edge&quot;&gt;
			  &lt;meta name=&quot;viewport&quot; content=&quot;width=device&#45;width, initial&#45;scale=1&quot;&gt;
			  &lt;meta name=&quot;description&quot; content=&quot;&quot;&gt;
			  &lt;meta name=&quot;author&quot; content=&quot;&quot;&gt;  &lt;link rel=&quot;icon&quot; href=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/favicon.ico&quot;&gt;
			  &lt;title&gt;UCSF Division of Infectious Diseases | UCSF Division of Infectious Diseases&lt;/title&gt;

			  &lt;!&#45;&#45; Core CSS &#45;&#45;&gt;
			  &lt;link href=&quot;/css/banners&#45;min.css&quot; rel=&quot;stylesheet&quot;&gt;
			  &lt;link href=&quot;/css/general&#45;theme.css&quot; rel=&quot;stylesheet&quot;&gt;
			  &lt;link href=&quot;/css/id&#45;theme.css&quot; rel=&quot;stylesheet&quot;&gt;

			  &lt;!&#45;&#45; IE10 viewport hack for Surface/desktop Windows 8 bug &#45;&#45;&gt;
			  &lt;!&#45;&#45;&lt;script src=&quot;javascripts/ie10&#45;viewport&#45;bug&#45;workaround.js&quot;&gt;&lt;/script&gt;&#45;&#45;&gt;

			  &lt;!&#45;&#45; HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries &#45;&#45;&gt;
			  &lt;!&#45;&#45;[if lt IE 9]&gt;
			    &lt;script src=&quot;https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js&quot;&gt;&lt;/script&gt;
			    &lt;script src=&quot;https://oss.maxcdn.com/respond/1.4.2/respond.min.js&quot;&gt;&lt;/script&gt;
			  &lt;![endif]&#45;&#45;&gt;

			  &lt;!&#45;&#45;Webfont&#45;&#45;&gt;
			  &lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://fast.fonts.net/cssapi/77d0232a&#45;e7ef&#45;400b&#45;821f&#45;1a659cfa472a.css&quot;/&gt;

			&lt;/head&gt;

			&lt;body&gt;

			&lt;!&#45;&#45; NAVBAR
			================================================== &#45;&#45;&gt;

			&lt;!&#45;&#45;UCSF Banner&#45;&#45;&gt;
			&lt;div class=&quot;top&#45;banner logo blue&quot; role=&quot;navigation&quot;&gt;
			  &lt;div class=&quot;inner&quot;&gt;
			    &lt;div&gt;
			      &lt;a class=&quot;logotype&quot; href=&quot;http://www.ucsf.edu/&quot;&gt;
			        &lt;span&gt;University of California San Francisco&lt;/span&gt;
			      &lt;/a&gt;
			    &lt;/div&gt;
			    &lt;div class=&quot;nav&quot;&gt;
			      &lt;ul class=&quot;top&#45;banner&#45;menu&quot;&gt;
			        &lt;li&gt;&lt;a href=&quot;http://www.ucsf.edu/about&quot;&gt;About UCSF&lt;/a&gt;&lt;/li&gt;
			        &lt;li&gt;&lt;a href=&quot;http://www.ucsf.edu/search&quot;&gt;Search UCSF&lt;/a&gt;&lt;/li&gt;
			        &lt;li&gt;&lt;a href=&quot;http://www.ucsfhealth.org/&quot;&gt;UCSF Medical Center&lt;/a&gt;&lt;/li&gt;
			      &lt;/ul&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;
			&lt;!&#45;&#45;End UCSF Banner&#45;&#45;&gt;

			&lt;!&#45;&#45;Geriatrics Topnav&#45;&#45;&gt;
			&lt;div class=&quot;navbar&#45;wrapper&quot; role=&quot;navigation&quot;&gt;

			  &lt;!&#45;&#45;Large screen only, 992px and larger&#45;&#45;&gt;
			  &lt;div class=&quot;branding container&#45;fluid&quot;&gt;
			    &lt;div class=&quot;media&quot;&gt;
			      &lt;div class=&quot;media&#45;left&quot;&gt;
			        &lt;div class=&quot;svg&#45;container&quot;&gt;
			   &lt;a href=&quot;/&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/idlogo.jpg&quot; alt=&quot;UCSF Division of Infectious Diseases&quot; border=&quot;0&quot; usemap=&quot;#Map&quot; class=&quot;brand&#45;logo&quot; style=&quot;width:250px;&quot;&gt;&lt;/a&gt;
			          &lt;map name=&quot;Map&quot;&gt;
			            &lt;area shape=&quot;rect&quot; coords=&quot;99,53,251,71&quot; href=&quot;http://medicine.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;
			          &lt;/map&gt;


			        &lt;/div&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;media&#45;body&quot;&gt;
			        &lt;div class=&quot;h5 text&#45;right&quot;&gt;
			          &lt;em&gt;Transforming medicine through innovation and collaboration.&lt;/em&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;  &lt;!&#45;&#45;Small screen navigation only, hidden on larger screens&#45;&#45;&gt;
			  &lt;div class=&quot;navbar navbar&#45;inverse&quot;  role=&quot;navigation&quot;&gt;
			    &lt;div class=&quot;navbar&#45;header&quot;&gt;
			      &lt;button type=&quot;button&quot; class=&quot;navbar&#45;toggle&quot; data&#45;toggle=&quot;collapse&quot; data&#45;target=&quot;.navbar&#45;collapse&quot;&gt;
			        &lt;span class=&quot;sr&#45;only&quot;&gt;Toggle navigation&lt;/span&gt;
			        &lt;span class=&quot;icon&#45;bar center&#45;block&quot;&gt;&lt;/span&gt;
			        &lt;span class=&quot;icon&#45;bar center&#45;block&quot;&gt;&lt;/span&gt;
			        &lt;span class=&quot;icon&#45;bar center&#45;block&quot;&gt;&lt;/span&gt;
			      &lt;/button&gt;
			      &lt;div class=&quot;navbar&#45;logo&quot;&gt;
			         &lt;a href=&quot;/&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/logo&#45;mobile.png&quot; alt=&quot;UCSF Division of Infectious Diseases&quot;&gt;&lt;/a&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;

			    &lt;div class=&quot;navbar&#45;collapse collapse&quot;&gt;
			      &lt;ul class=&quot;nav navbar&#45;nav&quot;&gt;
			        &lt;li&gt;&lt;a href=&quot;/&quot; class=&quot;glyphicon glyphicon&#45;home&quot;&gt;&lt;/a&gt;&lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/about/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;About &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/about/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/about/history.html&quot;&gt;History&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/about/administration.html&quot;&gt;Administration&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/about/news.html&quot;&gt;News&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/faculty/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Faculty &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/faculty/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Fellowship &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/fellowship/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/fellowship/clinicalexp.html&quot;&gt;Clinical Experiences&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/fellowship/programtracks.html&quot;&gt;Program Tracks&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/fellowship/application.html&quot;&gt;How to Apply&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/fellowship/current.html&quot;&gt;Current Fellows&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/education&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Education &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/education/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/education/medical.html&quot;&gt;Medical Students&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/education/residents.html&quot;&gt;Residents&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/education/cme.html&quot;&gt;Continuing Medical Education&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/education/visiting_faculty.html&quot;&gt;Visiting Faculty&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/protected/materials.html&quot;&gt;Educational Resources&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/care/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Patient Care &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/care/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;            &lt;li&gt;&lt;a href=&quot;/care/patients.html&quot;&gt;For Patients&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/research/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Research &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/research/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;
			        &lt;li class=&quot;dropdown&quot;&gt;
			          &lt;a href=&quot;/giving/&quot; class=&quot;dropdown&#45;toggle text&#45;uppercase&quot; data&#45;toggle=&quot;dropdown&quot;&gt;Giving &lt;span class=&quot;caret&quot;&gt;&lt;/span&gt;&lt;/a&gt;
			          &lt;ul class=&quot;dropdown&#45;menu&quot; role=&quot;menu&quot;&gt;            &lt;li&gt;&lt;a href=&quot;/giving/&quot;&gt;Overview&lt;/a&gt;&lt;/li&gt;          &lt;/ul&gt;
			        &lt;/li&gt;

			      &lt;/ul&gt;
			      &lt;form class=&quot;navbar&#45;form navbar&#45;right&quot; action=&quot;/news/search.html&quot;&gt;
			        &lt;input type=&quot;text&quot; class=&quot;form&#45;control&quot; name=q placeholder=&quot;Search site&quot;&gt;
			      &lt;/form&gt;

			    &lt;/div&gt;&lt;!&#45;&#45;end navbar&#45;collapse&#45;&#45;&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end navbar&#45;inverse&#45;&#45;&gt;

			&lt;/div&gt;&lt;!&#45;&#45;end navbar&#45;wrapper&#45;&#45;&gt;


			&lt;!&#45;&#45; Sliding Image Carousel
			================================================== &#45;&#45;&gt;
			&lt;div id=&quot;myCarousel&quot; class=&quot;carousel slide h&#45;spacing&#45;&#45;clear&#45;bottom&quot; data&#45;ride=&quot;carousel&quot;&gt;
			  &lt;!&#45;&#45; Indicators &#45;&#45;&gt;
			  &lt;ol class=&quot;carousel&#45;indicators&quot;&gt;
			    &lt;li data&#45;target=&quot;#myCarousel&quot; data&#45;slide&#45;to=&quot;0&quot; class='active'&gt;&lt;/li&gt;    &lt;li data&#45;target=&quot;#myCarousel&quot; data&#45;slide&#45;to=&quot;0&quot; &gt;&lt;/li&gt;    &lt;li data&#45;target=&quot;#myCarousel&quot; data&#45;slide&#45;to=&quot;0&quot; &gt;&lt;/li&gt;    &lt;li data&#45;target=&quot;#myCarousel&quot; data&#45;slide&#45;to=&quot;0&quot; &gt;&lt;/li&gt;    &lt;li data&#45;target=&quot;#myCarousel&quot; data&#45;slide&#45;to=&quot;0&quot; &gt;&lt;/li&gt;  &lt;/ol&gt;

			  &lt;div class=&quot;carousel&#45;inner&quot;&gt;
			    &lt;div class=&quot;item active&quot;&gt;
			      &lt;a href=&quot;&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home1.jpg&quot; alt=&quot;First slide&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			      &lt;div class=&quot;container&quot;&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;
			    &lt;div class=&quot;item &quot;&gt;
			      &lt;a href=&quot;&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home2.jpg&quot; alt=&quot;First slide&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			      &lt;div class=&quot;container&quot;&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;
			    &lt;div class=&quot;item &quot;&gt;
			      &lt;a href=&quot;&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home3.jpg&quot; alt=&quot;First slide&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			      &lt;div class=&quot;container&quot;&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;
			    &lt;div class=&quot;item &quot;&gt;
			      &lt;a href=&quot;&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/homepage/home5.jpg&quot; alt=&quot;First slide&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			      &lt;div class=&quot;container&quot;&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end carousel&#45;inner&#45;&#45;&gt;

			  &lt;a class=&quot;left carousel&#45;control&quot; href=&quot;#myCarousel&quot; data&#45;slide=&quot;prev&quot;&gt;&lt;span class=&quot;glyphicon glyphicon&#45;chevron&#45;left&quot;&gt;&lt;/span&gt;&lt;/a&gt;

			  &lt;a class=&quot;right carousel&#45;control&quot; href=&quot;#myCarousel&quot; data&#45;slide=&quot;next&quot;&gt;&lt;span class=&quot;glyphicon glyphicon&#45;chevron&#45;right&quot;&gt;&lt;/span&gt;&lt;/a&gt;

			&lt;/div&gt;&lt;!&#45;&#45; /.carousel &#45;&#45;&gt;





			&lt;!&#45;&#45; News &amp; Highlights
			================================================== &#45;&#45;&gt;

			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;

			       &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h3 class=&quot;media&#45;heading&quot;&gt;&lt;a href=&quot;/about/news.html?id=1947&quot;&gt;&lt;b&gt;Rare Case of Rat Lungworm Disease Diagnosed by Infectious Diseases Doctor Brian Schwartz&lt;b/&gt;&lt;/a&gt;&lt;/h3&gt;
			          &lt;div&gt;&lt;p&gt;&lt;a href=&quot;https://www.statnews.com/2017/05/02/rat&#45;lungworm&#45;disease&#45;parasites/&quot; target=&quot;_blank&quot;&gt;Read more about how Dr. Schwartz identified this mysterious illness...&lt;/div&gt;
			          &lt;p&gt;&lt;a class=&quot;btn btn&#45;default btn&#45;sm&quot; href=&quot;/about/news.html?id=1947&quot;&gt;Read more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;right&quot; &gt;
			        &lt;a href=&quot;/about/news.html?id=1947&quot;&gt;&lt;img src=&quot;&quot; class=&quot;thumbnail&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h3 class=&quot;media&#45;heading&quot;&gt;&lt;a href=&quot;/about/news.html?id=1915&quot;&gt;&lt;b&gt;ID Division Stands up for Science!&lt;/b&gt;&lt;/a&gt;&lt;/h3&gt;
			          &lt;div&gt;On Saturday, April 22, fellows, faculty, and researchers from the Infectious Diseases Division joined tens of thousands of protesters in San...&lt;/div&gt;
			          &lt;p&gt;&lt;a class=&quot;btn btn&#45;default btn&#45;sm&quot; href=&quot;/about/news.html?id=1915&quot;&gt;Read more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;right&quot; &gt;
			        &lt;a href=&quot;/about/news.html?id=1915&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/news/march_4.jpg&quot; class=&quot;thumbnail&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h3 class=&quot;media&#45;heading&quot;&gt;&lt;a href=&quot;/about/news.html?id=1923&quot;&gt;&lt;b&gt;ID Division Chief Joanne Engel Awarded Two&#45;Year Grant from the Cystic Fibrosis Foundation.&lt;b/&gt;&lt;/a&gt;&lt;/h3&gt;
			          &lt;div&gt;The grant is entitled “How surface contact regulates virulence and biofilm formation in...&lt;/div&gt;
			          &lt;p&gt;&lt;a class=&quot;btn btn&#45;default btn&#45;sm&quot; href=&quot;/about/news.html?id=1923&quot;&gt;Read more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;right&quot; &gt;
			        &lt;a href=&quot;/about/news.html?id=1923&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/news/engel_3.jpg&quot; class=&quot;thumbnail&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;

			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;

					&lt;div class=&quot;col&#45;sm&#45;4 calendar&quot; style=&quot;margin&#45;top:20px;&quot;&gt;
						&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;  style=&quot;background:#178ccb;&quot;&gt;&lt;a href=&quot;https://twitter.com/ucsfnephrology&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Follow us on Twitter&lt;/a&gt;&lt;/h2&gt;


			&lt;a class=&quot;twitter&#45;timeline&quot; data&#45;height=&quot;400&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;Tweets by UCSF ID Division&lt;/a&gt; &lt;script async src=&quot;//platform.twitter.com/widgets.js&quot; charset=&quot;utf&#45;8&quot;&gt;&lt;/script&gt;




						&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;https://twitter.com/UCSF_ID&quot;&gt;&lt;strong&gt;See all tweets&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

					&lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;

				&lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;


			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Our Mission&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Curing and healing ailments, innovative research advances in the treatment of diseases, and educating the next generation of infectious diseases professionals is our specialty. &lt;/p&gt;

			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;

			    &lt;/div&gt;

			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;

			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Fellowship&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/fellowship/&quot;&gt;&lt;img alt=&quot;Fellowship&quot; src=&quot;images/firstyearfellows.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&gt;
			        &lt;p&gt;The University of California, San Francisco offers outstanding fellowship training in Infectious Diseases with great breadth and depth in both clinical infectious diseases and research.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/fellowship/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
						&lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;

						&lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
							&lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
							&lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;


			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;left&quot;&gt;
			          &lt;div class=&quot;panel&#45;&#45;default text&#45;center&quot;&gt;
			            &lt;div class=&quot;panel&#45;heading panel&#45;&#45;calendar&#45;hd&quot;&gt;&lt;strong&gt;Jun&lt;/strong&gt;&lt;/div&gt;
			            &lt;div class=&quot;panel&#45;body panel&#45;&#45;cal&#45;date&quot;&gt;12&lt;/div&gt;
			          &lt;/div&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h4 class=&quot;media&#45;heading&quot;&gt;ID Grand Rounds&lt;/h4&gt;
			          &lt;div&gt; &lt;br&gt;&lt;span style=&quot;font&#45;size:.8em&quot;&gt;N&#45;729 8:00 am &#45; 9:00 am&lt;/span&gt;&lt;/div&gt;
			          &lt;p&gt;
			&lt;a class=&quot;btn btn&#45;default btn&#45;xs&quot; href=&quot;http://medicine.ucsf.edu/ical.ics?event=5523&quot;&gt;Add to calendar &amp;raquo;&lt;/a&gt;
			&lt;/p&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;

			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;left&quot;&gt;
			          &lt;div class=&quot;panel&#45;&#45;default text&#45;center&quot;&gt;
			            &lt;div class=&quot;panel&#45;heading panel&#45;&#45;calendar&#45;hd&quot;&gt;&lt;strong&gt;Jun&lt;/strong&gt;&lt;/div&gt;
			            &lt;div class=&quot;panel&#45;body panel&#45;&#45;cal&#45;date&quot;&gt;19&lt;/div&gt;
			          &lt;/div&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h4 class=&quot;media&#45;heading&quot;&gt;ID Grand Rounds&lt;/h4&gt;
			          &lt;div&gt; &lt;br&gt;&lt;span style=&quot;font&#45;size:.8em&quot;&gt; 8:00 am &#45; 9:00 am&lt;/span&gt;&lt;/div&gt;
			          &lt;p&gt;
			&lt;a class=&quot;btn btn&#45;default btn&#45;xs&quot; href=&quot;http://medicine.ucsf.edu/ical.ics?event=5524&quot;&gt;Add to calendar &amp;raquo;&lt;/a&gt;
			&lt;/p&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;

			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;left&quot;&gt;
			          &lt;div class=&quot;panel&#45;&#45;default text&#45;center&quot;&gt;
			            &lt;div class=&quot;panel&#45;heading panel&#45;&#45;calendar&#45;hd&quot;&gt;&lt;strong&gt;Jun&lt;/strong&gt;&lt;/div&gt;
			            &lt;div class=&quot;panel&#45;body panel&#45;&#45;cal&#45;date&quot;&gt;21&lt;/div&gt;
			          &lt;/div&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h4 class=&quot;media&#45;heading&quot;&gt;ID Core Curriculum Conference&lt;/h4&gt;
			          &lt;div&gt; &lt;br&gt;&lt;span style=&quot;font&#45;size:.8em&quot;&gt; 3:30 pm &#45; 5:30 pm&lt;/span&gt;&lt;/div&gt;
			          &lt;p&gt;
			&lt;a class=&quot;btn btn&#45;default btn&#45;xs&quot; href=&quot;http://medicine.ucsf.edu/ical.ics?event=5525&quot;&gt;Add to calendar &amp;raquo;&lt;/a&gt;
			&lt;/p&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;

			      &lt;div class=&quot;media h&#45;border&#45;bottom&quot;&gt;
			        &lt;div class=&quot;media&#45;left&quot;&gt;
			          &lt;div class=&quot;panel&#45;&#45;default text&#45;center&quot;&gt;
			            &lt;div class=&quot;panel&#45;heading panel&#45;&#45;calendar&#45;hd&quot;&gt;&lt;strong&gt;Dec&lt;/strong&gt;&lt;/div&gt;
			            &lt;div class=&quot;panel&#45;body panel&#45;&#45;cal&#45;date&quot;&gt;31&lt;/div&gt;
			          &lt;/div&gt;
			        &lt;/div&gt;
			        &lt;div class=&quot;media&#45;body&quot;&gt;
			          &lt;h4 class=&quot;media&#45;heading&quot;&gt;&lt;/h4&gt;
			          &lt;div&gt; &lt;br&gt;&lt;span style=&quot;font&#45;size:.8em&quot;&gt; &lt;/span&gt;&lt;/div&gt;
			          &lt;p&gt;
			&lt;a class=&quot;btn btn&#45;default btn&#45;xs&quot; href=&quot;http://medicine.ucsf.edu/ical.ics?event=5525&quot;&gt;Add to calendar &amp;raquo;&lt;/a&gt;
			&lt;/p&gt;
			        &lt;/div&gt;
			      &lt;/div&gt;
							&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;

						&lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
				&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
				&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;


			&lt;!&#45;&#45; Footer
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;footer h&#45;color&#45;&#45;bg&#45;brightblue&quot;&gt;
			  &lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; style=&quot;padding&#45;bottom:0px;&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;3&quot;&gt;        &lt;h4&gt;&lt;a href=&quot;/about/
			&quot;&gt;About&lt;/a&gt;&lt;/strong&gt;&lt;/h4&gt;
			        &lt;ul&gt;          &lt;li&gt; &lt;a href=&quot;/about/mission.html
			&quot;&gt;Mission&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/about/administration.html
			&quot;&gt;Administration&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/faculty/
			&quot;&gt;Faculty&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/giving/&quot;&gt;Giving&lt;/a&gt;&lt;/li&gt;        &lt;/ul&gt;
			        &lt;hr class=&quot;visible&#45;xs&quot;&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;col&#45;sm&#45;3&quot;&gt;        &lt;h4&gt;&lt;a href=&quot;/education/
			&quot;&gt;Education&lt;/a&gt;&lt;/strong&gt;&lt;/h4&gt;
			        &lt;ul&gt;          &lt;li&gt; &lt;a href=&quot;/education/medical.html
			&quot;&gt;Medical Students&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/education/residents.html
			&quot;&gt;Residents&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/education/fellowship.html
			&quot;&gt;Fellowship Program&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/education/cme.html
			&quot;&gt;Continuing Medical Education&lt;/a&gt;&lt;/li&gt;        &lt;/ul&gt;
			        &lt;hr class=&quot;visible&#45;xs&quot;&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;col&#45;sm&#45;3&quot;&gt;        &lt;h4&gt;&lt;a href=&quot;/care/
			&quot;&gt;Patient Care&lt;/a&gt;&lt;/strong&gt;&lt;/h4&gt;
			        &lt;ul&gt;          &lt;li&gt; &lt;a href=&quot;/care/patients.html
			&quot;&gt;For Patients&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/care/physicians.html
			&quot;&gt;For Referring Physicians&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/care/outpatient.html
			&quot;&gt;Outpatient Clinics&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/care/inpatient.html
			&quot;&gt;Inpatient Clinics&lt;/a&gt;&lt;/li&gt;        &lt;/ul&gt;
			        &lt;hr class=&quot;visible&#45;xs&quot;&gt;
			      &lt;/div&gt;
			      &lt;div class=&quot;col&#45;sm&#45;3 col&#45;md&#45;3&quot;&gt;         &lt;h4&gt;&lt;a href=&quot;/research/
			&quot;&gt;Research&lt;/a&gt;&lt;/strong&gt;&lt;/h4&gt;
			        &lt;ul&gt;          &lt;li&gt; &lt;a href=&quot;/research/global.html
			&quot;&gt;Global Health&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/research/microbial.html
			&quot;&gt;Microbial Pathology&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/research/immunology.html
			&quot;&gt;Immunology&lt;/a&gt;&lt;/li&gt;          &lt;li&gt; &lt;a href=&quot;/research/trials.html
			&quot;&gt;Clinical Trials&lt;/a&gt;&lt;/li&gt;        &lt;/ul&gt;
			        &lt;hr class=&quot;visible&#45;xs&quot;&gt;
			      &lt;/div&gt;


			    &lt;/div&gt;&lt;!&#45;&#45; end row &#45;&#45;&gt;

			    &lt;hr&gt;

			    &lt;p class=&quot;center&#45;block&quot;&gt;
			        &lt;span class=&quot;social&#45;links&quot;&gt;
			        &lt;/span&gt;

			        &lt;span class=&quot;copyright&quot;&gt;&amp;copy; &lt;script&gt;var today = new Date(); var yyyy = today.getFullYear();document.write(yyyy + &quot; &quot;);&lt;/script&gt; UCSF Division of Infectious Diseases&lt;/span&gt;

			        &lt;span class=&quot;hidden&#45;xs&quot;&gt;|&lt;/span&gt;

			        &lt;span class=&quot;contact&#45;foot&quot;&gt; &lt;a href=&quot;https://medicine.ucsf.edu&quot;&gt;Department of Medicine&lt;/a&gt; | &lt;strong&gt;Contact:&lt;/strong&gt; &lt;span class=&quot;glyphicon glyphicon&#45;envelope&quot;&gt;&lt;/span&gt; &lt;a href=&quot;mailto:webmaster@medicine.ucsf.edu&quot;&gt;webmaster@medicine.ucsf.edu&lt;/a&gt;&lt;/span&gt;
			    &lt;/p&gt;

			    &lt;p class=&quot;text&#45;center top&#45;foot&quot; style=&quot;padding&#45;bottom:0px;margin&#45;bottom:0px;&quot;&gt;&lt;a href=&quot;#&quot;&gt;&lt;span class=&quot;glyphicon glyphicon&#45;arrow&#45;up&quot;&gt;&lt;/span&gt; Back to top&lt;/a&gt;&lt;/p&gt;


			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end footer&#45;&#45;&gt;

			&lt;!&#45;&#45; Core JavaScript
			================================================== &#45;&#45;&gt;
			    &lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js&quot;&gt;&lt;/script&gt;
			    &lt;script type=&quot;text/javascript&quot; src=&quot;https://maxcdn.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js&quot;&gt;&lt;/script&gt;
			  &lt;/body&gt;
			&lt;/html&gt;
			  &lt;script&gt;
			  window._gaq = [['_setAccount','UA&#45;2823320&#45;25'],['_trackPageview'],['_trackPageLoadTime']];
			    Modernizr.load({
			      load: ('https:' == location.protocol ? '//ssl' : '//www') + '.google&#45;analytics.com/ga.js'
			    });
			  &lt;/script&gt;
			&lt;/body&gt;
			&lt;/html&gt;

		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/about/admin_contact.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/admin_contact.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Who we are paragraph.&lt;/p&gt;

			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/about/staff.html&quot;&gt;Staff List&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;Contact Info&lt;/p&gt;




					</FileBody>
	</node>
	<node>
		<Fname>
Staff ./id/about/admin_staff.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/admin_staff.html</Path>
		<FileBody>

			&lt;table&gt;
			&lt;thead&gt;&lt;tr&gt;
			&lt;td&gt;Name&lt;/td&gt;
			&lt;td&gt;Title&lt;/td&gt;
			&lt;td&gt;Email&lt;/td&gt;
			&lt;td&gt;Phone&lt;/td&gt;
			&lt;td&gt;Fax&lt;/td&gt;&lt;/tr&gt;
			&lt;/thead&gt;
			&lt;tbody&gt;&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;UCSF Parnassus&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Lan Pham&lt;/td&gt;
				&lt;td&gt;Division Administrator&lt;/td&gt;
				&lt;td&gt;Ipham@medicine.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;502&#45;1811&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9364&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Virginia Schuler&lt;/td&gt;
				&lt;td&gt;Fellowship Coordinator&lt;/td&gt;
				&lt;td&gt;vschuler@medicine.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9363&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9364&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;Laurel Heights&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Susan Lau&lt;/td&gt;
				&lt;td&gt;Research Financial Analyst&lt;/td&gt;
				&lt;td&gt;slau@medicine.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;502&#45;4507&lt;/td&gt;
				&lt;td&gt;415&#45;514&#45;0425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Andy Luong&lt;/td&gt;
				&lt;td&gt;Financial Assistant&lt;/td&gt;
				&lt;td&gt;aluong@medicine.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;514&#45;2654&lt;/td&gt;
				&lt;td&gt;415&#45;514&#45;0425&lt;/td&gt;
			&lt;/tr&gt;



			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;SFGH Infectious Diseases&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Barbara Murgado&lt;/td&gt;
				&lt;td&gt;Division Administrator&lt;/td&gt;
				&lt;td&gt;bmurgado@medsfgh.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;5438&lt;/td&gt;
				&lt;td&gt;415&#45;648&#45;8425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Peter Padilla&lt;/td&gt;
				&lt;td&gt;Financial Analyst&lt;/td&gt;
				&lt;td&gt;ppadilla@medsfgh.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;4908&lt;/td&gt;
				&lt;td&gt;415&#45;648&#45;8425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Aida Maluto&lt;/td&gt;
				&lt;td&gt;Administrative Assistant&lt;/td&gt;
				&lt;td&gt;amaluto@medsfgh.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415.206&#45;8189&lt;/td&gt;
				&lt;td&gt;415&#45;648&#45;8425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;SFVA Medical Center&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Inderji Singh&lt;/td&gt;
				&lt;td&gt;Director of Administration&lt;/td&gt;
				&lt;td&gt;ISingh@medicine.ucsf.edu&lt;/td&gt;
				&lt;td&gt;415.750&#45;6901&lt;/td&gt;
				&lt;td&gt;415.750.2182&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Victor Corchado&lt;/td&gt;
				&lt;td&gt;Program Support Assistant&lt;/td&gt;
				&lt;td&gt;victor.corchado@va.gov&lt;/td&gt;
				&lt;td&gt;415.221.4810 ex. 3684&lt;/td&gt;
				&lt;td&gt;415.750.6951&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;&lt;/table&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/about/admin_who.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/admin_who.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Who we are paragraph.&lt;/p&gt;

			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/about/staff.html&quot;&gt;Staff List&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;Contact Info&lt;/p&gt;




					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/about/administration.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/administration.html</Path>
		<FileBody>

			&lt;div style=&quot;height:280px;margin&#45;bottom:15px;&quot;&gt;&lt;strong&gt;Our administrative team consists of staff from the three sites (UCSF, Zuckerberg San Francisco General, and the Veteran Affairs Medical Center).&lt;/strong&gt;
			  &lt;div id=&quot;slideshow&quot; style=&quot;margin&#45;top:15px;&quot;&gt; &lt;img src=&quot;../images/banners/parn764.jpg&quot; alt=&quot;Parnassus&quot; width=&quot;710&quot; align=&quot;middle&quot; style=&quot;border:0px solid #CCCCCC;padding:5px;&quot; &gt;
			&lt;/div&gt;
			&lt;div id=&quot;slideshow&quot; style=&quot;margin&#45;left:250px;margin&#45;top:15px;&quot;&gt; &lt;!&#45;&#45; &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/id_admin3.jpg&quot;&quot; style=&quot;border:1px solid #CCCCCC;padding:5px;&quot; /&gt; &#45;&#45;&gt;
			&lt;/div&gt;


			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});

			&lt;/script&gt;


			&lt;/div&gt;



			&lt;table&gt;
			&lt;thead&gt;&lt;tr&gt;
			&lt;td&gt;Name&lt;/td&gt;
			&lt;td&gt;Title&lt;/td&gt;
			&lt;td&gt;Email&lt;/td&gt;
			&lt;td width=&quot;90&quot;&gt;Phone&lt;/td&gt;
			&lt;td width=&quot;90&quot;&gt;Fax&lt;/td&gt;&lt;/tr&gt;
			&lt;/thead&gt;
			&lt;tbody&gt;&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;UCSF Parnassus&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Tanjira Wilanwanchit&lt;/td&gt;
				&lt;td&gt;Division Manager&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:lpham@medicine.ucsf.edu&quot;&gt;tanjira.wilawanchit@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;502&#45;1811&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9364&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Natalie Williams&#45;Munger&lt;/td&gt;
				&lt;td&gt;Fellowship Administrator&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:natalie.williams&#45;munger@ucsf.edu&quot;&gt;natalie.williams&#45;munger@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9363&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9364&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr &gt;
				&lt;td&gt;Giang Vu&lt;/td&gt;
				&lt;td&gt;Financial Assistant&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:giang.vu2@ucsf.edu&quot;&gt;giang.vu2@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9362&lt;/td&gt;
				&lt;td&gt;415&#45;476&#45;9364&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;Laurel Heights Infectious Diseases&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			  &lt;td&gt;Serena Lee &lt;/td&gt;
			  &lt;td&gt;Senior Financial Analyst&lt;/td&gt;
			  &lt;td&gt;&lt;a href=&quot;mailto:serena.Lee2@ucsf.edu&quot;&gt;serena.lee2@ucsf.edu&lt;/a&gt;&lt;/td&gt;
			  &lt;td&gt;415&#45;502&#45;4507&lt;/td&gt;
			  &lt;td&gt;415&#45;514&#45;0425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;ZSFG Infectious Diseases&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Jennifer Fowler&lt;/td&gt;
				&lt;td&gt;Interim Division Manager&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:jennifer.fowler@medsfgh.ucsf.edu&quot;&gt;jennifer.fowler@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;8106&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;8091&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Peter Padilla&lt;/td&gt;
				&lt;td&gt;Financial Analyst&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:peter.padilla@ucsf.edu&quot;&gt;peter.padilla@mucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;4908&lt;/td&gt;
				&lt;td&gt;415&#45;648&#45;8425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Aida Maluto&lt;/td&gt;
				&lt;td&gt;Administrative Assistant&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:aida.maluto@ucsf.edu&quot;&gt;aida.maluto@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;206&#45;8189&lt;/td&gt;
				&lt;td&gt;415&#45;648&#45;8425&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;SFVA Medical Center&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
				&lt;td&gt;Inderjit Singh&lt;/td&gt;
				&lt;td&gt;Director of Administration&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:isingh@medicine.ucsf.edu&quot;&gt;isingh@medicine.ucsf.edu&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;750&#45;6901&lt;/td&gt;
				&lt;td&gt;415&#45;750&#45;2182&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr class=&quot;even&quot;&gt;
				&lt;td&gt;Victor Corchado&lt;/td&gt;
				&lt;td&gt;Program Support Assistant&lt;/td&gt;
				&lt;td&gt;&lt;a href=&quot;mailto:victor.corchado@va.gov&quot;&gt;victor.corchado@va.gov&lt;/a&gt;&lt;/td&gt;
				&lt;td&gt;415&#45;221&#45;4810 ex. 3684&lt;/td&gt;
				&lt;td&gt;415&#45;750&#45;6951&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;&lt;/table&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
calendar.html ./id/about/calendar.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/calendar.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
History ./id/about/history.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/history.html</Path>
		<FileBody>

			&lt;p&gt;UCSF consists of three primary teaching hospitals and clinical sites: UCSF (Parnassus and Mt Zion Medical Centers), San Francisco General Hospital, and The San Francisco Veterans Administration Hospital. The Parnassus ID division was created in 1986 under the direction of Dr. Richard Locksley as Division Chief. In the same year, the fellowship programs between the three sites were combined into one program. Dr. Locksley stepped down from this position in 2003 and Dr. Joanne Engel was appointed Division Chief of ID at Parnassus in 2005. The ID division at the VAMC was led by Dr. Peter Jensen until 2009, at which time Dr. Harry Lampiris was appointed acting chief. Dr. Henry (Chip) Chambers has served as ID Chief at SFGH since 1992.  He has recently stepped down. Dr. Philip Rosenthal has been appointed acting chief.&lt;/p&gt;

			&lt;table class=&quot;clear&quot; style=&quot;padding:0px;margin:0xp;&quot;&gt;
				&lt;tr&gt;
					&lt;td style=&quot;width:33%; padding:0px;margin:0xp;&quot;&gt;&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=c09aa087853993c3595742f3b273e668&amp;name=ENGEL%2CJOANNE+N&quot;&gt;Joanne Engel, MD&lt;/a&gt;&lt;/b&gt;
					&lt;/td&gt;
					&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;	 		&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=24709107&amp;name=LAMPIRIS%2CHARRY+W&quot;&gt;Harry Lampiris, MD&lt;/a&gt;&lt;/b&gt;
					&lt;/td&gt;
					&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;
						&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=4dae5bd5ca258627ab33f16344d5ed7e&amp;name=ROSENTHAL%2CPHILIP+J&quot;&gt;Philip Rosenthal, MD&lt;/a&gt;&lt;/b&gt;
			 		&lt;/td&gt;
			 	&lt;/tr&gt;
				&lt;tr&gt;
					&lt;td style=&quot;width:33%;padding:0px;margin:0xp;&quot;&gt;Chief, UCSF Medical Center
					&lt;a href=&quot;/faculty/index.html?key=c09aa087853993c3595742f3b273e668&amp;name=ENGEL%2CJOANNE+N&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/dr_engel.jpg&quot; class=&quot;image&quot; alt=&quot;Dr. Joanne Engel, MD&quot;  style=&quot;margin&#45;top: 5px;&quot;&gt;&lt;/a&gt;&lt;/td&gt;
					&lt;td style=&quot;width:33%;padding:0px;margin:0xp;&quot;&gt;Chief, SF VA Medical Center &lt;a href=&quot;/faculty/index.html?key=24709107&amp;name=LAMPIRIS%2CHARRY+W&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/dr_lampiris.jpg&quot; class=&quot;image&quot; alt=&quot;Dr. Harry Lampiris, MD&quot;  style=&quot;margin&#45;top: 5px;&quot;&gt;&lt;/a&gt;
					&lt;/td&gt;
					&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;Interim Chief, SF General Hospital
					&lt;a href=&quot;/faculty/index.html?key=4dae5bd5ca258627ab33f16344d5ed7e&amp;name=ROSENTHAL%2CPHILIP+J&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/dr_rosenthal.jpg&quot; class=&quot;image&quot; alt=&quot;Dr. Philip Rosenthal, MD&quot;  style=&quot;margin&#45;top: 5px;&quot;&gt;&lt;/a&gt;&lt;/td&gt;
				&lt;/tr&gt;
			&lt;/table&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
History ./id/about/history.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/history.html~</Path>
		<FileBody>

			&lt;p&gt;UCSF consists of three primary teaching hospitals and clinical sites: UCSF (Parnassus and Mt Zion Medical Centers), San Francisco General Hospital, and The San Francisco Veterans Administration Hospital. The Parnassus ID division was created in 1986 under the direction of Dr. Richard Locksley as Division Chief. In the same year, the fellowship programs between the three sites were combined into one program. Dr. Locksley stepped down from this position in 2003 and Dr. Joanne Engel was appointed Division Chief of ID at Parnassus in 2005. The ID division at the VAMC was led by Dr. Peter Jensen until 2009, at which time Dr. Harry Lampiris was appointed acting chief. Dr. Henry (Chip) Chambers has served as ID Chief at SFGH since 1992.&lt;/p&gt;

			&lt;table class=&quot;clear&quot; style=&quot;padding:0px;margin:0xp;&quot;&gt;&lt;tr&gt;&lt;td style=&quot;width:33%; padding:0px;margin:0xp;&quot;&gt;&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=c09aa087853993c3595742f3b273e668&amp;name=ENGEL%2CJOANNE+N&quot;&gt;Joanne Engel , MD&lt;/a&gt;&lt;/b&gt;&lt;/td&gt;	&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;	 		&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=24709107&amp;name=LAMPIRIS%2CHARRY+W&quot;&gt;Harry Lampiris, MD&lt;/a&gt;&lt;/b&gt;&lt;/td&gt;		&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;&lt;b&gt;&lt;a href=&quot;/faculty/index.html?key=646dcd7c0529d092e56718824dca3b0f&amp;name=CHAMBERS%2CHENRY+F&quot;&gt;Henry (Chip) Chambers, MD&lt;/a&gt;&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
			&lt;td style=&quot;width:33%;padding:0px;margin:0xp;&quot;&gt;Chief, UCSF Medical Center  &lt;/td&gt; 	&lt;td style=&quot;width:33%;padding:0px;margin:0xp;&quot;&gt;Chief, SF VA Medical Center &lt;a href=&quot;/faculty/index.html?key=24709107&amp;name=LAMPIRIS%2CHARRY+W&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/harry.jpg&quot; class=&quot;image&quot; alt=&quot;Chi&#45;yan Hsu&quot;  style=&quot;margin&#45;top: 5px;&quot;&gt;&lt;/a&gt;&lt;/td&gt;		&lt;td style=&quot;padding:0px;margin:0xp;&quot;&gt;Chief, SF General Hospital &lt;a href=&quot;/faculty/index.html?key=646dcd7c0529d092e56718824dca3b0f&amp;name=CHAMBERS%2CHENRY+F&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/chip.jpg&quot; class=&quot;image&quot; alt=&quot;Chi&#45;yan Hsu&quot; style=&quot;margin&#45;top: 5px;&quot;&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
About ./id/about/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/index.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Welcome to the UCSF Infectious Disease (ID) division.&lt;/p&gt;

			&lt;p&gt;We are based at three sites: the UCSF Medical Center at Parnassus, the San Francisco General Hospital (SFGH), and the San Francisco Veterans Administration Medical Center (SFVAMC). Our division includes 40 full&#45;time faculty, 17 trainees, and 65 administrative and research staff at these three different UCSF teaching hospitals. The Division is dedicated to the highest standards of clinical care and teaching, as well as, research leading to new approaches to the prevention, diagnosis, and treatment of infectious disease. Our mission is to maintain the high standard of excellence associated with UCSF by delivering outstanding patient care, developing cutting edge research, and training future leaders in Infectious Disease through our ACGME&#45;certified ID fellowship training program.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Mission ./id/about/mission.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/mission.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Welcome to the UCSF Infectious Disease (ID) division.&lt;/p&gt;

			&lt;p&gt;We are based at three sites: the UCSF Medical Center at Parnassus, the San Francisco General Hospital (SFGH), and the San Francisco Veterans Administration Medical Center (SFVAMC). Our division includes 40 full&#45;time faculty, 17 trainees, and 65 administrative and research staff at these three different UCSF teaching hospitals. The Division is dedicated to the highest standards of clinical care and teaching, as well as, research leading to new approaches to the prevention, diagnosis, and treatment of infectious disease. Our mission is to maintain the high standard of excellence associated with UCSF by delivering outstanding patient care, developing cutting edge research, and training future leaders in Infectious Disease through our ACGME&#45;certified ID fellowship training program.&lt;/p&gt;


			&lt;h1&gt;History&lt;/h1&gt;

			&lt;p&gt;UCSF consists of three primary teaching hospitals and clinical sites:  UCSF (Parnassus and Mt Zion Medical Centers), San Francisco General Hospital, and The San Francisco Veterans Administration Hospital. The Parnassus ID division was created in 1986 under the direction of &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=5070197&quot; target=&quot;_blank&quot;&gt;Dr. Richard Locksley&lt;/a&gt; as Division Chief. In the same year, the fellowship programs between the three sites were combined into one program. &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=5070197&quot; target=&quot;_blank&quot;&gt;Dr. Locksley&lt;/a&gt; stepped down from this position in 2003 and &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=4804510&quot; target=&quot;_blank&quot;&gt;Dr. Joanne Engel&lt;/a&gt; was appointed Division Chief of ID at Parnassus in 2005. The ID division at the VAMC was led by Dr. Peter Jensen until 2009, at which time &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=5040217&quot; target=&quot;_blank&quot;&gt;Dr. Harry Lampiris&lt;/a&gt; was appointed acting chief. Dr. Henry (Chip) Chambers has served as ID Chief at SFGH since 1992.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Recent News ./id/about/n2.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/n2.html</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
Recent News ./id/about/n2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/n2.html~</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
Recent News ./id/about/news.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/news.html</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
Recent News ./id/about/news.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/news.html~</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
Staff ./id/about/staff.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/about/staff.html~</Path>
		<FileBody>

			&lt;table&gt;
			&lt;thead&gt;&lt;tr&gt;
			&lt;td&gt;Name&lt;/td&gt;
			&lt;td&gt;Title&lt;/td&gt;
			&lt;td&gt;Email&lt;/td&gt;
			&lt;td&gt;Phone&lt;/td&gt;
			&lt;td&gt;Fax&lt;/td&gt;&lt;/tr&gt;
			&lt;/thead&gt;
			&lt;tbody&gt;&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;UCSF Parnassus&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
				    &lt;tr&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;

				    &lt;/tr&gt;
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;
				    &lt;td&gt;&lt;/td&gt;

				    &lt;/tr&gt;



			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;Laurel Heights&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;


			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;SFGH Nephrology&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;


			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;5&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;SFVA Medical Center&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;

			&lt;/tbody&gt;&lt;/table&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./id/care/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/index.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;One of the primary goals of the Division of Infectious Diseases at UCSF is to provide outstanding care to patients with a wide array of infectious diseases including HIV/AIDS.&lt;/p&gt;


			Our dedicated and caring clinicians are leading experts in infectious diseases and HIV/AIDS who strive to deliver quality care in a timely, safe and compassionate manner. We offer a full complement of infectious diseases specialists at each of three&#45;world class hospitals.


					</FileBody>
	</node>
	<node>
		<Fname>
Inpatient Services ./id/care/inpatient.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/inpatient.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;
			The Infectious Diseases Division runs a busy inpatient consult service at San Francisco General Hospital. The patients cared for reflect the diverse nature of San Francisco and the emphasis of the hospital in reaching out to vulnerable persons. Represented populations include trauma patients, HIV&#45;infected individuals, substance users, and non&#45;English speakers. Infections of particular importance include tuberculosis, HIV&#45;associated infections, staphylococcal bacteremia, bone and joint infections, and complicated skin and soft tissue infections.
			&lt;/p&gt;


			&lt;blockquote&gt;&lt;a href=&quot;http://www.ucsfhealth.org/clinics/infectious_disease/index.html&quot; target=&quot;_blank&quot;&gt;UCSF Medical Center&lt;/a&gt;&lt;br /&gt;
			505 Parnassus Avenue&lt;br /&gt;
			San Francisco, CA 94143&lt;br /&gt;
			Phone: 415&#45;476&#45;1000&lt;br /&gt;
			&lt;/blockquote&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Outpatient Clinics ./id/care/outpatient.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient.html</Path>
		<FileBody>

			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/id.html&quot;&gt;ID&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/hiv.html&quot;&gt;HIV&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/hpv.html&quot;&gt;HPV&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/neuro.html&quot;&gt;Neuro&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/transplant.html&quot;&gt;Transplant&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;









					</FileBody>
	</node>
	<node>
		<Fname>
For Patients ./id/care/patients.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/patients.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;The UCSF Division of Infectious Diseases offers an array of services for the evaluation and management of infectious diseases, HIV/AIDS, dysplasia, and travel medicine.  Many of our specialists are nationally and internationally recognized for providing the highest level of expertise in caring for many different infectious diseases.  Each of our hospitals has a full complement of clinical infectious diseases services; areas of special emphasis at each site are indicated below.&lt;/p&gt;


			&lt;h3&gt;Parnassus/Mount Zion&lt;/h3&gt;
			&lt;p&gt;The UCSF Medical Center’s Infectious Diseases Division provides outstanding care for patients with a wide range of infectious diseases, particularly providing care to patients with complex or unusual problems including those with compromised immune systems.  We see many patients from our local community, but we also care for those travelling to us from around the country. Infectious Diseases at UCSF Medical Center comprises several distinct ambulatory practices and inpatient services. &lt;/p&gt;
			&lt;h4&gt;Outpatient Clinics at Parnassus/Mount Zion&lt;/h4&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/outpatient/id.html&quot;&gt;Infectious Diseases Faculty Practice&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/outpatient/hiv.html&quot;&gt;HIV&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/outpatient/hpv.html&quot;&gt;Dysplasia Practice&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/outpatient/neuro.html&quot;&gt;Neurology &#45; Infectious Diseases&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/outpatient/transplant.html&quot;&gt;Transplant Infectious Diseases&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;

			&lt;h3&gt;Zuckerberg San Francisco General (ZSFG)&lt;/h3&gt;
			&lt;p&gt;Zuckerberg San Francisco General Hospital and Trauma Center provides comprehensive patient care for the residents of San Francisco regardless of their ability to pay.  UCSF has been affiliated with Zuckerberg San Francisco General Hospital (ZSFG) since 1884 and shares in the mission of providing quality healthcare and trauma services with compassion and respect. ZSFG is the only Level 1 trauma center in San Francisco and Northern San Mateo County and serves 1.5 million residents of the Bay Area. A new main hospital building was opened in 2016.&lt;/p&gt;

			&lt;p&gt;ZSFG has a long history as a major&#45;academic tertiary care medical center. Infectious diseases has played an important role in shaping ZSFG. In the 1980s, some of the nation’s first AIDS patients were cared for at ZSFG, and the hospital became a model for AIDS and HIV care.  Established in 1983 as one of the first HIV clinics in the country, the HIV clinic located at Ward 86 cares for nearly 3000 HIV&#45;infected San Francisco residents.&lt;/p&gt;

			&lt;!&#45;&#45;&lt;h5&gt;SFGH Infectious Diseases Research&lt;/h5&gt;

			&lt;p&gt;The malaria research program based at San Francisco General Hospital is a critical part of the Global Health focus at UCSF. Areas of research include the biology of malaria parasites, host and pathogen interactions, clinical and molecular studies of antimalarial drug resistance, malaria epidemiology, and co&#45;infection with malaria and HIV.&lt;/p&gt;

			&lt;p&gt;Research on Staphylococcus aureus at San Francisco General Hospital is diverse and includes disease pathogenesis, mechanisms of drug resistance, clinical and molecular epidemiology, and clinical trials.&lt;/p&gt;

			&lt;p&gt;Consistent with the mission of improving care for vulnerable populations, research is ongoing at SFGH regarding the intersection of substance use and infectious diseases. Areas of interest include the effects of injection drug use and alcohol on the epidemiology and clinical manifestations of HIV and hepatitis C.&lt;/p&gt;

			&lt;p&gt;The Infectious Diseases Division maintains close ties with the &lt;a href=&quot;http://medicine.ucsf.edu/divisions/experimental/&quot; target=&quot;_blank&quot;&gt;Division of Experimental Medicine&lt;/a&gt;, based at San Francisco General Hospital. Infectious Diseases fellows find research opportunities in basic and translational research within the Division of Experimental Medicine, which strives to understand the human immune system and to conduct patient&#45;oriented research in infectious diseases of global importance.  &lt;/p&gt;

			&lt;p&gt;Many faculty and fellows within the Infectious Diseases Division share clinical and research interests with members of the &lt;a href=&quot;http://hiv.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;UCSF HIV/AIDS Division&lt;/a&gt; at San Francisco General Hospital. The HIV/AIDS Division is known for its national and international leadership in clinical care, research, and HIV education. &lt;/p&gt;

			&lt;h5&gt;Inpatient Service&lt;/h5&gt;

			&lt;p&gt;The Infectious Diseases Division runs a busy inpatient consult service at San Francisco General Hospital. The patients cared for reflect the diverse nature of San Francisco and the emphasis of the hospital in reaching out to vulnerable persons. Represented populations include trauma patients, HIV&#45;infected individuals, substance users, and non&#45;English speakers. Infections of particular importance include tuberculosis, HIV&#45;associated infections, staphylococcal bacteremia, bone and joint infections, and complicated skin and soft tissue infections.&lt;/p&gt;

			&lt;h5&gt;Infectious Diseases Clinic&lt;/h5&gt;

			&lt;p&gt;An Infectious Diseases Clinic that serves San Francisco Community Health Network patients and Laguna Honda Hospital residents has been established at the newly rebuilt Laguna Honda Hospital and Rehabilitation Center.  Physician referral is required and occurs within the Community Health Network.&lt;/p&gt;


			&lt;h3&gt;Laguna Honda &lt;/h3&gt;

			&lt;p&gt;An Infectious Diseases Clinic that serves San Francisco Community Health Network patients and Laguna Honda Hospital residents has been established at the newly rebuilt Laguna Honda Hospital and Rehabilitation Center.  Physician referral is required and occurs within the Community Health Network.&lt;/p&gt;  &#45;&#45;&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
For Referring Physicians ./id/care/physicians.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/physicians.html</Path>
		<FileBody>
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Division of Infectious Diseases has world&#45;renowned physicians who provide expert care for a wide spectrum of infectious diseases in hosts with normal and compromised immune systems.  Our faculty specializes in a wide range of infectious diseases, HIV/AIDS, and travel medicine.&lt;/p&gt;
			&lt;p&gt;Our mission is to provide high quality, efficient and compassionate care.  Patients are referred to UCSF infectious diseases from all over Northern California.&lt;/p&gt;
			&lt;/p&gt;

			&lt;h3&gt;Outpatient Clinics&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;
			&lt;/li&gt;&lt;/ul&gt;




					</FileBody>
	</node>
	<node>
		<Fname>
trials.html ./id/care/trials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/trials.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
HIV ./id/care/outpatient/hiv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/hiv.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;At the 360: Positive Care Clinic, we take a wide view of all aspects of HIV/AIDS care and research that drives our commitment to develop innovative solutions to bringing all living with HIV/AIDS into optimal care and providing them the tools to maintain wellness.  The 360: Positive Care Center welcomes new patients and provides them with the tools to live a healthier life.  &lt;/p&gt;

			&lt;p&gt;Our work includes addressing the evolving issues of aging HIV &amp; Aging Program, disparities in HIV care among people of color &lt;a href=&quot;http://www.positivehealth.ucsf.edu/MOCP/index.aspx&quot; target=&quot;_blank&quot;&gt;Men of Color Program&lt;/a&gt;, and implementing cost&#45;efficient technology to increase our outreach to community clinics.  The Urban HIV Telemedicine Program uses real&#45;time broadband video technology to support underserved individuals and their medical providers.&lt;/p&gt;

			&lt;p&gt;It takes a community to stop HIV.  We welcome your support and involvement in our work.
			&lt;/p&gt;

			&lt;blockquote&gt;
			&lt;b&gt;&lt;a href=&quot;http://www.ucsfhealth.org/clinics/hiv_aids_program/index.html&quot; target=&quot;_blank&quot;&gt;360: The Positive Care Center &#45; UCSF Medical Center&lt;/a&gt;&lt;/b&gt;&lt;br /&gt;
			350 Parnassus Avenue, Suite 908&lt;br /&gt;
			Box 0378&lt;br /&gt;
			San Francisco, CA 94143&lt;br /&gt;
			Phone: (415) 353&#45;2119  &lt;br /&gt;
			FAX (415) 353&#45;2406&lt;/blockquote&gt;

			&lt;blockquote&gt;
			&lt;b&gt;&lt;a href=&quot;http://www.ucsfhealth.org/clinics/hiv_aids_program/index.html&quot; target=&quot;_blank&quot;&gt;AIDS Women &amp; Children &#45; UCSF Medical Center&lt;/a&gt;&lt;/b&gt; &lt;br /&gt;
			350 Parnassus Avenue, Suite 908&lt;br /&gt;
			Box 0378&lt;br /&gt;
			San Francisco, CA 94143&lt;br /&gt;
			Phone: (415) 353&#45;2119  &lt;br /&gt;
			FAX (415) 353&#45;2406
			&lt;/blockquote&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
HPV ./id/care/outpatient/hpv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/hpv.html</Path>
		<FileBody>

			&lt;p&gt;See &lt;a href=&quot;http://www.ucsfhealth.org/clinics/dysplasia/index.html&quot; target=&quot;_blank&quot;&gt;UCSF Medical Center&lt;/a&gt; for more information.&lt;/p&gt;

			&lt;blockquote&gt;&lt;b&gt;Gyn Dysplasia Practice&lt;/b&gt;&lt;br /&gt;
			1600 Divisadero Street&lt;br /&gt;
			4th Floor&lt;br /&gt;
			San Francisco, CA 9411&lt;br /&gt;
			Phone: (415) 514&#45;0800&lt;/blockquote&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Infectious Disease Clinic ./id/care/outpatient/id.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/id.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Our infectious diseases clinic serves as a referral center for a wide spectrum of infectious diseases in patients from all around Northern California.&lt;/p&gt;

			&lt;p&gt;We specialize in the evaluation and management of patients with complicated infectious diseases issues.  Many of our common referrals include recurrent skins and soft tissue infections, recurrent urinary tract infections, recurrent herpes virus infections, mycobacterial infections of the lungs and skin, coccidioidomycosis, fever of unknown origin, bone and joint infections, evaluations for possible Lyme disease (we follow the guidelines of the Infectious Diseases Society of America), and many others.&lt;/p&gt;


			&lt;blockquote&gt;&lt;b&gt;&lt;a href=&quot;http://www.ucsfhealth.org/clinics/infectious_diseases_at_parnassus/index.html&quot; target=&quot;_blank&quot;&gt;Adult General Infectious Diseases and Transplant Infectious Diseases&lt;/a&gt;&lt;/b&gt;&lt;br /&gt;
			400 Parnassus Avenue&lt;br /&gt;
			5th Floor&lt;br /&gt;
			San Francisco, CA 94143&lt;br /&gt;
			Phone: (415) 353&#45;2626&lt;br /&gt;
			Fax: (415) 353&#45;2568&lt;/blockquote&gt;

			&lt;p&gt;To make an appointment at the Outpatient Infectious Diseases Clinic at UCSF have your physician fax us a referral with a written history and relevant labs to our clinic at fax # 415&#45;353&#45;2568. Our physician will review the referral and then you will be contacted by our clinic to schedule an appointment. The Infectious Diseases Clinic can be contacted at 415&#45;353&#45;2626 for an appointment and/or inquiries.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Neuro ./id/care/outpatient/neuro.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/neuro.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Our neuro&#45;infectious diseases clinic is one of the only in the country staffed with neurologists who also receive additional training in infectious diseases.   &lt;/p&gt;
			&lt;p&gt;We provide care for patients with a wide range of neurological infections including brain abscesses, chronic meningitis, neurocysticercosis, encephalitis, and many others.  Procedures such as lumbar punctures can be performed in the clinic.&lt;/p&gt;
			&lt;p&gt;See &lt;a href=&quot;http://www.ucsfhealth.org/clinics/infectious_diseases_at_parnassus/index.html&quot;&gt;UCSF Medical Center&lt;/a&gt; for more information.&lt;/p&gt;

			&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Transplant ./id/care/outpatient/transplant.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/transplant.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Our transplant infectious diseases clinic cares for immunocompromised hosts who suffer from infectious diseases following solid organ and stem cell transplants. &lt;/p&gt;
			&lt;p&gt;We provide care for patients suffering from a wide&#45;range of infections including bacterial, viral, fungal, and parasitic that may occur following transplantation of solid organs or hematopoietic stem cells.&lt;/p&gt;
			&lt;p&gt;Please see &lt;a href=&quot;http://www.ucsfhealth.org/clinics/infectious_diseases_at_parnassus/index.html&quot; target=&quot;_blank&quot;&gt;UCSF Medical Center&lt;/a&gt; for more information.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Travel Medicine ./id/care/outpatient/travel.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/care/outpatient/travel.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;&amp;nbsp;&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Continuing Medical Education ./id/education/cme.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/cme.html</Path>
		<FileBody>
			&lt;img src=&quot;../images/banners/main/hippocrates754.jpg&quot; width=&quot;754&quot; align=middle height=&quot;130&quot; alt=&quot;Hippocrates&quot;/&gt;
			&lt;p class=&quot;introduction&quot;&gt;&lt;br&gt; The following CME courses are directed and organized by the UCSF Infectious Diseases Division.&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;Advances in Infectious Diseases: New Directions in Patient Care: Annual course held in Downtown San Francisco each April&lt;/li&gt;
			&lt;li&gt;Infectious Diseases in Clinical Practice: Update on Inpatient and Outpatient Infectious Diseases: Annual course held in Hawaii each February&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;More information can be found at UCSF's &lt;a href=&quot;http://meded.ucsf.edu/cme&quot;&gt;Office of Continuing Medical Education&lt;/a&gt;.&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Program ./id/education/fellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/firstyearfellows.jpg&quot;&gt;

			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;The University  of California, San Francisco offers outstanding fellowship training in  Infectious Diseases with great breadth and depth in both clinical infectious  diseases and research. &amp;nbsp;The program offers two tracks, a research track  (four fellows per year) and a clinical educator track (one fellow per  year).&amp;nbsp; All fellows spend the first year of the program immersed in robust  clinical infectious diseases training. &amp;nbsp;Following a two&#45;week intensive  didactic core curriculum, fellows rotate in four&#45;week blocks on inpatient  consult services at three UCSF&#45;affiliated hospitals &#45;&#45; UCSF Medical Center, San  Francisco General Hospital, and the San Francisco Veterans Affairs Medical  Center.&amp;nbsp;&amp;nbsp; Teams include fellows, students, residents, infectious  diseases faculty, and infectious diseases specialty pharmacists.  &amp;nbsp;Longitudinal outpatient experiences are ongoing throughout the year in  HIV clinics, General and Transplant Infectious Diseases Clinics, San Francisco  Department of Public Health TB Clinic, and the San Francisco Department of  Public Health STD Clinic.&amp;nbsp; Additional educational experiences include  rotating on the Pediatric Infectious Diseases Consult Service at UCSF Benioff  Children’s Hospital and working alongside microbiologists at the San Francisco  Veterans Affairs Medical Center Microbiology Laboratory.&amp;nbsp; Fellows  participate in at least two hours per week of teaching conferences.  &amp;nbsp;&amp;nbsp;After the first year of training, fellows’ activities differ  depending on the track chosen.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Research Track&lt;/strong&gt;: The  second year and beyond are devoted to research in the fellow's area of interest  under the guidance of a faculty preceptor. &lt;a href=&quot;http://id.medicine.ucsf.edu/research/&quot;&gt;Research training  opportunities&lt;/a&gt; are vast and are available in the fields of clinical, translational, and  basic laboratory sciences.&amp;nbsp; Fellows are guaranteed support for two years  of research, although many go on to pursue additional time in their research  training posititions.&amp;nbsp;&amp;nbsp; Education in research methods may be obtained  through the &lt;a href=&quot;http://sph.berkeley.edu/&quot;&gt;University of California,  Berkeley School of Public Health&lt;/a&gt; Master of Public Health Degree or the UCSF  Department of Epidemiology and Biostatistics via the &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/ATCR.html&quot;&gt;Advanced  Training in Clinical Research Certificate Program&lt;/a&gt; or &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/masters.html&quot;&gt;Master’s  Degree Program in Clinical Research&lt;/a&gt;. &amp;nbsp;&amp;nbsp;Fellows engaged in research are  often supported by one of the following NIH&#45;funded training grants:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;UCSF Biology of Infectious Disease  (PI &#45; Henry Chambers)&lt;/li&gt;
			  &lt;li&gt;Traineeship in AIDS Prevention Studies  (PI &#45; Susan Kegeles)&lt;/li&gt;
			  &lt;li&gt;Training in HIV Translational Research (PI &#45; Diane  Havlir)&lt;/li&gt;
			  &lt;li&gt;Clinical  Pharmacology; Drug Action and Pharmacogenetics (PI &#45; Esteban Burchard)&lt;/li&gt;
			  &lt;li&gt;Microbial Pathogenesis and Host Defense  (PI &#45; Joanne Engel)&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;&lt;strong&gt;Clinical Educator Track&lt;/strong&gt;:  The  second&#45;year is devoted to (1) enhancing the fellow’s clinical expertise in the care  of immunocompromised hosts (with and without HIV infection), (2) obtaining  formal training in medical education, and (3) engaging in scholarly  activity.&amp;nbsp; The clinical program in the second year includes inpatient time  on the HIV consult service at San Francisco General Hospital as well as additional  dedicated time on the Transplant Infectious Diseases Consult Service at UCSF  Medical Center.&amp;nbsp; Ambulatory experiences include an HIV continuity care  clinic at San Francisco General Hospital (“Ward 86”) as well as Transplant  Infectious Diseases Clinic at UCSF Medical Center.&amp;nbsp; Formal training in  educational methods may be obtained through the &lt;a href=&quot;http://meded.ucsf.edu/hpe&quot;&gt;Pathways  Program for Health Professions Education&lt;/a&gt;.&amp;nbsp; Scholarly activities include development  of educational curricula, clinical research, writing a scholarly review, and/or  participation in quality improvement projects. Fellows will have access to  internationally renowned medical educators within the Division of Infectious  Diseases and Department of Medicine, as well as the larger UCSF community. If you are interested in learning more about the Clinical Educator Track, please click &lt;a href=&quot;/education/fellowship/ce_track_faqs.pdf&quot;&gt;here&lt;/a&gt; to access our FAQ document.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Antimicrobial Stewardship(AS)/Infection Control(IC) Track&lt;/strong&gt;:  The AS/IC Track is available as a 2&#45;year clinical AS/IC track or 3&#45;year research AS/IC track. Both tracks provide advanced training in antimicrobial stewardship and infection control through didactics, hands&#45;on practical training, and scholarly projects. The 3&#45;year research track is designed for fellows interested in advanced training in clinical research through additional coursework/degrees while completing a mentored research project. Applicants interested in the 2&#45;year track would apply via the Clinician Educator Track and the 3&#45;year track via the Research Track in ERAS.  Fellows would complete the standard clinical requirements during the first two years of training.  Additional details about this track are outlined &lt;a href=&quot;/education/fellowship/ucsf_id_fel_asp_track_ed_com_16&#45;17.pdf&quot;&gt;here&lt;/a&gt;.&lt;/p&gt;


			&lt;blockquote&gt;
			Brian S. Schwartz, MD – Program Director&lt;br&gt;
			Harry Lampiris, MD – Associate Program Director&lt;br&gt;
			Natalie Williams&#45;Munger– Fellowship Coordinator&lt;br&gt;
			&lt;/blockquote&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Program ./id/education/fellowship.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship.html~</Path>
		<FileBody>

			&lt;p&gt;The School of Medicine at the University of California, San Francisco offers a fellowship training in Infectious Diseases. The minimum program is two years, but three years are strongly recommended. The first year is devoted to training in clinical Infectious Diseases. An intensive didactic core curriculum, which includes core microbiology didactic sessions, is covered in the first two weeks of the program.  Thereafter, fellows rotate in 4&#45;week blocks through each of the three affiliated UCSF hospitals (U.C. Moffitt&#45;Long Hospitals, San Francisco General Hospital, and the San Francisco Veteran Affairs Medical Center) to manage the Infectious Diseases Consult Service under the supervision of an attending physician. Residents and students in medicine and pharmacy also staff the consultation services. Fellows participate in a didactic teaching conference and a weekly Diagnostic Microbiology conference at each of the hospitals in conjunction with faculty and fellows from the Pediatric Infectious Diseases Program. Attendance at the Infectious Diseases Clinic and monthly meetings of the Infection Control Committee, are also a part of the program. A continuity clinic is maintained a half day a week throughout the first two years of training.  Fellows also rotate through the San Francisco Department of Public Health Sexually Transmitted Diseases Clinic, the San Francisco Department of Public Health Tuberculosis Clinic, the SFVAMC Clinical Microbiology Laboratory, and the Pediatric In&#45;Patient Consultation Service. &lt;/p&gt;

			&lt;p&gt;The second and third years are devoted to research in the fellow's area of interest under the guidance of a faculty preceptor. Research training opportunities in basic laboratory research (many with an emphasis in molecular biology techniques) are available in a number of laboratories within the Infectious Diseases program or in laboratories closely associated with the program. Research opportunities that focus on epidemiological methods and population and/or clinical studies are also available through a number of programs at UCSF, offering the opportunity for Master's degree training in Epidemiology, and at the UC Berkeley School of Public Health, offering a Master’s degree in Public Health. Fellows wishing to become independent investigators, regardless of their area of research, should anticipate two to four years of training beyond the first year. &lt;a href=&quot;http://id.medicine.ucsf.edu/about/faculty.html&quot;&gt;Research interests&lt;/a&gt; of the faculty are very diverse and range from molecular and cell biology to epidemiology and clinical trials.&lt;/p&gt;

			&lt;blockquote&gt;
			Henry (Chip) Chambers, MD – Program Director&lt;br&gt;
			Harry Lampiris, MD – Associate Program Director&lt;br&gt;
			Virginia Schuler – Fellowship Coordinator&lt;br&gt;
			&lt;/blockquote&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Education ./id/education/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/index.html</Path>
		<FileBody>

			&lt;img src=&quot;../images/id_education1.jpg&quot; width=&quot;165&quot;  height=&quot;150&quot; alt=&quot;&quot;/&gt;
			&lt;img src=&quot;../images/id_education2.jpg&quot; width=&quot;214&quot;  height=&quot;150&quot; alt=&quot;&quot;/&gt;
			&lt;img src=&quot;../images/id_education3.jpg&quot; width=&quot;168&quot;  height=&quot;150&quot; alt=&quot;&quot;/&gt;
			&lt;br&gt;
			&lt;p class=&quot;introduction&quot;&gt;&lt;br&gt;The Division of Infectious Diseases at the University of California, San Francisco offers opportunities for various types of Infectious Disease training including a world&#45;class &lt;a href=&quot;/fellowship/index.html&quot;&gt;fellowship training program&lt;/a&gt;, opportunities for &lt;a href=&quot;/education/medical.html&quot;&gt;visiting medical students&lt;/a&gt;, &lt;a href=&quot;/education/residents.html&quot;&gt;visiting residents&lt;/a&gt;, and &lt;a href=&quot;/education/visiting_faculty.html&quot;&gt;visiting faculty&lt;/a&gt;.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Education ./id/education/index_new.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/index_new.html</Path>
		<FileBody>

			&lt;img src=&quot;../images/id_education11.jpg&quot; width=&quot;215&quot;  height=&quot;200&quot; alt=&quot;&quot;/&gt;
			&lt;img src=&quot;../images/id_education2.jpg&quot; width=&quot;285&quot;  height=&quot;200&quot; alt=&quot;&quot;/&gt;
			&lt;img src=&quot;../images/id_education3.jpg&quot; width=&quot;207&quot;  height=&quot;200&quot; alt=&quot;&quot;/&gt;
			&lt;p class=&quot;introduction&quot;&gt;The Division of Infectious Diseases at the University of California, San Francisco offers opportunities for various types of Infectious Disease training including a world&#45;class fellowship training program, opportunities for visiting medical students,  visiting residents, and visiting faculty.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Medical Students ./id/education/medical.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/medical.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Medical student education is of  great importance to the infectious diseases faculty across the UCSF campuses.&lt;/p&gt;

			&lt;p&gt;Fourth&#45;year medical student inpatient infectious diseases consult rotations are available at UCSF Moffitt&#45;Long Hospital, San Francisco General Hospital, and San Francisco VA Medical Center.  UCSF medical students can request these rotations through the registrars’ office.  Non&#45;UCSF medical students who are interested in away rotations can request more information from Emerald Wong at &lt;a href=&quot;mailto: Emerald.Wong@ucsf.edu &quot;&gt;Emerald.Wong@ucsf.edu&lt;/a&gt; or (415) 476&#45;1964.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Residents ./id/education/residents.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/residents.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Resident education by infectious diseases faculty at UCSF occurs in the both the inpatient setting and outpatient clinics across all three campuses.&lt;/p&gt;

			&lt;p&gt;Inpatient infectious diseases consult rotations are available at UCSF Moffitt&#45;Long and San Francisco General Hospital for internal medicine residents at UCSF.  Non&#45;UCSF medical residents who are interested in away rotations at Moffitt&#45;Long (Outpatient General ID and Inpatient Transplant ID) should contact Natalie Williams&#45;Munger at &lt;a href=&quot;mailto:natalie.williams&#45;munger@ucsf.edu&quot;&gt;natalie.williams&#45;munger@ucsf.edu&lt;/a&gt; or (415) 476&#45;9363. &lt;br&gt; &lt;br&gt; Non&#45;UCSF medical residents who are interested in away rotations at ZSFG's Infectious Diseases&#45;HIV Division should contact Stephen May at &lt;a href=&quot;mailto:Stephen.May@ucsf.edu@ucsf.edu&quot;&gt;stephen.may@ucsf.edu@ucsf.edu&lt;/a&gt; or (415) 476&#45;4082 ext. 138.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Visiting Faculty ./id/education/visiting_faculty.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/visiting_faculty.html</Path>
		<FileBody>

			&lt;p&gt;
			Visiting faculty are not being accepted at this time. Please check back for future opportunities.
			&lt;/p&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Application Process ./id/education/fellowship/application.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship/application.html</Path>
		<FileBody>

			&lt;p&gt;&lt;strong&gt;The Division of Infectious  Diseases at UCSF participates in ERAS (Electronic Residency Application  Service) and the fellowship match program administered by the National  Residency Matching Program (NRMP).&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;ERAS Application&lt;/strong&gt;&lt;br /&gt;
			  &lt;br /&gt;
			  Instructions for  completing and submitting the ERAS application can be found at&amp;nbsp;&lt;a href=&quot;https://www.aamc.org/students/medstudents/eras/187146/imsub_change.html&quot; target=&quot;_blank&quot;&gt;ERAS application&lt;/a&gt;.&lt;br /&gt;
			  &lt;br /&gt;
			Please be sure to  complete the following items:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;Submit three letters of recommendation, including letters from  your residency training director, research mentor (if applicable), and current  employer (if you have completed residency training)&lt;/li&gt;
			  &lt;li&gt;Submit a concise personal statement of your career goals in Infectious  Diseases, previous research background/training and possible research interests  (if applicable)&lt;/li&gt;
			  &lt;li&gt;Apply to at least one of our two fellowship tracks:&amp;nbsp;Clinical  Educator or Research&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;Requirements for our  fellowship program include a Medical Degree, two&#45;three years of Internal  Medicine residency training in an ACGME accredited program, and US citizenship  or permanent residence status.&lt;br /&gt;
			  &lt;br /&gt;
			Our fellows have diverse  racial, ethnic, and socioeconomic backgrounds. We encourage minorities and  women to apply.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;NRMP Registration&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;All applicants to the Infectious Diseases fellowship program are  required to register with the National Resident Matching Program (NRMP). View  information on how to register and important deadlines at&amp;nbsp;&lt;a href=&quot;http://www.nrmp.org/fellow/schedule.html&quot;&gt;NRMP&lt;/a&gt;.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Calendar&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;712&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July    6, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;550&quot; valign=&quot;top&quot;&gt;&lt;p&gt; ERAS    website opens to applicants to begin working on their applications&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July 17, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt; UCSF will begin downloading    applications for review&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;By August, 2017 (exact date TBA)&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt; Interview offers will    be sent out to select applicants via email &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;br /&gt;
			        &lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;br /&gt;
			            &lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;br /&gt;
			      Interviews conducted (exact dates pending) &lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;TBA&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Rank Order Lists (ROL) due&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;December, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Match results    available&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July 1, 2018&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Fellowship begins&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;strong&gt;&lt;/strong&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Natalie Williams&#45;Munger&lt;/strong&gt;&lt;br&gt;
			      Fellowship Coordinator&lt;br&gt;
			      UCSF Division of Infectious Disease&lt;br&gt;
			      513 Parnassus Avenue, Room S&#45;380&lt;br&gt;
			      San Francisco, CA 94143&lt;br&gt;
			      Tel: (415) 476&#45;9363&lt;br&gt;
			      Fax: (415) 476&#45;9364&lt;br&gt;
			    Email: &lt;u&gt;&lt;a href=&quot;mailto:mauna.minagar@ucsf.edu&quot;&gt;natalie.williams&#45;munger@ucsf.edu&lt;/a&gt;&lt;/u&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
						&lt;/p&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./id/education/fellowship/current.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship/current.html</Path>
		<FileBody>



			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows3.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows4.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;




			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;h3&gt;1st&#45;Year Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Emily Abdoler&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jessica.briggs&quot;&gt;Jessica Briggs&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.bystritsky&quot;&gt;Rachel Bystritsky&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;https://profiles.ucsf.edu/monica.fung&quot;&gt;Monica Fung&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew.spinelli&quot;&gt;Matthew Spinelli&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;


			&lt;h3&gt;2nd&#45;Year Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/angelo.clemenzi&#45;allen&quot;&gt;Angelo (Asa) Clemenzi&#45;Allen&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/aaloke.mody&quot;&gt;Aaloke Mody&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/david&#45;huy.nguyen&quot;&gt;David Nguyen&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/erika.wallender&quot;&gt;Erika Wallender&lt;/a&gt;&lt;/li&gt;

				&lt;/ul&gt;

			&lt;h3&gt;Advanced Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/lillian.brown&quot;&gt;Lillian Brown&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/john.d.kelly&quot;&gt;Dan Kelly&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.rutishauser&quot;&gt;Rachel Rutishauser&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/shereen.katrak&quot;&gt;Shereen Katrak&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/monika.roy&quot;&gt;Monika Roy&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/michael.j.reid&quot;&gt;Michael Reid&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Curriculum ./id/education/fellowship/curriculum.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship/curriculum.html</Path>
		<FileBody>

			&lt;h3&gt;Statement of Educational Purpose&lt;/h3&gt;

			&lt;p&gt;The primary goal of the UCSF Fellowship in Infectious Diseases is to provide clinical and research training in infectious diseases. Through a combination of structured educational programs, mentored clinical practice rotations, and direct patient care in three unique health care delivery settings, the UCSF training program provides outstanding opportunities for fellows to obtain and demonstrate competence in patient care and the diagnosis, management, and treatment of a wide variety of
			Infectious diseases. Fellows receive intensive clinical training during the first year, which includes: (i) inpatient consultation at three different hospitals, including a dedicated consult service for immunosuppressed patients and a rotation on the pediatric infectious diseases service; (ii) outpatient infectious diseases clinical training, including a weekly HIV/infectious diseases continuity clinic; and (iii) training in clinical microbiology and infection control. Fellows consolidate and refine their patient care skills during the second year with occasional weekend coverage and 2 weeks of inpatient consultation and the continuation of the longitudinal outpatient experience with one outpatient clinic per week. The training curriculum is designed for fellows to obtain competence in patient care at the level expected of a new practitioner by the end of the second year of fellowship.&lt;/p&gt;

			&lt;p&gt;A major goal of the program is to train and develop future leaders in infectious diseases. The program, therefore, encourages a high level of academic performance in its trainees and actively fosters the development of academic infectious diseases physicians who will advance the field and train future physicians. Accordingly, the training program also strongly emphasizes investigative infectious diseases through a combination of structured educational sessions, career development support and mentoring, and the availability of a diverse and experienced group of research mentors within UCSF. &lt;/p&gt;

			&lt;h3&gt;Competency&#45;Based Overall Educational Goals&lt;/h3&gt;

			&lt;p class=&quot;introduction&quot;&gt;The training program fosters and expects fellows to obtain competence in the following areas:&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Patient Care:&lt;/b&gt; The essence of being an infectious diseases specialist is the ability to use data derived about a patient (history, physical examination, laboratory, microbiology, and imaging studies) along with medical knowledge to orderly synthesize a differential diagnosis, plan for further evaluation, and comprehensively manage a patient with an infectious disease. Competence in this area results in care that is compassionate, appropriate, and effective for the treatment of disease and the promotion of health. &lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Medical Knowledge:&lt;/b&gt; Trainees must gain a thorough understanding of established and evolving biomedical, clinical, and epidemiological and social&#45;behavioral sciences relating to infectious diseases and apply this knowledge to patient care. &lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Practice&#45;based Learning and Improvement:&lt;/b&gt; The development of skills in self&#45;directed learning and practice improvement will facilitate the delivery of state&#45;of&#45;the&#45;art, evidence&#45;based patient care that maximizes the likelihood for successful clinical outcomes. Essential components of this competency include the ability to investigate and evaluate patient care, to appraise and assimilate scientific evidence, and to continuously improve patient care based on constant self&#45;evaluation and life&#45;long learning.&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Interpersonal and Communication Skills:&lt;/b&gt; Competency in this area is essential for the formation of a desirable and effective physician&#45;patient relationship, The complexity of most infectious diseases and their management requires a working partnership between patient and physician, and often between physician and the patient's family. Competency in this area also results in the effective exchange of Information and collaboration with other health professionals.&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Professionalism:&lt;/b&gt; Professionalism is one of the foundations of the practice of medicine and is an inherent character trait in a well&#45;rounded infectious diseases physician. Professionalism is manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to patients of diverse backgrounds&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Systems&#45;based Practice:&lt;/b&gt; Competence in this area reflects an understanding of and responsiveness to the larger context and system of health care, as well as the ability to call effectively on other resources in the system to provide optimal care for patients with infectious diseases.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Former Fellows ./id/education/fellowship/former.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship/former.html</Path>
		<FileBody>

			&lt;ul&gt;
				&lt;li&gt;Juliet Stoltey&lt;/li&gt;
				&lt;li&gt;Anuj Gaggar&lt;/li&gt;
				&lt;li&gt;Jennifer Babik&lt;/li&gt;
				&lt;li&gt;Gabriel Chamie&lt;/li&gt;
				&lt;li&gt;Gabriel Ortiz&lt;/li&gt;
				&lt;li&gt;Prasanna Jagannathan&lt;/li&gt;
				&lt;li&gt;Vivek Jain&lt;/li&gt;
				&lt;li&gt;Chris Keh&lt;/li&gt;
				&lt;li&gt;Oren Rosenberg&lt;/li&gt;
			&lt;/ul&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
History ./id/education/fellowship/history.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/education/fellowship/history.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;The current three hospital based ID fellowship at UCSF was initiated in 1987 by Dr. Richard Locksley, the chief of the ID division at UCSF from 1987 to 2005, when Dr. Joanne Engel became the interim chief and then the subsequent chief of the division.  The program was initially focused almost exclusively on training laboratory&#45;focused infectious disease academic researchers, and subsequently has expanded to have our graduates develop academic careers in clinical research, translational research, and public health. &lt;/p&gt;




					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./id/faculty/faculty.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/faculty/faculty.html</Path>
		<FileBody>


			&lt;p class=&quot;introduction&quot;&gt;The Division of Infectious Diseases has over 40 faculty located throughout our three UCSF campuses.&lt;/p&gt;
			&lt;div&gt;

				&lt;div class=&quot;left_column&quot;&gt;
					&lt;h3&gt;Parnassus&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=c09aa087853993c3595742f3b273e668&amp;name=ENGEL%2CJOANNE+N&quot;&gt;Engel, Joanne, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=74923fa9a525e882c4f47d8a334d97c2&amp;name=BABIK%2CJENNIFER+M.&quot;&gt;Babik, Jennifer, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=58c5c247343de259ffbf19b693106c79&amp;name=CHIN&#45;HONG%2CPETER+V&quot;&gt;Chin&#45;Hong, Peter, MD, MAS&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=6624de5b3826bbb4df847369d69f3b23&amp;name=DOERNBERG%2CSARAH+B&quot;&gt;Doernberg, Sarah, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=29cf627f8cccff6eb074842eb7711671&amp;name=HOLLANDER%2CHARRY&quot;&gt;Hollander, Harry, MD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=8c03e38d9e482c9053d1e46944b1f972&amp;name=JOHN%2CMALCOLM+D+V&quot;&gt;John, Malcolm, MD, MPH&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=6004fd72af09ee0f9de1f87a71975722&amp;name=KOEHLER%2CJANE+E&quot;&gt;Koehler, Jane, MA, MD&lt;/a&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=027887157&amp;name=CHAZ%2LANGELIER&quot;&gt;Langelier, Chaz, MD, PhD&lt;/a&gt;&lt;/p&gt;
			&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=28373405&amp;name=NOBLE%2CSUZANNE+M&quot;&gt;Noble, Suzanne, MD, PhD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;http://id.medicine.ucsf.edu/faculty/index.html?key=029341237&amp;amp;name=JESSE%2NUSSBAUM&quot;&gt;Nussbaum, Jesse, MD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=d9fbb1e99ca98d3d9efddb76bda220eb&amp;name=PALEFSKY%2CJOEL+M&quot;&gt;Palefsky, Joel, MD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=021466453&amp;name=BENNETT%2PENN&quot;&gt;Penn, Bennett, MD, PhD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=027849728&amp;name=ROSENBERG%2COREN&quot;&gt;Rosenberg, Oren, MD, PhD&lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=bed3ac3027cbecf4044754f76d76d7fd&amp;name=SCHWARTZ%2CBRIAN+S&quot;&gt;Schwartz, Brian, MD &lt;/a&gt;&lt;/p&gt;
				  &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=28476430&amp;name=TUGIZOV%2CSHAROF&quot;&gt;Tugizov, Sharof, DSc, PhD&lt;/a&gt;&lt;/p&gt;
				&lt;br /&gt;  &lt;h3&gt;Emeritus Faculty&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=44a5f3ae04c9fadeeb0fc64f70fee2b8&amp;name=JACOBS%2CRICHARD+A&quot;&gt;Jacobs, Richard A, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;br /&gt; &lt;h3&gt;VA&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=24709107&amp;name=LAMPIRIS%2CHARRY+W&quot;&gt;Lampiris, Harry W., MD &lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;Maddix, Daniel, Pharm D&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=22235279&amp;name=PILLAI%2CSATISH+KUMAR&quot;&gt;Pillai, Satish, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=26755405&amp;name=PULLIAM%2CD+LYNN&quot;&gt;Pulliam, Lynn, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=23277502&amp;name=TIEN%2CPHYLLIS+C&quot;&gt;Tien, Phyllis, MD, MPH&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;Vu, Mai, Pharm D&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=21286174&amp;name=WONG%2CJOSEPH+K&quot;&gt;Wong, Joseph, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/paul.sullam&quot;&gt;Sullam, Paul, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;https://search.knodeinc.com/viewProfile.action?oauth_signature=%2B2hNEvdDdm5tzT6u5cRNY%2FzeYao%3D&amp;oauth_body_hash=2jmj7l5rSw0yVb%2FvlWAYkK%2FYBwk%3D&amp;oauth_version=1.0&amp;oauth_nonce=1439632276075564209&amp;oauth_consumer_key=UCSF&amp;oauth_signature_method=HMAC&#45;SHA1&amp;sc.query=Yukl%2C+Steven&amp;opensocial_app_id=http%3A%2F%2Fwww.knodeinc.com%2Fapp%2Fopensocial%2Fucsfsearch.xml&amp;_d=1366395013107&amp;opensocial_app_url=http%3A%2F%2Fwww.knodeinc.com%2Fapp%2Fopensocial%2Fucsfsearch.xml&amp;oauth_timestamp=1366395013&amp;profile.profileId=C2893812#.UXGIiHnn_cs&quot; target=&quot;_blank&quot;&gt;Yukl, Steven, MD &lt;/a&gt;&lt;/p&gt;
					&lt;br /&gt; &lt;h1&gt;Affiliated Faculty&lt;/h1&gt;
					&lt;h3&gt;Biochemistry and Biophysics&lt;/h3&gt;
					&lt;p&gt;Derisi, Joe, PhD&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=4742259&quot; target=&quot;_blank&quot;&gt;Craik, Charles, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=4838331&quot; target=&quot;_blank&quot;&gt;Frankel, Alan, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=5088007&quot; target=&quot;_blank&quot;&gt;Madhani, Hiten, MD, PhD&lt;/a&gt;&lt;/p&gt;
				&lt;br /&gt; 	&lt;h3&gt;Clinical Pharmacy &#45; Infectious Diseases&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=24311896&amp;name=CHAN%2C+DOMINIC+K&quot; &gt;Chan, Dominic, Pharm D, BCPS&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;Deck, Dan, Pharm D&lt;/p&gt;
					&lt;p&gt;Dudas, Vicky, Pharm D&lt;/p&gt;
					&lt;p&gt;Guglielmo, Joseph B., Pharm D&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=23086762&amp;name=MACDOUGALL%2CCONAN&quot;&gt;Macdougall, Conan, Pharm D&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=29677374&amp;name=YANG%2C+KATHERINE+Y&quot; &gt;Yang, Katherine, Pharm D, MPH&lt;/a&gt;&lt;/p&gt;
					&lt;br /&gt; &lt;h3&gt;Laboratory Medicine&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=26460436&amp;name=CHIU%2CCHARLES+Y.&quot;&gt;Chiu, Charles, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;Drew, Lawrence, MD, PhD&lt;/p&gt;
				&lt;br /&gt; 	&lt;h3&gt;Medicine&lt;/h3&gt;

					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=23155898&amp;name=GREENE%2CWARNER+C&quot;&gt;Greene, Warner, MD, PhD&lt;/a&gt;&lt;/p&gt;

					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=24896516&amp;name=LEVY%2CJAY+A&quot;&gt;Levy, Jay, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=25469644&amp;name=MCCUNE%2CJOSEPH+M&quot;&gt;McCune, Joseph M., MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=28615508&amp;name=VOLBERDING%2CPAUL+A&quot;&gt;Volberding, Paul, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=28819605&amp;name=WEISS%2CARTHUR&quot;&gt;Weiss, Art, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=20117792&amp;name=BARON%2CJODY+LYNN&quot;&gt;Baron, Jody, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=29165479&amp;name=LYNCH%2CSUSAN&quot; &gt;Lynch, Susan, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=23039498&amp;name=MA%2CAVERIL+I&quot; &gt;Ma, Averil, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=26522888&amp;name=PETERLIN%2CBORIS+M&quot;&gt;Peterlin, Matija, MD&lt;a/&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=25181942&amp;name=NIXON%2CDOUGLAS&quot; &gt;Nixon, Doug, MD, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=20903373&amp;name=NORRIS%2CPHILIP+J&quot;&gt;Norris, Phillip, MD &lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=27792589&amp;name=LANIER%2CMARY+F.&quot; &gt;Premenko&#45;Lanier, Mary, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=24897373&amp;name=KIM%2CCHARLES+C&quot; &gt;Kim, Charles, PhD&lt;/a&gt;&lt;/p&gt;
				&lt;/div&gt;
				&lt;div&gt;
					&lt;h3&gt;ZSFG Division of HIV, ID, and Global Medicine&lt;/h3&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=25744939&amp;name=BACON%2COLIVER+M&quot;&gt;Bacon, Oliver, MD, MPH&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=646dcd7c0529d092e56718824dca3b0f&amp;name=CHAMBERS%2CHENRY+F&quot;&gt;Chambers, Henry, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=21823463&amp;name=CHAMIE%2CGABRIEL&quot;&gt;Chamie, Gabriel, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=021515903&amp;name=CHATTERJEE%2CSOM&quot;&gt;Chatterjee, Som, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=020918009&amp;name=CHRISTOPOULOS%2CKATERINA&quot;&gt;Christopoulos, Katerina, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=021543343&amp;name=COFFEY%2CSUSAN&quot;&gt;Coffey, Susan, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=21946702&amp;name=DEEKS%2CSTEVEN+G&quot;&gt;Deeks, Steven, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=21253604&amp;name=DIEP%2CBINH+A&quot;&gt;Diep, Binh, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=afe8b51a2e521ada3f3dc835a8fb1aea&amp;name=DORSEY%2CMATTHEW+G&quot;&gt;Dorsey, Grant, MD, PhD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=26353656&amp;name=GANDHI%2CMONICA&quot;&gt;Gandhi, Monica, MD, MPH&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=27013457&amp;name=GENG%2CELVIN+H&quot;&gt;Geng, Elvin, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=022676019&amp;name=GOOSBY%2CERIC&quot;&gt;Goosby, Eric, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=d9ed5723ef87cc38d573306731e43ab0&amp;name=GREENHOUSE%2CBRYAN+R.&quot;&gt;Greenhouse, Bryan, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=2bc060b53761d637c7d3a03812026eea&amp;name=HAHN%2CJUDITH+A&quot;&gt;Hahn, Judith, MA, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=28467454&amp;name=HALLER%2C+BARBARA+L&quot; &gt;Haller, Barbara, MD, PhD&lt;/a&gt;&lt;/p&gt;
			       	&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=25009820&amp;name=HAVLIR%2CDIANE+V&quot;&gt;Havlir, Diane, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=023913007&amp;name=HUANG%2CLAURENCE&quot;&gt;Huang, Laurence, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=24401572&amp;name=HUNT%2CPETER+W.&quot;&gt;Hunt, Peter, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=022605794&amp;name=JAGANNATHAN%2CPRASANNA&quot;&gt;Jagannathan, Prasanna, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=21646880&amp;name=JAIN%2CVIVEK&quot;&gt;Jain, Vivek, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=025154907&amp;name=CATHERINE%2KOSS&quot;&gt;Koss, Catherine (Cait), MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=021525092&amp;name=LEE%2CSULGGI&quot;&gt;Lee, Sulggi, MD, PhD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=024936502&amp;name=LIEGLER%2CTERI&quot;&gt;Liegler, Teri, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=20671194&amp;name=LUETKEMEYER%2CANNE+F&quot;&gt;Luetkemeyer, Annie, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=025109117&amp;name=LUM%2CPAULA+J&quot;&gt;Lum, Paula, MD, MPH&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=020654018&amp;name=MARQUEZ%2CCARINA&quot;&gt;Marquez, Carina, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=028403020&amp;name=PALAR%2CKARTIKA&quot;&gt;Palar, Kartika, PhD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=025270430&amp;name=PILCHER%2CCHRISTOPHER&quot;&gt;Pilcher, Christopher, MD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=20609863&amp;name=RILEY%2CELISE&quot;&gt;Riley, Elise, PhD&lt;/a&gt;&lt;/p&gt;
					&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=4dae5bd5ca258627ab33f16344d5ed7e&amp;name=ROSENTHAL%2CPHILIP+J&quot;&gt;Rosenthal, Philip, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=021305636&amp;name=WEISER%SHERI&quot;&gt;Weiser, Sheri, MD&lt;/a&gt;&lt;/p&gt;
			       	&lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=ca3370de7011159ea3713f9cfe048e7b&amp;name=WINSTON%2CLISA+GAIL&quot;&gt;Winston, Lisa, MD&lt;/a&gt;&lt;/p&gt;
				&lt;/div&gt;
				&lt;br/&gt;
				&lt;div&gt;

					&lt;h3&gt;Department of Public Health&lt;/h3&gt;
					&lt;p&gt;&lt;p&gt;&lt;a href=&quot;http://www.sfhiv.org/research/principal&#45;investigators/phillip&#45;coffin/&quot; target=&quot;new&quot;&gt;Coffin, Phillip, MD&lt;/a&gt;&lt;/p&gt;
			         &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=025124645&amp;name=COHEN%2CSTEPHANIE&quot;&gt;Cohen, Stephanie, MD&lt;/a&gt;&lt;/p&gt;
			         &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=023708225&amp;name=PHILIP%2CSUSAN&quot;&gt;Philip, Susan, MD&lt;/a&gt;&lt;/p&gt;
			        &lt;p&gt;&lt;a href=&quot;/faculty/index.html?key=029387180&amp;name=SCOTTN%2CHYMAN&quot;&gt;Scott, Hyman, MD&lt;/a&gt;&lt;/p&gt;




				&lt;/div&gt;
			&lt;/div&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./id/faculty/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/faculty/index.html</Path>
		<FileBody>

		</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Application Process ./id/fellowship/application.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/application.html</Path>
		<FileBody>

			&lt;p&gt;&lt;strong&gt;The Division of Infectious  Diseases at UCSF participates in ERAS (Electronic Residency Application  Service) and the fellowship match program administered by the National  Residency Matching Program (NRMP).&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;ERAS Application&lt;/strong&gt;&lt;br /&gt;
			  &lt;br /&gt;
			  Instructions for  completing and submitting the ERAS application can be found at&amp;nbsp;&lt;a href=&quot;https://www.aamc.org/students/medstudents/eras/187146/imsub_change.html&quot; target=&quot;_blank&quot;&gt;ERAS application&lt;/a&gt;.&lt;br /&gt;
			  &lt;br /&gt;
			Please be sure to  complete the following items:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;Submit three letters of recommendation, including letters from  your residency training director, research mentor (if applicable), and current  employer (if you have completed residency training)&lt;/li&gt;
			  &lt;li&gt;Submit a concise personal statement of your career goals in Infectious  Diseases, previous research background/training and possible research interests  (if applicable)&lt;/li&gt;
			  &lt;li&gt;Apply to at least one of our two fellowship tracks:&amp;nbsp;Clinical  Educator or Research&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;Requirements for our  fellowship program include a Medical Degree, two&#45;three years of Internal  Medicine residency training in an ACGME accredited program, and US citizenship  or permanent residence status.&lt;br /&gt;
			  &lt;br /&gt;
			Our fellows have diverse  racial, ethnic, and socioeconomic backgrounds. We encourage minorities and  women to apply.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;NRMP Registration&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;All applicants to the Infectious Diseases fellowship program are  required to register with the National Resident Matching Program (NRMP). View  information on how to register and important deadlines at&amp;nbsp;&lt;a href=&quot;http://www.nrmp.org/fellow/schedule.html&quot;&gt;NRMP&lt;/a&gt;.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Calendar (exact dates to be determined)&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;712&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July, 2018&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;550&quot; valign=&quot;top&quot;&gt;&lt;p&gt; ERAS website opens to applicants to begin working on their applications&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July, 2018&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt; UCSF will begin downloading applications for review&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;August, 2018&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt; Interview offers will be sent out to select applicants via email &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;September &#45; October, exact dates TBD&lt;/strong&gt; &lt;/p&gt;
			    &lt;p&gt;&lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;br /&gt;
			      Interviews conducted &lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;TBA&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Rank Order Lists (ROL) due&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;December, 2018&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Match results    available&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July 1, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Fellowship begins&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;strong&gt;&lt;/strong&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Natalie Williams&#45;Munger&lt;/strong&gt;&lt;br&gt;
			      Program Administrator&lt;br&gt;
			      UCSF Division of Infectious Disease&lt;br&gt;
			      513 Parnassus Avenue, Room S&#45;380&lt;br&gt;
			      San Francisco, CA 94143&lt;br&gt;
			      Tel: (415) 476&#45;9363&lt;br&gt;
			      Fax: (415) 476&#45;9364&lt;br&gt;
			    Email: &lt;u&gt;&lt;a href=&quot;mailto:natalie.williams&#45;munger@ucsf.edu&quot;&gt;natalie.williams&#45;munger@ucsf.edu&lt;/a&gt;&lt;/u&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
						&lt;/p&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Application Process ./id/fellowship/application.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/application.html~</Path>
		<FileBody>

			&lt;p&gt;&lt;strong&gt;The Division of Infectious  Diseases at UCSF participates in ERAS (Electronic Residency Application  Service) and the fellowship match program administered by the National  Residency Matching Program (NRMP).&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;ERAS Application&lt;/strong&gt;&lt;br /&gt;
			  &lt;br /&gt;
			  Instructions for  completing and submitting the ERAS application can be found at&amp;nbsp;&lt;a href=&quot;https://www.aamc.org/students/medstudents/eras/187146/imsub_change.html&quot; target=&quot;_blank&quot;&gt;ERAS application&lt;/a&gt;.&lt;br /&gt;
			  &lt;br /&gt;
			Please be sure to  complete the following items:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;Submit three letters of recommendation, including letters from  your residency training director, research mentor (if applicable), and current  employer (if you have completed residency training)&lt;/li&gt;
			  &lt;li&gt;Submit a concise personal statement of your career goals in Infectious  Diseases, previous research background/training and possible research interests  (if applicable)&lt;/li&gt;
			  &lt;li&gt;Apply to at least one of our two fellowship tracks:&amp;nbsp;Clinical  Educator or Research&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;Requirements for our  fellowship program include a Medical Degree, two&#45;three years of Internal  Medicine residency training in an ACGME accredited program, and US citizenship  or permanent residence status.&lt;br /&gt;
			  &lt;br /&gt;
			Our fellows have diverse  racial, ethnic, and socioeconomic backgrounds. We encourage minorities and  women to apply.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;NRMP Registration&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;All applicants to the Infectious Diseases fellowship program are  required to register with the National Resident Matching Program (NRMP). View  information on how to register and important deadlines at&amp;nbsp;&lt;a href=&quot;http://www.nrmp.org/fellow/schedule.html&quot;&gt;NRMP&lt;/a&gt;.&lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Calendar&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;712&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July    6, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;550&quot; valign=&quot;top&quot;&gt;&lt;p&gt; ERAS    website opens to applicants to begin working on their applications&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July 17, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt; UCSF will begin downloading    applications for review&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;By August, 2017 (exact date TBA)&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt; Interview offers will    be sent out to select applicants via email &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;br /&gt;
			        &lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;br /&gt;
			            &lt;strong&gt;Fall 2017&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;br /&gt;
			      Interviews conducted (exact dates pending) &lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;TBA&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Rank Order Lists (ROL) due&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;December, 2017&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Match results    available&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;150&quot; valign=&quot;top&quot;&gt;&lt;p&gt;&lt;strong&gt;July 1, 2018&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;570&quot; valign=&quot;top&quot;&gt;&lt;p&gt;Fellowship begins&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
			&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;strong&gt;&lt;/strong&gt;
			&lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;713&quot;&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Natalie Williams&#45;Munger&lt;/strong&gt;&lt;br&gt;
			      Fellowship Coordinator&lt;br&gt;
			      UCSF Division of Infectious Disease&lt;br&gt;
			      513 Parnassus Avenue, Room S&#45;380&lt;br&gt;
			      San Francisco, CA 94143&lt;br&gt;
			      Tel: (415) 476&#45;9363&lt;br&gt;
			      Fax: (415) 476&#45;9364&lt;br&gt;
			    Email: &lt;u&gt;&lt;a href=&quot;mailto:mauna.minagar@ucsf.edu&quot;&gt;natalie.williams&#45;munger@ucsf.edu&lt;/a&gt;&lt;/u&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br /&gt;
						&lt;/p&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
Program Tracks ./id/fellowship/asictrack.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/asictrack.html</Path>
		<FileBody>
			&lt;img src=&quot;../images/research2.jpg&quot; width=&quot;600&quot;&gt;

			&lt;h3&gt;Antimicrobial Stewardship(AS)/Infection Control(IC) Track:&lt;/h3&gt;
			&lt;p class=&quot;introduction&quot;&gt;The AS/IC Track is available as a 2&#45;year clinical AS/IC track or 3&#45;year research AS/IC track. &lt;/p&gt;
			&lt;p&gt; Both tracks provide advanced training in antimicrobial stewardship and infection control through didactics, hands&#45;on practical training, and scholarly projects. The 3&#45;year research track is designed for fellows interested in advanced training in clinical research through additional coursework/degrees while completing a mentored research project. Applicants interested in the 2&#45;year track would apply via the Clinician Educator Track and the 3&#45;year track via the Research Track in ERAS. Fellows would complete the standard clinical requirements during the first two years of training.  Additional details about this track are outlined below.&lt;/p&gt;


			&lt;table border=1&quot;&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td&gt;&amp;nbsp;&lt;/td&gt;
			&lt;td&gt;&lt;strong&gt;Clinical Track (2 years)&lt;/strong&gt;&lt;/td&gt;
			&lt;td&gt;&lt;strong&gt;Research Track (3 years)&lt;/strong&gt;&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;strong&gt;Formal Coursework&lt;/strong&gt;&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;1&quot;&gt;&lt;em&gt;AS/IC&lt;/em&gt;&lt;/td&gt;
			&lt;td colspan=&quot;2&quot;&gt;Fellows&amp;rsquo; Course on Healthcare Epidemiology, Infection Prevention, Antimicrobial Stewardship&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;em&gt;Leadership&lt;/em&gt;&lt;/td&gt;
			&lt;td colspan=&quot;2&quot;&gt;UCSF&#45;based curriculum will include large and small group learning as well as assigned reading&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;em&gt;QI/High&#45;Value Care&lt;/em&gt;&lt;/td&gt;
			&lt;td colspan=&quot;2&quot;&gt;&lt;a href=&quot;https://www.acponline.org/clinical&#45;information/high&#45;value&#45;care/medical&#45;educators&#45;resources/curriculum&#45;for&#45;subspecialty&#45;fellows&quot; target=&quot;_blank&quot;&gt;AAIM/ACP High Value Care Curriculum for Subspecialty Fellows&lt;/a&gt;&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;em&gt;Research&lt;br /&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;td&gt;&lt;a href=&quot;http://ticr.ucsf.edu/courses/summerworkshop.html&quot; target=&quot;_blank&quot;&gt;Summer Clinical Workshop&lt;/a&gt; (optional)&lt;/td&gt;
			&lt;td&gt;&lt;a href=&quot;https://graduate.ucsf.edu/programs/clinical&#45;cert&quot; target=&quot;_blank&quot;&gt;Advanced Training in Clinical Research&lt;/a&gt;&amp;nbsp;OR Implementation Science Cerificate OR Master's Degree in Clinical Research&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;em&gt;Med Ed (optional)&lt;/em&gt;&lt;/td&gt;
			&lt;td&gt;&lt;a href=&quot;http://meded.ucsf.edu/cfe/educational&#45;skills&#45;workshops&quot; target=&quot;_blank&quot;&gt;UCSF Center for Faculty Educators Teaching Skills Workshops&lt;/a&gt;; &lt;a href=&quot;http://meded.ucsf.edu/hpe&quot; target=&quot;_blank&quot;&gt;Health&#45;Profession Education Pathway&lt;/a&gt;&lt;/td&gt;
			&lt;td&gt;&amp;nbsp;n/a&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;strong&gt;AS/IC hands&#45;on training&lt;/strong&gt;&lt;/td&gt;
			&lt;td colspan=&quot;2&quot;&gt;
			&lt;ul&gt;
			&lt;li&gt;Antimicrobial Stewardship (all sites)
			&lt;ul&gt;
			&lt;li&gt;Prospective audit and feedback of antibiotics o Prior authorization of restricted antibiotics&lt;/li&gt;
			&lt;li&gt;Coordination and promotion of interventions to ensure appropriate use of antibiotics&lt;/li&gt;
			&lt;li&gt;Development of clinical guidelines for antibiotic use&lt;/li&gt;
			&lt;li&gt;Tracking antibiotic use and outcomes related to AS interventions&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/li&gt;
			&lt;li&gt;Infection control (all sites)
			&lt;ul&gt;
			&lt;li&gt;Infection Control meetings&lt;/li&gt;
			&lt;li&gt;Co&#45;lead medical center initiatives o Cluster/contact investigations&lt;/li&gt;
			&lt;li&gt;Drafting/revising infection control policies&lt;/li&gt;
			&lt;li&gt;Working with medical center unit&#45;based leadership teams on various IC&#45;related projects&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/li&gt;
			&lt;li&gt;Mentored literature review of key papers in antimicrobial stewardship and infection control&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td&gt;&lt;strong&gt;Scholarly Work&lt;/strong&gt;&lt;/td&gt;
			&lt;td&gt;Participate in mentored AS/IC scholarly project that may include clinical research, QI, or curriculum design. Dissemination is aspirational.&lt;/td&gt;
			&lt;td&gt;Complete a mentored AS/IC research project while completing rigorous training in research techniques (see above). Dissemination is expected and hopefully will serve as a starting point for career in AS/IC research.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;		</FileBody>
	</node>
	<node>
		<Fname>
Program Tracks ./id/fellowship/clinicaleducator.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/clinicaleducator.html</Path>
		<FileBody>
			&lt;img src=&quot;../images/research3.jpg&quot; width=&quot;600&quot;&gt;

			&lt;h3&gt;Clinical Educator Track&lt;/h3&gt;

			&lt;p class=&quot;introduction&quot;&gt;The  second&#45;year is devoted to (1) enhancing the fellow’s clinical expertise in the care  of immunocompromised hosts (with and without HIV infection), (2) obtaining  formal training in medical education, and (3) engaging in scholarly  activity.&lt;/p&gt;

			&lt;p&gt; The clinical program in the second year includes inpatient time  on the HIV consult service at San Francisco General Hospital as well as additional  dedicated time on the Transplant Infectious Diseases Consult Service at UCSF  Medical Center. Ambulatory experiences include an HIV continuity care  clinic at San Francisco General Hospital (“Ward 86”) as well as Transplant  Infectious Diseases Clinic at UCSF Medical Center.&amp; Formal training in  educational methods may be obtained through the &lt;a href=&quot;http://meded.ucsf.edu/hpe&quot;&gt;Pathways  Program for Health Professions Education&lt;/a&gt;. Scholarly activities include development  of educational curricula, clinical research, writing a scholarly review, and/or  participation in quality improvement projects. Fellows will have access to  internationally renowned medical educators within the Division of Infectious  Diseases and Department of Medicine, as well as the larger UCSF community.&lt;/p&gt;

			&lt;h3&gt; Clinical Educator Pathway FAQs&lt;/h3&gt;

			&lt;ol&gt;
			&lt;li&gt;&lt;strong&gt;How does the first&#45;&amp;shy;year of fellowship differ for the CE Fellow? &lt;/strong&gt;First year of fellowship is the same for CE and Research Tracks.&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;How does the clinical experience in the second year of fellowship differ from the first? &lt;/strong&gt;The second year is very different from the first year; it is focused on the care of the HIV and non&#45;HIV immunocompromised host and training to become a master clinician and educator.
			&lt;ol style=&quot;list&#45;style&#45;type: lower&#45;alpha;&quot;&gt;
			&lt;li&gt;Inpatient clinical experience:
			&lt;ol&gt;
			&lt;li&gt;Transplant ID consult service &#45; 2 months&lt;/li&gt;
			&lt;li&gt;HIV consult service &#45; 2 months&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;Outpatient clinical experience:
			&lt;ol&gt;
			&lt;li&gt;HIV Clinic at ZSFG (&quot;Ward 86&quot;)&lt;/li&gt;
			&lt;li&gt;ID Clinic (General and Transplant) at UCSFMC&lt;/li&gt;
			&lt;li&gt;Other: HIV&#45;HCV Coninfection Clinic (Ward 86), STD, TB, etc.&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;How will the CE fellow learn about medical education? &lt;/strong&gt;Most fellows will apply and be accepted into the Health Professions Education (HPE) Pathway Program, a one&#45;&amp;shy;‐year program dedicated to providing learners with a strong foundational understanding of medical There is a&amp;nbsp;&lt;a href=&quot;http://meded.ucsf.edu/hpe/residents&#45;&quot; target=&quot;_blank&quot;&gt;one&#45;&amp;shy;month intensive in class learning program&lt;/a&gt; and support for an educational research project.&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;&lt;strong&gt;What hands on teaching experiences will the CE fellow have?&lt;/strong&gt;&lt;/strong&gt;
			&lt;ol style=&quot;list&#45;style&#45;type: lower&#45;alpha;&quot;&gt;
			&lt;li&gt;Small group leader during second&#45;&amp;shy;‐year medical student microbiology course&lt;/li&gt;
			&lt;li&gt;Provide didactic lectures on clinical topics for students, residents, and CME courses&lt;/li&gt;
			&lt;li&gt;Dedicated time for teaching residents/students on inpatient rotations&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt; Will the CE fellow be involved in scholarship?&lt;/strong&gt;
			&lt;ol style=&quot;list&#45;style&#45;type: lower&#45;alpha;&quot;&gt;
			&lt;li&gt;CE fellow will be required to generate a scholarly project in medical education to enroll in the HPE Pathway Program&lt;/li&gt;
			&lt;li&gt;CE fellow will be encouraged to take on clinical research projects, case reports, etc. &lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;Will the CE fellow be supported to travel to conferences?&lt;/strong&gt; Yes.
			&lt;ol style=&quot;list&#45;style&#45;type: lower&#45;alpha;&quot;&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.idsociety.org/Fellows_Clinical_Meeting/&quot; target=&quot;_blank&quot;&gt;IDSA Clinical Fellows Meeting&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;ID Week&lt;/li&gt;
			&lt;li&gt;Other depending on research: Western Group on Educational Affairs of the AAMC (WGEA), American Conference for the Treatment of HIV (ACTHIV), etc.&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;Will the&lt;/strong&gt; &lt;strong&gt;CE fellow be able to influence their clinical experience in the second year? &lt;/strong&gt;Yes, there can be flexibility in outpatient and potentially inpatient clinical experiences.&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;&amp;nbsp;What other areas of focus during the clinician educator year would be possible outside of medical education?&lt;/strong&gt;
			&lt;ol style=&quot;list&#45;style&#45;type: lower&#45;alpha;&quot;&gt;
			&lt;li&gt;Infection control&lt;/li&gt;
			&lt;li&gt;Antimicrobial stewardship&lt;/li&gt;
			&lt;li&gt;Quality Improvement&lt;/li&gt;
			&lt;/ol&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;strong&gt;Will&lt;/strong&gt; &lt;strong&gt;the&lt;/strong&gt; &lt;strong&gt;CE fellow be able to stay for a third year? &lt;/strong&gt;This is a two&#45;&amp;shy;year program, the fellow would need to apply and obtain funding to continue training (usually research) during a third year. &lt;/li&gt;
			&lt;/ol&gt;
			&lt;/ol&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
Clinical Experiences ./id/fellowship/clinicalexp.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/clinicalexp.html</Path>
		<FileBody>
			&lt;p&gt;The clinical training at UCSF exposes fellows to a diversity of patients while rotating at UCSF Medical Center, Zuckerberg San Francisco General Hospital, and the San Francisco VA Medical Center. Faculty committed to providing outstanding fellow education lead all three clinical sites. Infectious diseases specialty pharmacists are embedded into all three training sites contributing to a rich learning experience.&lt;/p&gt;

			&lt;p&gt;&lt;strong&gt;UCSF Medical Center&lt;/strong&gt; (UCSFMC) is a quaternary care medical referral center for Northern California. The inpatient infectious diseases teams include the General Infectious Diseases Consult Service and the Immunocompromised Host (Transplant) Infectious Diseases Service. Fellows are exposed to a wide range of infectious diseases in different hosts. UCSFMC is one of the largest solid organ transplant centers in the country. There is also a large hematologic malignancy program where many patients receive hematopoietic stem cell transplantation. Outpatient training experiences at this site include the 360 Wellness Center (the HIV clinic of UCSF Medical Center) and the UCSF Infectious Diseases Clinic.&lt;/p&gt;

			&lt;img src=&quot;../images/parnassus2.jpg&quot; width=&quot;800&quot;&gt;

			&lt;p&gt;&lt;strong&gt;Zuckerberg San Francisco General Hospital&lt;/strong&gt; (ZSFG) is the county hospital of San Francisco and a level&#45;one trauma center. The hospital cares for patients of diverse backgrounds across San Francisco. In the early 1980s, ZSFG physicians were leaders in the care of patients with HIV/AIDS and created the country's first outpatient HIV/AIDS clinics (&quot;Ward 86&quot;) and one of the first dedicated HIV/AIDS inpatient wards. Fellows care for patients both on the ID and HIV inpatient consult services. Many fellows starting in their second year of fellowship have their HIV continuity clinic at &quot;Ward 86&quot;.&lt;/p&gt;

			&lt;img src=&quot;../images/zsfg.jpg&quot; width=&quot;800&quot;&gt;

			&lt;p&gt;&lt;strong&gt;San Francisco VA Medical Center&lt;/strong&gt; (SFVAMC) is a large VA hospital in San Francisco. It is a referral center for veterans care from across Northern California. Fellows work on the inpatient consult service during their first year of fellowship. The HIV clinic at the VA serves as the primary continuity clinic site for fellows during their first year of fellowship.&lt;/p&gt;

			&lt;img src=&quot;../images/vamc.jpg&quot; width=&quot;800&quot;&gt;

			&lt;p&gt;&lt;strong&gt;Other clinical experiences&lt;/strong&gt; include a four&#45;week rotation in the SFVAMC Microbiology Laboratory and four weeks on the Pediatric Infectious Diseases Consult service at the UCSFMC&#45;Mission Bay Campus. Other outpatient experiences include rotations at San Francisco City Clinic (STD clinic of San Francisco) and SF Department of Public Health Tuberculosis Clinic.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./id/fellowship/current.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/current.html</Path>
		<FileBody>


			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;h3&gt;1st&#45;Year Fellows&lt;/h3&gt;
			&lt;ul&gt;
			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../images/fellowprofilepictures/budak_j.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jehan.budak&quot;&gt;Jehan Budak MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Clinical Educator Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/kerkhoff_a.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;150&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/andrew.kerkhoff&quot;&gt;Andrew Kerkhoff, MD, PhD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/mulliken_j.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jennifer.mulliken&quot;&gt;Jennifer Mulliken, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/peluso_m.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;195&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/michael.peluso&quot;&gt;Michael Peluso, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/puryear_s.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/sarah.puryear&quot;&gt;Sarah Puryear, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;

			&lt;h3&gt;2nd&#45;Year Fellows&lt;/h3&gt;
			&lt;table&gt;
			&lt;tbody&gt;

			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../images/fellowprofilepictures/abdoler_e.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Emily Abdoler, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Clinical Educator Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/briggs_jessica.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;188&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jessica.briggs&quot;&gt;Jessica Briggs, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/bystritsky_r.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;193&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.bystritsky&quot;&gt;Rachel Bystritsky, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Antimicrobial Stewardship/Infection Control Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/fung_m.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;163&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/monica.fung&quot;&gt;Monica Fung, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/spinelli_m.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;181&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew.spinelli&quot;&gt;Matthew Spinelli, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;/tbody&gt;
			&lt;/table&gt;

			&lt;h3&gt;Advanced Fellows&lt;/h3&gt;
			&lt;table&gt;
			&lt;tbody&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../images/fellowprofilepictures/clemenzi&#45;allen_angelo.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/angelo.clemenzi&#45;allen&quot;&gt;Angelo (Asa) Clemenzi&#45;Allen, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;e&lt;/tResidency

			&gt;&lt;tr&gt;
			&lt;td style&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style
			=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/mody_aaloke.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;182&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/aaloke.mody&quot;&gt;Aaloke Mody, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/nguyen_david.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;193&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/david&#45;huy.nguyen&quot;&gt;David Nguyen, MD, PhD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/wallender_e.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;209&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/erika.wallender&quot;&gt;Erika Wallender, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../images/fellowprofilepictures/brown_l.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;194&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/lillian.brown&quot;&gt;Lillian Brown, MD, PhD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;

			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/kelly_daniel.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;187&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/john.d.kelly&quot;&gt;Dan Kelly, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../images/fellowprofilepictures/Rusitshauser_r.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;173&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.rutishauser&quot;&gt;Rachel Rutishauser, MD, PhD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./id/fellowship/current.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/current.html~</Path>
		<FileBody>



			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows3.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows4.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;




			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;h3&gt;1st&#45;Year Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Emily Abdoler&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jessica.briggs&quot;&gt;Jessica Briggs&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.bystritsky&quot;&gt;Rachel Bystritsky&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;https://profiles.ucsf.edu/monica.fung&quot;&gt;Monica Fung&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew.spinelli&quot;&gt;Matthew Spinelli&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;


			&lt;h3&gt;2nd&#45;Year Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/angelo.clemenzi&#45;allen&quot;&gt;Angelo (Asa) Clemenzi&#45;Allen&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/aaloke.mody&quot;&gt;Aaloke Mody&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/david&#45;huy.nguyen&quot;&gt;David Nguyen&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/erika.wallender&quot;&gt;Erika Wallender&lt;/a&gt;&lt;/li&gt;

				&lt;/ul&gt;

			&lt;h3&gt;Advanced Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/lillian.brown&quot;&gt;Lillian Brown&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/john.d.kelly&quot;&gt;Dan Kelly&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.rutishauser&quot;&gt;Rachel Rutishauser&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/shereen.katrak&quot;&gt;Shereen Katrak&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/monika.roy&quot;&gt;Monika Roy&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/michael.j.reid&quot;&gt;Michael Reid&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./id/fellowship/current_working.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/current_working.html</Path>
		<FileBody>



			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows3.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/fellows4.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;




			&lt;script type=&quot;text/javascript&quot; src=&quot;https://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;

			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');

			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');

			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }

			    var $next = $active.next();

			    $active.addClass('last&#45;active');

			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}

			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});

			&lt;/script&gt;



			&lt;!&#45;&#45;

			&lt;p&gt; &#45;&#45;&gt;


			&lt;h3&gt;1st&#45;Year Fellows&lt;/h3&gt;

			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../../images/Fellow Profile Pictures/abdoler_e.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Emily Abdoler, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Medical School&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Residency&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Clinical Educator Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;2&quot;&gt;Lorem ipsum dolor sit amet, vim dicunt rationibus ei, at tota iudicabit accommodare vix. Pro fierent democritum eu, et diam veniam temporibus vel. Iisque vivendo vulputate est ne, incorrupte adversarium no his. Sea senserit rationibus intellegam an, augue tritani consulatu usu ne. Oporteat pertinacia sea in, ea has solet splendide scriptorem. Id mel alia posse posidonium, mei ad minim doctus omittantur, falli labores explicari ei vel.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;

			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../../images/Fellow Profile Pictures/briggs_j.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Jessica Briggs, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Medical School&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Residency&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;2&quot;&gt;Lorem ipsum dolor sit amet, vim dicunt rationibus ei, at tota iudicabit accommodare vix. Pro fierent democritum eu, et diam veniam temporibus vel. Iisque vivendo vulputate est ne, incorrupte adversarium no his. Sea senserit rationibus intellegam an, augue tritani consulatu usu ne. Oporteat pertinacia sea in, ea has solet splendide scriptorem. Id mel alia posse posidonium, mei ad minim doctus omittantur, falli labores explicari ei vel.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;

			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../../images/Fellow Profile Pictures/placeholder_photo.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.bystritsky&quot;&gt;Rachel Bystritsky, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Medical School&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Residency&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;2&quot;&gt;Lorem ipsum dolor sit amet, vim dicunt rationibus ei, at tota iudicabit accommodare vix. Pro fierent democritum eu, et diam veniam temporibus vel. Iisque vivendo vulputate est ne, incorrupte adversarium no his. Sea senserit rationibus intellegam an, augue tritani consulatu usu ne. Oporteat pertinacia sea in, ea has solet splendide scriptorem. Id mel alia posse posidonium, mei ad minim doctus omittantur, falli labores explicari ei vel.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;

			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../../images/Fellow Profile Pictures/placeholder_photo.jpg&quot; alt=&quot;&quot; width=&quot;150&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/monica.fung&quot;&gt;Monica Fung, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Medical School&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Residency&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;2&quot;&gt;Lorem ipsum dolor sit amet, vim dicunt rationibus ei, at tota iudicabit accommodare vix. Pro fierent democritum eu, et diam veniam temporibus vel. Iisque vivendo vulputate est ne, incorrupte adversarium no his. Sea senserit rationibus intellegam an, augue tritani consulatu usu ne. Oporteat pertinacia sea in, ea has solet splendide scriptorem. Id mel alia posse posidonium, mei ad minim doctus omittantur, falli labores explicari ei vel.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;

			&lt;table&gt;
			&lt;tbody&gt;
			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img style=&quot;border&#45;width: 0px; float: left;&quot; src=&quot;../../images/Fellow Profile Pictures/spinelli_m.jpg&quot; alt=&quot;&quot; width=&quot;146&quot; height=&quot;175&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew/spinelli&quot;&gt;Matthew Spinelli, MD&lt;/a&gt;&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;em&gt;Medical School&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Residency&lt;/em&gt;&lt;/li&gt;
			&lt;li&gt;&lt;em&gt;Research Track&lt;/em&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
			&lt;td colspan=&quot;2&quot;&gt;Lorem ipsum dolor sit amet, vim dicunt rationibus ei, at tota iudicabit accommodare vix. Pro fierent democritum eu, et diam veniam temporibus vel. Iisque vivendo vulputate est ne, incorrupte adversarium no his. Sea senserit rationibus intellegam an, augue tritani consulatu usu ne. Oporteat pertinacia sea in, ea has solet splendide scriptorem. Id mel alia posse posidonium, mei ad minim doctus omittantur, falli labores explicari ei vel.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/tbody&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;

			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/emily.abdoler&quot;&gt;Emily Abdoler&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jessica.briggs&quot;&gt;Jessica Briggs&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.bystritsky&quot;&gt;Rachel Bystritsky&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;https://profiles.ucsf.edu/monica.fung&quot;&gt;Monica Fung&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew.spinelli&quot;&gt;Matthew Spinelli&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;h3&gt;2nd&#45;Year Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/angelo.clemenzi&#45;allen&quot;&gt;Angelo (Asa) Clemenzi&#45;Allen&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/aaloke.mody&quot;&gt;Aaloke Mody&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/david&#45;huy.nguyen&quot;&gt;David Nguyen&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/erika.wallender&quot;&gt;Erika Wallender&lt;/a&gt;&lt;/li&gt;

				&lt;/ul&gt;

			&lt;h3&gt;Advanced Fellows:&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/lillian.brown&quot;&gt;Lillian Brown&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/john.d.kelly&quot;&gt;Dan Kelly&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rachel.rutishauser&quot;&gt;Rachel Rutishauser&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/shereen.katrak&quot;&gt;Shereen Katrak&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/monika.roy&quot;&gt;Monika Roy&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/michael.j.reid&quot;&gt;Michael Reid&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;

			&lt;h3&gt;And a big welcome to our Incoming 2017&#45;2018 Fellows!&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jehan.budak&quot;&gt;Jehan Budak&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/andrew.kerkhoff&quot;&gt;Andrew Kerkhoff&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jennifer.mulliken&quot;&gt;Jennifer Mulliken&lt;/a&gt;&lt;/li&gt;
			    &lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/michael.peluso&quot;&gt;Michael Peluso&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/sarah.puryear&quot;&gt;Sarah Puryear&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Curriculum ./id/fellowship/curriculum.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/curriculum.html~</Path>
		<FileBody>

			&lt;h3&gt;Statement of Educational Purpose&lt;/h3&gt;

			&lt;p&gt;The primary goal of the UCSF Fellowship in Infectious Diseases is to provide clinical and research training in infectious diseases. Through a combination of structured educational programs, mentored clinical practice rotations, and direct patient care in three unique health care delivery settings, the UCSF training program provides outstanding opportunities for fellows to obtain and demonstrate competence in patient care and the diagnosis, management, and treatment of a wide variety of
			Infectious diseases. Fellows receive intensive clinical training during the first year, which includes: (i) inpatient consultation at three different hospitals, including a dedicated consult service for immunosuppressed patients and a rotation on the pediatric infectious diseases service; (ii) outpatient infectious diseases clinical training, including a weekly HIV/infectious diseases continuity clinic; and (iii) training in clinical microbiology and infection control. Fellows consolidate and refine their patient care skills during the second year with occasional weekend coverage and 2 weeks of inpatient consultation and the continuation of the longitudinal outpatient experience with one outpatient clinic per week. The training curriculum is designed for fellows to obtain competence in patient care at the level expected of a new practitioner by the end of the second year of fellowship.&lt;/p&gt;

			&lt;p&gt;A major goal of the program is to train and develop future leaders in infectious diseases. The program, therefore, encourages a high level of academic performance in its trainees and actively fosters the development of academic infectious diseases physicians who will advance the field and train future physicians. Accordingly, the training program also strongly emphasizes investigative infectious diseases through a combination of structured educational sessions, career development support and mentoring, and the availability of a diverse and experienced group of research mentors within UCSF. &lt;/p&gt;

			&lt;h3&gt;Competency&#45;Based Overall Educational Goals&lt;/h3&gt;

			&lt;p class=&quot;introduction&quot;&gt;The training program fosters and expects fellows to obtain competence in the following areas:&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Patient Care:&lt;/b&gt; The essence of being an infectious diseases specialist is the ability to use data derived about a patient (history, physical examination, laboratory, microbiology, and imaging studies) along with medical knowledge to orderly synthesize a differential diagnosis, plan for further evaluation, and comprehensively manage a patient with an infectious disease. Competence in this area results in care that is compassionate, appropriate, and effective for the treatment of disease and the promotion of health. &lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Medical Knowledge:&lt;/b&gt; Trainees must gain a thorough understanding of established and evolving biomedical, clinical, and epidemiological and social&#45;behavioral sciences relating to infectious diseases and apply this knowledge to patient care. &lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Practice&#45;based Learning and Improvement:&lt;/b&gt; The development of skills in self&#45;directed learning and practice improvement will facilitate the delivery of state&#45;of&#45;the&#45;art, evidence&#45;based patient care that maximizes the likelihood for successful clinical outcomes. Essential components of this competency include the ability to investigate and evaluate patient care, to appraise and assimilate scientific evidence, and to continuously improve patient care based on constant self&#45;evaluation and life&#45;long learning.&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Interpersonal and Communication Skills:&lt;/b&gt; Competency in this area is essential for the formation of a desirable and effective physician&#45;patient relationship, The complexity of most infectious diseases and their management requires a working partnership between patient and physician, and often between physician and the patient's family. Competency in this area also results in the effective exchange of Information and collaboration with other health professionals.&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Professionalism:&lt;/b&gt; Professionalism is one of the foundations of the practice of medicine and is an inherent character trait in a well&#45;rounded infectious diseases physician. Professionalism is manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to patients of diverse backgrounds&lt;/p&gt;

			&lt;p&gt;&lt;b&gt;Systems&#45;based Practice:&lt;/b&gt; Competence in this area reflects an understanding of and responsiveness to the larger context and system of health care, as well as the ability to call effectively on other resources in the system to provide optimal care for patients with infectious diseases.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Former Fellows ./id/fellowship/former.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/former.html</Path>
		<FileBody>

			&lt;ul&gt;
				&lt;li&gt;Juliet Stoltey&lt;/li&gt;
				&lt;li&gt;Anuj Gaggar&lt;/li&gt;
				&lt;li&gt;Jennifer Babik&lt;/li&gt;
				&lt;li&gt;Gabriel Chamie&lt;/li&gt;
				&lt;li&gt;Gabriel Ortiz&lt;/li&gt;
				&lt;li&gt;Prasanna Jagannathan&lt;/li&gt;
				&lt;li&gt;Vivek Jain&lt;/li&gt;
				&lt;li&gt;Chris Keh&lt;/li&gt;
				&lt;li&gt;Oren Rosenberg&lt;/li&gt;
			&lt;/ul&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
Funding Opportunities ./id/fellowship/funding.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/funding.html</Path>
		<FileBody>

			&lt;p&gt;A variety of funding opportunities are available to support research training.  These include T32 training grants awarded to the Division of Infectious Diseases, the Positive Health Program (Division of HIV/AIDS at San Francisco General Hospital, the UCSF Microbial Pathogenesis Program, the Center for AIDS Prevention Studies, and the Department of Clinical Pharmacology.  Other sources of support include post&#45;doctoral training slots funded by individual investigators and fellowship awards form The Giannini foundation, The Doris Duke Charitable Foundation, the Center for AIDS research, and the American Heart Association. &lt;/p&gt;



					</FileBody>
	</node>
	<node>
		<Fname>
History ./id/fellowship/history.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/history.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;The current three hospital based ID fellowship at UCSF was initiated in 1987 by Dr. Richard Locksley, the chief of the ID division at UCSF from 1987 to 2005, when Dr. Joanne Engel became the interim chief and then the subsequent chief of the division.  The program was initially focused almost exclusively on training laboratory&#45;focused infectious disease academic researchers, and subsequently has expanded to have our graduates develop academic careers in clinical research, translational research, and public health. &lt;/p&gt;




					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Program ./id/fellowship/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/index.html</Path>
		<FileBody>
			&lt;img src=&quot;../images/fellows7.jpg&quot; width=&quot;800&quot;&gt;

			&lt;p&gt;The University  of California, San Francisco offers outstanding fellowship training in  Infectious Diseases with great breadth and depth in both clinical infectious  diseases and research. The program offers two tracks, a research track  (four fellows per year) and a clinical educator track (one fellow per  year).&lt;br&gt; &lt;br&gt;All fellows spend the first year of the program immersed in robust  clinical infectious diseases training. Following a two&#45;week intensive  didactic core curriculum, fellows rotate in four&#45;week blocks on inpatient  consult services at three UCSF&#45;affiliated hospitals &#45; UCSF Medical Center, Zuckerberg San  Francisco General, and the San Francisco Veterans Affairs Medical  Center. Teams include fellows, students, residents, infectious  diseases faculty, and infectious diseases specialty pharmacists. Longitudinal outpatient experiences are ongoing throughout the year in  HIV clinics, General and Transplant Infectious Diseases Clinics, San Francisco  Department of Public Health TB Clinic, and the San Francisco Department of  Public Health STD Clinic.&lt;br&gt; &lt;br&gt;Additional educational experiences include  rotating on the Pediatric Infectious Diseases Consult Service at UCSF Benioff  Children’s Hospital and working alongside microbiologists at the San Francisco  Veterans Affairs Medical Center Microbiology Laboratory. Fellows participate in at least two hours per week of teaching conferences. After the first year of training, fellows’ activities differ  depending on the track chosen.&lt;/p&gt;

			&lt;h3&gt;Program Tracks&lt;/h3&gt;
			&lt;ul&gt;
			  &lt;li&gt;&lt;a href=&quot;/fellowship/researchtrack.html&quot;&gt;Research Track&lt;/a&gt;&lt;/li&gt;
			  &lt;li&gt;&lt;a href=&quot;/fellowship/clinicaleducator.html&quot;&gt;Clinical Educator Track&lt;/a&gt;&lt;/li&gt;
			  &lt;li&gt;&lt;a href=&quot;/fellowship/asictrack.html&quot;&gt;Antimicrobial Stewardship(AS) / Infection Control(IC) Track&lt;/a&gt;&lt;/li&gt;

			&lt;/ul&gt;

			&lt;br&gt;

			&lt;h3&gt;Contact Information&lt;/h3&gt;

			&lt;blockquote&gt;&lt;b&gt;Natalie Williams&#45;Munger, M.A.&lt;/b&gt;&lt;br /&gt;
			    Program Administrator&lt;br /&gt;
			    UCSF Division of Infectious Diseases&lt;br /&gt;
			    513 Parnassus Ave, S&#45;380, Box 0654&lt;br /&gt;
			    San Francisco, CA 94143&lt;br /&gt;
			    Tel: (415) 476&#45;9363&lt;br /&gt;
			    Ryan Tel: (415) 502&#45;4831&lt;br/&gt;
			    Fax: (415) 476&#45;9364&lt;br /&gt;
			    Email: &lt;a href=&quot;mailto:natalie.williams&#45;munger@ucsf.edu&quot;&gt;Natalie Williams&#45;Munger&lt;/a&gt;
			&lt;/blockquote&gt;

			&lt;blockquote&gt;&lt;b&gt;Brian Schwartz, M.D.&lt;/b&gt;&lt;br /&gt;
			Program Director&lt;br /&gt;
			UCSF Division of Infectious Diseases&lt;br /&gt;
			Email: &lt;a href=&quot;mailto:brian.schwartz@ucsf.edu&quot;&gt;Brian Schwartz&lt;/a&gt;
			&lt;/blockquote&gt;

			&lt;blockquote&gt;&lt;b&gt;Harry Lampiris, M.D. &lt;/b&gt;&lt;br /&gt;
			Associate Program Director&lt;br /&gt;
			VAMC Division of Infectious Diseases&lt;br /&gt;
			Email: &lt;a href=&quot;mailto:harry.lampiris@va.gov&quot;&gt;Harry Lampiris&lt;/a&gt;
			&lt;/blockquote&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Life in ID Fellowship ./id/fellowship/lifeinidfellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/lifeinidfellowship.html</Path>
		<FileBody>

			&lt;h3&gt;Quotes from ID fellows about life at UCSF and living in the Bay Area&lt;/h3&gt;

			&lt;ul&gt;
			&lt;table&gt;
			&lt;tbody&gt;

			&lt;td &lt;img style=&quot;margin&#45;bottom: 5px; width: 20px;&quot; src=&quot;../images/strictly.jpg&quot; alt=&quot;&quot; width=&quot;200&quot; height=&quot;113&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;img src=&quot;../images/balmy.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;188&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;img src=&quot;../images/ocean_beach.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;187&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;/td&gt;

			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&quot;I'm always stunned by how beautiful the city is. Both from within the streets and from atop the hills, the sites, the smells, the people all encourage a sense of creative potential; it percolates around you, wrapping you in deep allure.&lt;br&gt;&lt;br&gt;Regardless of the fact that I was born and raised across the country, coming back to this place, stepping out of the hospital, or peeking out from behind my computer, I strongly feel a sense of home here.
			&quot;&lt;br&gt;&lt;br&gt;&#45; Asa Clemenzi&#45;Allen, Third&#45;Year Fellow&lt;/br\&gt;&lt;br&gt;&lt;p&gt;&lt;em&gt;&lt;a href=&quot;http://www.balmyalley.com/Welcome.html&quot;&gt;Balmy Alley Murals&lt;/a&gt;&lt;br&gt;&lt;a href=&quot;http://www.parksconservancy.org/visit/park&#45;sites/sutro&#45;historic&#45;district.html&quot;&gt;Sutro Heights Park&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td style=&quot;width: 20px;&quot;&gt;&lt;img src=&quot;../images/aldea.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;259&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;/td&gt;
			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&quot;For me, I think UCSF housing at Aldea was a really great for people arriving with kids.  We felt grateful to have landed there when we were new to SF. There was tons of communal space and shared babysitting/nanny opportunities.  ‘Campus life’ organized activities for the kids like weekend art activities, etc. It has incredibly affordable rent and a beautiful albeit cloud&#45;veiled location!&quot;&lt;br&gt;&lt;br&gt;&#45; Mike Reid, Fourth&#45;Year Fellow&lt;/br\&gt;&lt;br&gt;&lt;p&gt;&lt;em&gt;&lt;a href=&quot;http://campuslifeservices.ucsf.edu/housing/services/on_campus_housing/aldea_san_miguel&quot;&gt;Aldea Housing Info&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;/tr&gt;

			&lt;tr&gt;
			&lt;td &lt;img style=&quot;margin&#45;bottom: 5px; width: 20px;&quot; src=&quot;../images/strictly.jpg&quot; alt=&quot;&quot; width=&quot;200&quot; height=&quot;113&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;img src=&quot;../images/strictly.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;141&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;img src=&quot;../images/fellows_march.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;187&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;/td&gt;


			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&quot;My three favorite things about ID fellowship in San Francisco:
			&lt;br&gt;&lt;br&gt;1. The wonderful cultural events (Hardly Strictly Bluegrass Music Festival, Oakland First Friday, Sunday Streets Festivals, Pride, Cherry Blossom Festival, etc);&lt;br&gt; &lt;br&gt;
			2. The ID division's and my co&#45;fellows's enthusiastic advocacy for science and our patients;
			&lt;br&gt;&lt;br&gt;3. Biking around town!&quot;
			&lt;br&gt;&lt;br&gt;&#45; Erika Wallender, Third&#45;Year Fellow&lt;p&gt;&lt;em&gt;&lt;a href=&quot;http://sf.funcheap.com/event&#45;series/monthly&#45;san&#45;francisco&#45;critical&#45;mass/&quot;&gt;Critical Mass&lt;/a&gt;&lt;br&gt;&lt;a href=&quot;http://www.hardlystrictlybluegrass.com/2016/&quot;&gt;Hardly Strictly Bluegrass&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;td &lt;img style=&quot;margin&#45;bottom: 5px; width: 20px;&quot; src=&quot;../images/strictly.jpg&quot; alt=&quot;&quot; width=&quot;200&quot; height=&quot;113&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;img src=&quot;../images/icecream.png&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;180&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;img src=&quot;../images/cal_academy.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;171&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;/td&gt;


			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&quot;I like the city's walk&#45;ability, incredible parks and playgrounds, and mild weather all contribute to a great environment for kids. Our family's favorite spots include the California Academy of Sciences (get a membership if you can &#45; it's a place your kids will want to return to many times), the public library, getting ice cream (Ice Cream Bar, Bi&#45;Rite, Humphrey Slocombe), and pretty much any public park (Alamo Square, Stow Lake and Golden Gate Park playground, Buena Vista, and many more).&quot; &lt;br&gt; &lt;br&gt;&#45; Shereen Katrak, 2017 Graduate&lt;p&gt;&lt;em&gt;&lt;a href=&quot;http://biritecreamery.com/&quot;&gt;Bi&#45;Rite&lt;/a&gt;&lt;br&gt;&lt;a href=&quot;http://www.calacademy.org/&quot;&gt;California Academy of Sciences&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;/tr&gt;


			&lt;tr&gt;
			&lt;td &lt;img style=&quot;margin&#45;bottom: 5px; width: 20px;&quot; src=&quot;../images/strictly.jpg&quot; alt=&quot;&quot; width=&quot;200&quot; height=&quot;113&quot; style=&quot;border&#45;width: 0px; float: left;&quot; /&gt;&lt;img src=&quot;../images/spinellis.jpg&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;226&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: left;&quot; /&gt;
			&lt;img src=&quot;../images/tomales_spring.png&quot; alt=&quot;&quot; width=&quot;250&quot; height=&quot;235&quot; style=&quot;margin&#45;top: 10px; border&#45;width: 0px; float: righ;&quot; /&gt;
			&lt;/td&gt;


			&lt;td style=&quot;text&#45;align: left;&quot;&gt;
			&lt;p&gt;&quot;This is me and my wife at Marshall Store. I love reserving a table at Hog Island and barbecuing oysters, reserving the tomales bay kayak&#45;in campsites, and having a drink at Nick's Cove in the detached boathouse with wood burning stove. Other great activities include hiking on lands end trail or walking on baker beach after work at the VA.&quot; &lt;br&gt; &lt;br&gt;&#45; Matthew Spinelli, Second&#45;Year Fellow&lt;/p&gt;&lt;em&gt;&lt;a href=&quot;http://www.themarshallstore.com/&quot;&gt;The Marshall Store&lt;/a&gt;&lt;br&gt;&lt;a href=&quot;http://www.parks.ca.gov/?page_id=470&quot;&gt;Tomales Bay State Park&lt;/a&gt;&lt;/em&gt;
			&lt;/td&gt;
			&lt;/tr&gt;


			&lt;/tbody&gt;
			&lt;/table&gt;







		</FileBody>
	</node>
	<node>
		<Fname>
Program Tracks ./id/fellowship/programtracks.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/programtracks.html</Path>
		<FileBody>

			&lt;img src=&quot;../images/fellows8.jpg&quot; width=&quot;600&quot;&gt;

			&lt;h3&gt;Prospective Fellows may apply to one of three different program tracks, depending on their individual research and/or career goals. &lt;/h3&gt;
			&lt;p&gt;Read more about the respective tracks here:&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/fellowship/researchtrack.html&quot;&gt;Research Track&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/fellowship/clinicaleducator.html&quot;&gt;Clinical Educator&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/fellowship/asictrack.html&quot;&gt;Antimicrobial Stewardship/Infection Control&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;

		</FileBody>
	</node>
	<node>
		<Fname>
Recent Graduates ./id/fellowship/recentgraduates.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/recentgraduates.html</Path>
		<FileBody>




			&lt;p class=&quot;introduction&quot;&gt;Among those who have graduated from our training program, many have gone on to pursue careers in academia, public health, medicine, and research. Many choose to continue their career right here at UCSF.

			&lt;br /&gt;&lt;br /&gt;A partial listing (including current institution/organization) includes:&lt;/p&gt;
			&lt;table&gt;

			&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Mike Reid&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
			&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Monika Roy&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
				&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Byrn Boslett&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco

				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Alex Marson&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Sarah Lewis&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Santa Clara County DPH

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Chaz Langelier&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Luke Strnad&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Oregon Health &amp; Science University

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Catherine Koss&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Marc Solomon&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Kasier Permanente

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Melicent Peck&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Genentech &amp; UCSF

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Carina Marquez&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco

			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;David Sears&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco


			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Oren Rosenberg&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Leslie Cockerham&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Medical College of Wisconsin
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Janet Kim&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Stanford University
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Hyman Scott&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;San Francisco DPH &amp; UCSF
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Jonathan Volk&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Kaiser Permanente
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Juliet Stoltey&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;California Department of Public Health
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Sulggi Lee&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Tara Vijayan&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California Los Angeles &lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Prasanna Jagannathan&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Stanford University
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Sarah Doernberg&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Bennett Penn&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, Davis
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Stephanie Cohen&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;San Francisco DPH &amp; UCSF
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Jennifer Babik&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Gabriel Chamie&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Vivek Jain&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of California, San Francisco
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Amy Dechet&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Portland Providence Medical Center &amp;amp; OHSU &lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Dylan Pillain&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;University of Calgary
			&lt;/td&gt;
				&lt;/tr&gt;
					&lt;tr&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Brinda Emu&lt;/td&gt;
					&lt;td bgcolor=&quot;#EFE5CD&quot;&gt;Yale University

					&lt;tr&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;Sanjiv Baxi&lt;/td&gt;
					&lt;td bgcolor=&quot;#F5F6E8&quot;&gt;San Francisco VA Medical Center



			&lt;/table&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Program Tracks ./id/fellowship/researchtrack.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/fellowship/researchtrack.html</Path>
		<FileBody>

			&lt;img src=&quot;../images/research1.jpg&quot; width=&quot;500&quot;&gt;

			&lt;h3&gt;Research Track&lt;/h3&gt;
			&lt;p class=&quot;introduction&quot;&gt; The  second year and beyond are devoted to research in the fellow's area of interest  under the guidance of a faculty preceptor.&lt;/p&gt;
			 &lt;a href=&quot;http://id.medicine.ucsf.edu/research/&quot;&gt;Research training  opportunities&lt;/a&gt; are vast and are available in the fields of clinical, translational, and  basic laboratory sciences. Fellows are guaranteed support for two years  of research, although many go on to pursue additional time in their research  training posititions. Education in research methods may be obtained  through the &lt;a href=&quot;http://sph.berkeley.edu/&quot;&gt;University of California,  Berkeley School of Public Health&lt;/a&gt; Master of Public Health Degree or the UCSF  Department of Epidemiology and Biostatistics via the &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/ATCR.html&quot;&gt;Advanced  Training in Clinical Research Certificate Program&lt;/a&gt; or &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/masters.html&quot;&gt;Master’s  Degree Program in Clinical Research&lt;/a&gt;. Fellows engaged in research are  often supported by one of the following NIH&#45;funded training grants:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;UCSF Biology of Infectious Disease  (PI &#45; Henry Chambers)&lt;/li&gt;
			  &lt;li&gt;Traineeship in AIDS Prevention Studies  (PI &#45; Susan Kegeles)&lt;/li&gt;
			  &lt;li&gt;Training in HIV Translational Research (PI &#45; Diane  Havlir)&lt;/li&gt;
			  &lt;li&gt;Clinical  Pharmacology; Drug Action and Pharmacogenetics (PI &#45; Esteban Burchard)&lt;/li&gt;
			  &lt;li&gt;Microbial Pathogenesis and Host Defense  (PI &#45; Joanne Engel)&lt;/li&gt;
			&lt;/ul&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
Giving ./id/giving/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/giving/index.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Philanthropy plays a crucial role in supporting the activities of the Division of Infectious Diseases. The faculty of the Division of Infectious Diseases provide the best possible care to our patients, conduct leading&#45;edge research and train the next generation of medical professionals. Your gift to the Division of Infectious Diseases will allow us to continue this commitment to excellence.&lt;/p&gt;

			&lt;p&gt;The mission of the UCSF Division of Infectious Diseases is to change the course of deadly diseases through research advances, clinical excellence, and compassionate care. Through our prestigious fellowship programs, we educate the next generation of infectious diseases professionals in shaping the future of diseases. Our faculty publish medical journals and advise decision&#45;makers at the highest levels. We are committed to bringing discoveries to vulnerable and underserved communities in San Francisco and around the world.&lt;/p&gt;
			&lt;p&gt;Private support is vital to every aspect of our work. Philanthropy helps us recruit the most outstanding faculty and trainees.  Gifts from individuals and foundations play a vital role in enhancing our patient care, sustaining our teaching, training, and research mission. Your generosity is the path that leads to future discoveries of diseases and cure. &lt;/p&gt;


			&lt;p&gt;For a look at what some of our researchers are currently investigating, please see below:&lt;/p&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;img src=&quot;http://profiles.ucsf.edu/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=371702&quot; class=&quot;imgLeft&quot; alt=&quot;Dr. Lisa Winston&quot; /&gt;&lt;a href=&quot;http://hospital&#45;sfgh.medicine.ucsf.edu/faculty/?key=ca3370de7011159ea3713f9cfe048e7b&amp;name=WINSTON%2CLISA+GAIL&quot; target=&quot;_blank&quot;&gt;Lisa Winston&lt;/a&gt;, SFGH's Hospital Epidemiologist, is featured in this story regarding whooping cough vaccinations for all pregnant women. The advice comes as an unprecedented number of cases of the highly contagious disease have been reported this year.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/li&gt;
				&lt;li&gt;XIX International AIDS Conference &#45; Washington DC July 22&#45;27, 2012: &lt;a href=&quot;http://www.aids2012.org/&quot; target=&quot;_blank&quot;&gt;www.aids2012.org&lt;/a&gt;.  Dr. Diane Havlir, Chief of the HIV/AIDS Division at SFGH, is US co&#45;chair of this historic conference. This will be the first time in 22 years the U.S. will again host this conference, thanks to the removal of the U.S. travel ban against HIV+ persons.&lt;/li&gt;
			&lt;/ul&gt;

			&lt;p&gt;For a look at some awards that our faculty has recently won, please see below:&lt;/p&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;img src=&quot;http://www.ucsfhealth.org/images/doctors/544.jpg&quot; class=&quot;imgLeft&quot; alt=&quot;Dr. Harry Hollander&quot; /&gt;
					&lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?Person=4949359&quot;&gt;Harry Hollander&lt;/a&gt; was honored as the recipient of the Distinction in Teaching Award for 2012 for faculty in the “Over Five Years” category. &lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;
				&lt;/li&gt;
				&lt;li&gt;
				Congratulations to Drs. Henry (Chip) Chambers and Harry Lampiris for being &lt;a href=&quot;http://medicine.ucsf.edu/news/fom/frontiers.html?key=37&quot; target=&quot;_blank&quot;&gt;awarded&lt;/a&gt; the title of “Master Clinician” at UCSF in 2011.
				&lt;/li&gt;
				&lt;li&gt;&lt;img src=&quot;http://www.ucsfhealth.org/images/doctors/28784.jpg&quot; class=&quot;imgLeft&quot; alt=&quot;Dr. Brian Schwartz&quot; /&gt;Congratulations to &lt;a href=&quot;http://profiles.ucsf.edu/brian.schwartz&quot; target=&quot;_blank&quot;&gt;Dr. Brian Schwartz&lt;/a&gt; for his induction as a new member of the Academy of Medical Educators in August 2012.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;
				&lt;/li&gt;
			&lt;/ul&gt;

			&lt;h2&gt;How You Can Help&lt;/h2&gt;

			&lt;div class=&quot;donate_right_box&quot;&gt;
				&lt;h5&gt;Donate:&lt;/h5&gt;
				&lt;a href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot; target=&quot;_blank&quot;&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/make&#45;a&#45;gift.jpg&quot; style=&quot;border:none;&quot;&gt;&lt;/a&gt;
			&lt;/div&gt;
			&lt;p&gt;There are a variety of ways to support the UCSF Division of Infectious Diseases: pledges; outright gifts; planned giving options; including trusts and bequests; and endowed giving opportunities. Gifts and pledges may support current programs, establish or continue to support a named endowment or provide capital improvements.&lt;/p&gt;
			&lt;p&gt;For further information about giving to the Division of Infectious Diseases, visit &lt;a href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Department%20of%20Medicine&amp;ACode=B1768&quot; target=&quot;_blank&quot;&gt;Support UCSF&lt;/a&gt; or please contact:&lt;/p&gt;


			&lt;blockquote&gt;&lt;b&gt;Olivia Herbert&lt;/b&gt;&lt;br /&gt;
			Executive Director of Development, UCSF&lt;br /&gt;
			220 Montgomery Street, 5th Floor&lt;br /&gt;
			Department of Medicine         &lt;br /&gt;
			University of California, San Francisco  &lt;br /&gt;
			San Francisco, CA 94104&lt;br /&gt;&lt;br /&gt;
			Office Tel: (415) 476&#45;9878&lt;br /&gt;
			Fax: (415) 476&#45;3264&lt;br /&gt;
			Email: &lt;a href=&quot;mailto:oherbert@support.ucsf.edu&quot;&gt;oherbert@support.ucsf.edu&lt;/a&gt;&lt;/blockquote&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
$custom[entity] Search ./id/news/search.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/news/search.html</Path>
		<FileBody>
			/* &lt;![CDATA[ */

			#ucsfheadercontainer {
			  width: 100%;
			  background&#45;color: #000000;
			}
			td{
			    border:hidden;
			padding:1px;
			}


			/* ]]&gt; */
					</FileBody>
	</node>
	<node>
		<Fname>
Global Health ./id/research/global.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/global.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
HPV ./id/research/hpv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/hpv.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Research ./id/research/i2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/i2.html~</Path>
		<FileBody>
			&lt;p&gt;The faculty associated with the Division of Infectious Diseases at UCSF have diverse and complementary research interests in clinical, translational, and basic research. ID faculty have a rich tradition of well&#45;funded grant support as part of the top two NIH&#45;funded departments of medicine in the country. The ID faculty are leading critical studies which include: &lt;a href=&quot;http://mphd.ucsf.edu/&quot; target=&quot;_new&quot;&gt;microbial pathogenesis&lt;/a&gt;, the nature of allergic and inflammatory immunity, the development of microarray and deep sequencing technologies for viral pathogen discovery and clinical diagnostics, and HPV immunology, epidemiology, and clinical trials on HPV disease treatment and prevention. Faculty in our &lt;a href=&quot;http://www.muucsf.org/about.html&quot; target=&quot;_new&quot;&gt;Training in Malarial Research in Uganda Program&lt;/a&gt; study optimal treatment and prevention strategies for malaria control as well as the immunology of malaria and mechanisms of antimalarial drug resistance. Our &lt;a href=&quot;http://hiv.ucsf.edu/research/&quot; target=&quot;_new&quot;&gt;AIDS faculty&lt;/a&gt; are critically evaluating new treatments for HIV and associated complications such as TB and hepatitis, and are looking at novel approaches to HIV care delivery in the US and overseas. As a testament to the rich and collaborative environment here, infectious diseases research at UCSF often transcends traditional disciplines and occurs in a variety of affiliated sites. These range from Mission Bay, Parnassus, the VA Hospital, and San Francisco General Hospital campuses to the San Francisco Department of Public Health, the Center for AIDS Prevention Studies, and the University of California at Berkeley, as well as other countries as part of our global health research program.&lt;/p&gt;
			&lt;h3&gt;Research for fellows&lt;/h3&gt;
			&lt;p&gt;Infectious diseases fellows typically devote most of their time to research starting in the second year of fellowship. A variety of NIH&#45;supported training grants support ID fellows during this period, such as the UCSF Biology of Infectious Disease Training grant, &lt;a href=&quot;http://caps.ucsf.edu/training/taps/&quot; target=&quot;_new&quot;&gt;Traineeship in AIDS Prevention Studies&lt;/a&gt;. Depending on the specific training grant, interested fellows may also undertake coursework at the UC Berkeley School of Public Health (for a Masters of Public Health), as well as the &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/overview.html&quot; target=&quot;_new&quot;&gt;UCSF Department of Epidemiology and Biostatistics and the Clinical and Translational Sciences Institute Training Program&lt;/a&gt; (towards a Certificate Program or a Masters in Clinical Research). In addition to several University&#45;wide and Division&#45;sponsored research colloquia that occur during the year, the Division of Infectious Diseases sponsors an annual Biology of Infectious Diseases research retreat, where fellows and junior faculty present their research works&#45;in&#45;progress to a wide array of faculty and trainees.&lt;/p&gt;
			&lt;p&gt;We recommend that applicants identify potential areas of research prior to the interview. During the interview process, we will attempt to make connections between applicants and potential mentors and research areas of interest. In addition, we hold a variety of sessions prior to and during the first year of fellowship to help fellows choose the appropriate mentorship team and projects. The research mentor then works closely with the mentor assigned from the ID training program to ensure fellows’ success and happiness.&lt;/p&gt;
			&lt;p&gt;A partial list of potential research areas and mentors follows.&lt;/p&gt;

			&lt;h4&gt;Clinical/Translational Research&lt;/h4&gt;
			&lt;b&gt;Chagas disease&lt;/b&gt;
			&lt;ul&gt;&lt;li&gt;Caryn Bern&lt;/li&gt;&lt;/ul&gt;

			&lt;b&gt;Clinical pharmacy&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Conan Macdougall&lt;/li&gt;
				&lt;li&gt;Kathy Yang&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Emerging diseases&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Art Reingold&lt;/li&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Hepatitis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Marion Peters&lt;/li&gt;
				&lt;li&gt;Norah Terrault&lt;/li&gt;
				&lt;li&gt;Phyllis Tien&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV epidemiology&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Moupali Das&lt;/li&gt;
				&lt;li&gt;Hiroyu Hatano&lt;/li&gt;
				&lt;li&gt;Peter Hunt&lt;/li&gt;
				&lt;li&gt;Monica Gandhi&lt;/li&gt;
				&lt;li&gt;Ruth Greenblatt&lt;/li&gt;
				&lt;li&gt;Jeff Martin&lt;/li&gt;
				&lt;li&gt;Elise Riley&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV global health
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Gabriel Chamie&lt;/li&gt;
				&lt;li&gt;Craig Cohen&lt;/li&gt;
				&lt;li&gt;Monica Gandhi&lt;/li&gt;
				&lt;li&gt;Elvin Geng&lt;/li&gt;
				&lt;li&gt;Diane Havlir&lt;/li&gt;
				&lt;li&gt;Vivek Jain&lt;/li&gt;
				&lt;li&gt;Jeff Martin&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV transplant
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Stock&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV treatment
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Steve Deeks&lt;/li&gt;
				&lt;li&gt;Diane Havlir&lt;/li&gt;
				&lt;li&gt;Harry Lampiris&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV prevention
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Susan Buchbinder&lt;/li&gt;
				&lt;li&gt;Al Liu&lt;/li&gt;
				&lt;li&gt;Robert Grant&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Human papillomavirus
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Infection control
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
				&lt;li&gt;Lisa Winston&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Malaria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Grant Dorsey&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Bryan Greenhouse&lt;/li&gt;
				&lt;li&gt;Philip Rosenthal&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Sexually transmitted infections
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Gail Bolan&lt;/li&gt;
				&lt;li&gt;Stephanie Cohen&lt;/li&gt;
				&lt;li&gt;Susan Philip&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;S. aureus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Henry (Chip) Chambers&lt;/li&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Transplant Infectious Disease
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Tropical diseases
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Tuberculosis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Payam Nahid&lt;/li&gt;
				&lt;li&gt;Lee Riley&lt;/li&gt;
			&lt;/ul&gt;


			&lt;h4&gt;Basic Research&lt;/h4&gt;
			&lt;b&gt;Bartonella&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Jane Koehler&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Cryptococcus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Hiten Madhani&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Candida&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Alexander (Sandy) Johnson&lt;/li&gt;
				&lt;li&gt;Suzanne Noble&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Chlamydia&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joanne Engel&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Dengue&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Eva Harris&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Drug discovery (parasites)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jim McKerrow&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;E. Coli&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Carol Gross&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Genomics and pathogen discovery
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe Derisi&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Herpesviruses&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Leor Weinberger&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Hepatitis B
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jody Baron&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Hepatitis C
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Melanie Ott&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Histoplasma&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Anita Sil&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;HIV&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Paul Baum&lt;/li&gt;
				&lt;li&gt;Charles Craik&lt;/li&gt;
				&lt;li&gt;Steve Deeks&lt;/li&gt;
				&lt;li&gt;Gilad Doitsh&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Alan Frankel&lt;/li&gt;
				&lt;li&gt;Robert Grant&lt;/li&gt;
				&lt;li&gt;Warner Greene&lt;/li&gt;
				&lt;li&gt;Nevan Krogan&lt;/li&gt;
				&lt;li&gt;Jay Levy&lt;/li&gt;
				&lt;li&gt;Mike McCune&lt;/li&gt;
				&lt;li&gt;Doug Nixon&lt;/li&gt;
				&lt;li&gt;Melanie Ott&lt;/li&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
				&lt;li&gt;Shomyseh Sanjabi&lt;/li&gt;
				&lt;li&gt;Leor Weinberger&lt;/li&gt;
				&lt;li&gt;Joseph Wong&lt;/li&gt;
				&lt;li&gt;Eric Verdin&lt;/li&gt;
				&lt;li&gt;Steven Yukl&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Human papillomavirus
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
				&lt;li&gt;Sharof Tugizov&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Immunology&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Mark Anderson&lt;/li&gt;
				&lt;li&gt;Mark Ansel&lt;/li&gt;
				&lt;li&gt;Jason Cyster&lt;/li&gt;
				&lt;li&gt;Anthony DeFranco&lt;/li&gt;
				&lt;li&gt;Laurence Fong&lt;/li&gt;
				&lt;li&gt;Matthew (Max) Krummel&lt;/li&gt;
				&lt;li&gt;Lewis Lanier&lt;/li&gt;
				&lt;li&gt;Clifford Lowell&lt;/li&gt;
				&lt;li&gt;Richard Locksley&lt;/li&gt;
				&lt;li&gt;Averil Ma&lt;/li&gt;
				&lt;li&gt;Philip Norris&lt;/li&gt;
				&lt;li&gt;Jeroen Roose&lt;/li&gt;
				&lt;li&gt;Eric Verdin&lt;/li&gt;
				&lt;li&gt;Arthur Weiss&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Leishmania&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Richard Locksley&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Listeria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Anna Bakardjiev&lt;/li&gt;
				&lt;li&gt;Dan Portnoy&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Malaria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
				&lt;li&gt;Grant Dorsey&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Bryan Greenhouse&lt;/li&gt;
				&lt;li&gt;Charlie Kim&lt;/li&gt;
				&lt;li&gt;Philip Rosenthal&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Microbiota&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
				&lt;li&gt;Michael Fischbach&lt;/li&gt;
				&lt;li&gt;Susan Lynch&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Neglected tropical diseases
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jim McKerrow&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Poliovirus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Raul Andino&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Pseudomonas&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joanne Engel&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;S. aureus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Henry (Chip) Chambers&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Streptococci&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Paul Sullam&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Tuberculosis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Jeffery Cox&lt;/li&gt;
				&lt;li&gt;Paul Ortiz de Montellano&lt;/li&gt;
				&lt;li&gt;Lee Riley&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Viral discovery
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Viral transcription regulation (non&#45;HIV)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;JJ Miranda&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Viral vaccine development (non&#45;HIV)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Mary Premenko&#45;Lanier&lt;/li&gt;
			&lt;/ul&gt;
			&lt;h4&gt;Education&lt;/h4&gt;
			&lt;ul&gt;
				&lt;li&gt;Jennifer Babik&lt;/li&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Harry Hollander&lt;/li&gt;
				&lt;li&gt;Harry Lampiris&lt;/li&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Immunology ./id/research/immunology.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/immunology.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Research ./id/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/index.html</Path>
		<FileBody>
			&lt;p&gt;The faculty associated with the Division of Infectious Diseases at UCSF have diverse and complementary research interests in clinical, translational, and basic research. ID faculty have a rich tradition of well&#45;funded grant support as part of the top two NIH&#45;funded departments of medicine in the country. The ID faculty are leading critical studies which include: &lt;a href=&quot;http://mphd.ucsf.edu/&quot; target=&quot;_new&quot;&gt;microbial pathogenesis&lt;/a&gt;, the nature of allergic and inflammatory immunity, the development of microarray and deep sequencing technologies for viral pathogen discovery and clinical diagnostics, and HPV immunology, epidemiology, and clinical trials on HPV disease treatment and prevention. Faculty in our &lt;a href=&quot;http://www.muucsf.org/about.html&quot; target=&quot;_new&quot;&gt;Training in Malarial Research in Uganda Program&lt;/a&gt; study optimal treatment and prevention strategies for malaria control as well as the immunology of malaria and mechanisms of antimalarial drug resistance. Our &lt;a href=&quot;http://hiv.ucsf.edu/research/&quot; target=&quot;_new&quot;&gt;AIDS faculty&lt;/a&gt; are critically evaluating new treatments for HIV and associated complications such as TB and hepatitis, and are looking at novel approaches to HIV care delivery in the US and overseas. As a testament to the rich and collaborative environment here, infectious diseases research at UCSF often transcends traditional disciplines and occurs in a variety of affiliated sites. These range from Mission Bay, Parnassus, the VA Hospital, and San Francisco General Hospital campuses to the San Francisco Department of Public Health, the Center for AIDS Prevention Studies, and the University of California at Berkeley, as well as other countries as part of our global health research program.&lt;/p&gt;
			&lt;h3&gt;Research for fellows&lt;/h3&gt;
			&lt;p&gt;Infectious diseases fellows typically devote most of their time to research starting in the second year of fellowship. A variety of NIH&#45;supported training grants support ID fellows during this period, such as the UCSF Biology of Infectious Disease Training grant, &lt;a href=&quot;http://caps.ucsf.edu/training/taps/&quot; target=&quot;_new&quot;&gt;Traineeship in AIDS Prevention Studies&lt;/a&gt;. Depending on the specific training grant, interested fellows may also undertake coursework at the UC Berkeley School of Public Health (for a Masters of Public Health), as well as the &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/overview.html&quot; target=&quot;_new&quot;&gt;UCSF Department of Epidemiology and Biostatistics and the Clinical and Translational Sciences Institute Training Program&lt;/a&gt; (towards a Certificate Program or a Masters in Clinical Research). In addition to several University&#45;wide and Division&#45;sponsored research colloquia that occur during the year, the Division of Infectious Diseases sponsors an annual Biology of Infectious Diseases research retreat, where fellows and junior faculty present their research works&#45;in&#45;progress to a wide array of faculty and trainees.&lt;/p&gt;
			&lt;p&gt;We recommend that applicants identify potential areas of research prior to the interview. During the interview process, we will attempt to make connections between applicants and potential mentors and research areas of interest. In addition, we hold a variety of sessions prior to and during the first year of fellowship to help fellows choose the appropriate mentorship team and projects. The research mentor then works closely with the mentor assigned from the ID training program to ensure fellows’ success and happiness.&lt;/p&gt;
			&lt;p&gt;A partial list of potential research areas and mentors follows.&lt;/p&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Research ./id/research/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/index.html~</Path>
		<FileBody>
			&lt;p&gt;The faculty associated with the Division of Infectious Diseases at UCSF have diverse and complementary research interests in clinical, translational, and basic research. ID faculty have a rich tradition of well&#45;funded grant support as part of the top two NIH&#45;funded departments of medicine in the country. The ID faculty are leading critical studies which include: &lt;a href=&quot;http://mphd.ucsf.edu/&quot; target=&quot;_new&quot;&gt;microbial pathogenesis&lt;/a&gt;, the nature of allergic and inflammatory immunity, the development of microarray and deep sequencing technologies for viral pathogen discovery and clinical diagnostics, and HPV immunology, epidemiology, and clinical trials on HPV disease treatment and prevention. Faculty in our &lt;a href=&quot;http://www.muucsf.org/about.html&quot; target=&quot;_new&quot;&gt;Training in Malarial Research in Uganda Program&lt;/a&gt; study optimal treatment and prevention strategies for malaria control as well as the immunology of malaria and mechanisms of antimalarial drug resistance. Our &lt;a href=&quot;http://hiv.ucsf.edu/research/&quot; target=&quot;_new&quot;&gt;AIDS faculty&lt;/a&gt; are critically evaluating new treatments for HIV and associated complications such as TB and hepatitis, and are looking at novel approaches to HIV care delivery in the US and overseas. As a testament to the rich and collaborative environment here, infectious diseases research at UCSF often transcends traditional disciplines and occurs in a variety of affiliated sites. These range from Mission Bay, Parnassus, the VA Hospital, and San Francisco General Hospital campuses to the San Francisco Department of Public Health, the Center for AIDS Prevention Studies, and the University of California at Berkeley, as well as other countries as part of our global health research program.&lt;/p&gt;
			&lt;h3&gt;Research for fellows&lt;/h3&gt;
			&lt;p&gt;Infectious diseases fellows typically devote most of their time to research starting in the second year of fellowship. A variety of NIH&#45;supported training grants support ID fellows during this period, such as the UCSF Biology of Infectious Disease Training grant, &lt;a href=&quot;http://caps.ucsf.edu/training/taps/&quot; target=&quot;_new&quot;&gt;Traineeship in AIDS Prevention Studies&lt;/a&gt;. Depending on the specific training grant, interested fellows may also undertake coursework at the UC Berkeley School of Public Health (for a Masters of Public Health), as well as the &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/overview.html&quot; target=&quot;_new&quot;&gt;UCSF Department of Epidemiology and Biostatistics and the Clinical and Translational Sciences Institute Training Program&lt;/a&gt; (towards a Certificate Program or a Masters in Clinical Research). In addition to several University&#45;wide and Division&#45;sponsored research colloquia that occur during the year, the Division of Infectious Diseases sponsors an annual Biology of Infectious Diseases research retreat, where fellows and junior faculty present their research works&#45;in&#45;progress to a wide array of faculty and trainees.&lt;/p&gt;
			&lt;p&gt;We recommend that applicants identify potential areas of research prior to the interview. During the interview process, we will attempt to make connections between applicants and potential mentors and research areas of interest. In addition, we hold a variety of sessions prior to and during the first year of fellowship to help fellows choose the appropriate mentorship team and projects. The research mentor then works closely with the mentor assigned from the ID training program to ensure fellows’ success and happiness.&lt;/p&gt;
			&lt;p&gt;A partial list of potential research areas and mentors follows.&lt;/p&gt;

			&lt;h4&gt;Clinical/Translational Research&lt;/h4&gt;
			&lt;b&gt;Chagas disease&lt;/b&gt;
			&lt;ul&gt;&lt;li&gt;Caryn Bern&lt;/li&gt;&lt;/ul&gt;

			&lt;b&gt;Clinical pharmacy&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Conan Macdougall&lt;/li&gt;
				&lt;li&gt;Kathy Yang&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Emerging diseases&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Art Reingold&lt;/li&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe DeRisis&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Hepatitis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Marion Peters&lt;/li&gt;
				&lt;li&gt;Norah Terrault&lt;/li&gt;
				&lt;li&gt;Phyllis Tien&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV epidemiology&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Moupali Das&lt;/li&gt;
				&lt;li&gt;Hiroyu Hatano&lt;/li&gt;
				&lt;li&gt;Peter Hunt&lt;/li&gt;
				&lt;li&gt;Monica Gandhi&lt;/li&gt;
				&lt;li&gt;Ruth Greenblatt&lt;/li&gt;
				&lt;li&gt;Jeff Martin&lt;/li&gt;
				&lt;li&gt;Elise Riley&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV global health
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Gabriel Chamie&lt;/li&gt;
				&lt;li&gt;Craig Cohen&lt;/li&gt;
				&lt;li&gt;Monica Gandhi&lt;/li&gt;
				&lt;li&gt;Elvin Geng&lt;/li&gt;
				&lt;li&gt;Diane Havlir&lt;/li&gt;
				&lt;li&gt;Vivek Jain&lt;/li&gt;
				&lt;li&gt;Jeff Martin&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV transplant
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Stock&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV treatment
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Steve Deeks&lt;/li&gt;
				&lt;li&gt;Diane Havlir&lt;/li&gt;
				&lt;li&gt;Harry Lampiris&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;HIV prevention
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Susan Buchbinder&lt;/li&gt;
				&lt;li&gt;Al Liu&lt;/li&gt;
				&lt;li&gt;Robert Grant&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Human papillomavirus
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Infection control
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
				&lt;li&gt;Lisa Winston&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Malaria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Grant Dorsey&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Bryan Greenhouse&lt;/li&gt;
				&lt;li&gt;Philip Rosenthal&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Sexually transmitted infections
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Gail Bolan&lt;/li&gt;
				&lt;li&gt;Stephanie Cohen&lt;/li&gt;
				&lt;li&gt;Susan Philip&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;S. aureus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Henry (Chip) Chambers&lt;/li&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Transplant Infectious Disease
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Catherine Liu&lt;/li&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Tropical diseases
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Tuberculosis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Payam Nahid&lt;/li&gt;
				&lt;li&gt;Lee Riley&lt;/li&gt;
			&lt;/ul&gt;


			&lt;h4&gt;Basic Research&lt;/h4&gt;
			&lt;b&gt;Bartonella&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Jane Koehler&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Cryptococcus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Hiten Madhani&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Candida&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Alexander (Sandy) Johnson&lt;/li&gt;
				&lt;li&gt;Suzanne Noble&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Chlamydia&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joanne Engel&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Dengue&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Eva Harris&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Drug discovery (parasites)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jim McKerrow&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;E. Coli&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Carol Gross&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Genomics and pathogen discovery
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe Derisi&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Herpesviruses&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Leor Weinberger&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Hepatitis B
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jody Baron&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Hepatitis C
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Melanie Ott&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Histoplasma&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Anita Sil&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;HIV&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Paul Baum&lt;/li&gt;
				&lt;li&gt;Charles Craik&lt;/li&gt;
				&lt;li&gt;Steve Deeks&lt;/li&gt;
				&lt;li&gt;Gilad Doitsh&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Alan Frankel&lt;/li&gt;
				&lt;li&gt;Robert Grant&lt;/li&gt;
				&lt;li&gt;Warner Greene&lt;/li&gt;
				&lt;li&gt;Nevan Krogan&lt;/li&gt;
				&lt;li&gt;Jay Levy&lt;/li&gt;
				&lt;li&gt;Mike McCune&lt;/li&gt;
				&lt;li&gt;Doug Nixon&lt;/li&gt;
				&lt;li&gt;Melanie Ott&lt;/li&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
				&lt;li&gt;Shomyseh Sanjabi&lt;/li&gt;
				&lt;li&gt;Leor Weinberger&lt;/li&gt;
				&lt;li&gt;Joseph Wong&lt;/li&gt;
				&lt;li&gt;Eric Verdin&lt;/li&gt;
				&lt;li&gt;Steven Yukl&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Human papillomavirus
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Joel Palefsky&lt;/li&gt;
				&lt;li&gt;Sharof Tugizov&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Immunology&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Mark Anderson&lt;/li&gt;
				&lt;li&gt;Mark Ansel&lt;/li&gt;
				&lt;li&gt;Jason Cyster&lt;/li&gt;
				&lt;li&gt;Anthony DeFranco&lt;/li&gt;
				&lt;li&gt;Laurence Fong&lt;/li&gt;
				&lt;li&gt;Matthew (Max) Krummel&lt;/li&gt;
				&lt;li&gt;Lewis Lanier&lt;/li&gt;
				&lt;li&gt;Clifford Lowell&lt;/li&gt;
				&lt;li&gt;Richard Locksley&lt;/li&gt;
				&lt;li&gt;Averil Ma&lt;/li&gt;
				&lt;li&gt;Philip Norris&lt;/li&gt;
				&lt;li&gt;Jeroen Roose&lt;/li&gt;
				&lt;li&gt;Eric Verdin&lt;/li&gt;
				&lt;li&gt;Arthur Weiss&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Leishmania&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Richard Locksley&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Listeria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Anna Bakardjiev&lt;/li&gt;
				&lt;li&gt;Dan Portnoy&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Malaria&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
				&lt;li&gt;Grant Dorsey&lt;/li&gt;
				&lt;li&gt;Margaret Feeney&lt;/li&gt;
				&lt;li&gt;Bryan Greenhouse&lt;/li&gt;
				&lt;li&gt;Charlie Kim&lt;/li&gt;
				&lt;li&gt;Philip Rosenthal&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Microbiota&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
				&lt;li&gt;Michael Fischbach&lt;/li&gt;
				&lt;li&gt;Susan Lynch&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Neglected tropical diseases
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Jim McKerrow&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Poliovirus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Raul Andino&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Pseudomonas&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Joanne Engel&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;S. aureus&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Henry (Chip) Chambers&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Streptococci&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Paul Sullam&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Tuberculosis&lt;/b&gt;
			&lt;ul&gt;
				&lt;li&gt;Jeffery Cox&lt;/li&gt;
				&lt;li&gt;Paul Ortiz de Montellano&lt;/li&gt;
				&lt;li&gt;Lee Riley&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Viral discovery
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Charles Chiu&lt;/li&gt;
				&lt;li&gt;Joe DeRisi&lt;/li&gt;
			&lt;/ul&gt;

			&lt;b&gt;Viral transcription regulation (non&#45;HIV)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;JJ Miranda&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;Viral vaccine development (non&#45;HIV)
			&lt;/b&gt;&lt;ul&gt;
				&lt;li&gt;Mary Premenko&#45;Lanier&lt;/li&gt;
			&lt;/ul&gt;
			&lt;h4&gt;Education&lt;/h4&gt;
			&lt;ul&gt;
				&lt;li&gt;Jennifer Babik&lt;/li&gt;
				&lt;li&gt;Peter Chin&#45;Hong&lt;/li&gt;
				&lt;li&gt;Harry Hollander&lt;/li&gt;
				&lt;li&gt;Harry Lampiris&lt;/li&gt;
				&lt;li&gt;Brian Schwartz&lt;/li&gt;
			&lt;/ul&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Microbial Pathology ./id/research/microbial.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/microbial.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Pathogen Discovery ./id/research/pathogen.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/pathogen.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Translational ./id/research/translational.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/translational.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Open Clinical Trials ./id/research/trials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/research/trials.html</Path>
		<FileBody>

			&lt;p class=&quot;introduction&quot;&gt;Content goes here.&lt;/p&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
About Us ./id/x/about.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/about.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;


			Dr. Palefsky is Professor of Medicine at UCSF and Program Director of the UCSF/Moffitt General Clinical Research Center. A native of Montreal, Canada and graduate of the McGill University School of Medicine, Dr. Palefsky was a resident in Internal Medicine at McGill University and did his fellowship in Infectious Diseases at Stanford University. He is the Director of the world's first clinic devoted to anal dysplasia, the Anal Dysplasia Clinic at the UCSF Cancer Center.  His research focus is on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections. He is an internationally recognized expert in the manifestations of HPV infection and precancerous disease in the anus and has performed many of the pioneering studies in this field.  He is active in HPV vaccine research.  He is the head of the HPV Working Group of the AIDS Malignancy Consortium, the Program Leader of the Doris Duke Charitable Foundation Clinical Research Fellowship for Medical Students at UCSF and the Program Leader of the UCSF Roadmap T32 predoctoral clinical/translational research program.  He is the author of over 140 publications and a Time&#45;Warner Book entitled &quot;What your doctor may not tell you about HPV and abnormal Pap smears,&quot; a book about HPV for the general public.&lt;/p&gt;


			Dr. Berry is an Associate Clinical Professor of Medicine at UCSF in the Division of Hematology Oncology.  Born in Chicago, but raised in Miami, Florida, he graduated from the University of Miami School of Medicine in 1982.  Dr. Berry was a resident in Internal Medicine at UCSF and completed his fellowship in Medical Oncology at Stanford University in 1989.  In 1993, when Naomi Jay took several months off after the birth of her son, he joined Dr. Palefsky and Naomi in the UCSF Anal Neoplasia Study.  What was supposed to be a commitment for a few months has now turned into a lifetime career.  The group has pioneered the use of high&#45;resolution anoscopy (HRA) as a way of managing patients with anal squamous intraepithelial lesions (ASIL).  Michael Berry and Naomi Jay are the Associate Directors of HPV&#45;Related Clinical Studies and have been the primary clinicians for the natural history study, vaccine trials, evaluation of infrared coagulation, and also evaluation of Traditional Chinese Medicine as a treatment for anal HSIL.  Together they maintain a busy clinical practice in the UCSF Anal Dysplasia Clinic and are committed to training clinicians to become proficient in HRA.  Dr. Berry's clinical interest has been in developing the use of HRA in the operating room to optimize the surgical treatment of ASIL.  He is an active member of the HPV Working Group of the AIDS Malignancy Consortium.&lt;/p&gt;


			Naomi Jay is a nurse practitioner in the UCSF Division of Medicine.  A New Yorker by birth, she completed high school in Milwaukee, Wisconsin, and her undergraduate work at McGill University in Montreal.  After a 5&#45;year sojourn in Israel growing wine grapes on Kibbutz Gezer, she attended graduate school at the Massachusetts General Hospital Institute of Health Professions where she received a Masters in Nursing, specializing in Women's Health in 1989. She then completed her doctorate in nursing at UCSF in 2007.  Since 1991 she has worked in San Francisco with Drs. Palefsky and Berry, pioneering the use of the colposcope in the detection and diagnosis of HPV&#45;related diseases in the anal canal.  She has also worked in cervical HPV clinical studies of adolescents and young women.  She currently divides her time between a busy practice in the UCSF Dysplasia Clinic, where she is a provider of colposcopy and high&#45;resolution anoscopy, and HPV&#45;related research trials which have included the natural history of HPV&#45;related anal disease in men and women, and  treatment studies using vaccines, infrared coagulation, and topical medications. Dr. Jay has a particular interest in the use of Traditional Chinese Medicine and other alternative therapies and has worked on several studies evaluating the efficacy of TCM creams for treatment of anal dysplasia.  In her spare time she gardens.&lt;/p&gt;


			Dr. Mary Rubin is an Associate Clinical Professor at UCSF in the Department of OB/Gyn and the School of Nursing. She is also a Research Coordinator for Gyn Oncology/Dysplasia Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Rubin pioneered the role of the nurse colposcopist in the 1970's and has practiced as a nurse practitioner since then. She is a fellow in the American Academy of Nurse Practitioners. She joined the anal neoplasia group in 2006. She received her diploma from Johnstown Mercy Hospital School of Nursing and her BSN, MSN, and PhD from the University of Pennsylvania. She has been a clinician, educator, and researcher in the field of Health Care of Women and disease of the lower genital tract for the past 40 years.&lt;/p&gt;


			Fred Fishman first came to the HPV research group as a patient.  He has been the project assistant and clinical coordinator for UCSF's HPV related studies since 1999.  He brings broad administrative, operational, and project management skills from twelve years in the computer industry as a senior analyst.  He has always been interested in biology and holds a BS in botany, Magna Cum Laude, from the University of Maryland, and has volunteered as a botanist with the California Nature Conservancy and California Academy of Sciences.&lt;br clear=all&gt;&lt;p&gt;


			Marya Krogstad has been a clinical research nurse and study coordinator for the UCSF HPV anal dysplasia treatment studies since 2000.  She really enjoys meeting with the study volunteers and working with her caring clinical team.  Previous nursing experiences include HIV clinical trials and AIDS nursing.&lt;/p&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/all_providers.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/all_providers.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/all_providers.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/all_providers.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Contact Us ./id/x/contact.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/contact.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin:64px;&quot;&gt;&lt;b&gt;To make an appointment to be seen in the UCSF Dysplasia Clinic, please call the clinic main desk at (415) 353&#45;7100.&lt;/b&gt;&lt;/p&gt;

			&lt;hr color=#B33700 size=1px width=75%&gt;&lt;br&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:64px;margin&#45;top:24px;&quot;&gt;For all other questions, please contact:&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:76px;&quot;&gt;Rachel Silverstein&lt;br&gt;
			(415) 353&#45;7443&lt;br&gt;
			&lt;a href=&quot;mailto:Rachel.Silverstein@ucsf.edu&quot;&gt;Silverstein, Rachel&lt;/a&gt;&lt;/p&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;br&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
handler.html ./id/x/handler.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/handler.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
handler.html~ ./id/x/handler.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/handler.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Welcome ./id/x/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;Welcome to the Anal Cancer Information website! This website is designed to provide patients and their doctors with some of the latest information on anal cancer, its likely precursor, anal intraepithelial neoplasia (AIN), and the virus that we believe to be responsible for AIN and anal cancer, human papillomavirus (HPV).  HPV is also the cause of warts.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Anal cancer is a growing problem in the United States and many other developed countries.  Like cancer of the cervix, it is caused by HPV.  As you will learn by going to different links, HPV infection of the anal canal is surprisingly common.  Anal HPV infection is most commonly acquired through anal intercourse, but it can also be acquired from other genital areas that are infected, particularly from the vulva in women, or from the penis in men.   Fingers, toys, etc, can probably lead to anal HPV infection as well.  Our research tells us that sexually active individuals, both men and women, may be at risk.  The good news is that only a fraction of people with anal HPV infection will develop a lasting case of AIN, and even fewer will develop anal cancer.  Men and women who are immunocompromised by human immunodeficiency virus (HIV) infection, organ transplant or other reasons are at especially high risk.  So who should be interested in this website?&lt;/p&gt;

			&lt;ul&gt;
			&lt;li class=&quot;aci&quot;&gt;Men and women with a history of anal intercourse
			&lt;li class=&quot;aci&quot;&gt;Men and women with a history of perianal (outside the anus) or vulvar
			warts
			&lt;li class=&quot;aci&quot;&gt;Men and women who are immunocompromised, such as those who are HIV positive, or have received organ transplants
			&lt;/ul&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;This website was made possible by the generous support of the American Cancer Society.  It is designed to tell patients and their doctors about:&lt;/p&gt;

			&lt;ul&gt;
			&lt;li class=&quot;aci&quot;&gt;Who is at risk for anal HPV infection, AIN and anal cancer
			&lt;li class=&quot;aci&quot;&gt;Who should be screened for AIN and anal cancer
			&lt;li class=&quot;aci&quot;&gt;How screening should be performed
			&lt;li class=&quot;aci&quot;&gt;How AIN and anal cancer can be treated
			&lt;li class=&quot;aci&quot;&gt;Names and contact information of clinicians around the United States and Canada with experience treating AIN
			&lt;/ul&gt;

			&lt;p class=&quot;aci&quot; align=center&gt;&lt;img src=&quot;/analcancerinfo/images/ucsfart452.jpg&quot;&gt;&lt;br&gt;&lt;font style=&quot;color:#666666;font&#45;style:italic;font&#45;size:10px;&quot;&gt;Artistic representation of anal neoplasia by artist Danny Tague&lt;/font&gt;&lt;/p&gt;

			&lt;hr color=#B33700 size=1px width=75%&gt;&lt;br&gt;


			&lt;table border=0 align=center cellpadding=0 cellspacing=0 bgcolor=#99bbcc style=&quot;margin&#45;left:13px;margin&#45;right:13px;&quot;&gt;
			&lt;tr&gt;&lt;td width=12&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/99bbcc&#45;topleft&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td width=12&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/99bbcc&#45;topright&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;

			&lt;big&gt;&lt;b&gt;Who Are We?&lt;/b&gt;&lt;/big&gt;&lt;p&gt;

			&lt;div style=&quot;margin&#45;left:12px;margin&#45;right:12px;&quot;&gt;
			&lt;p class=&quot;aci&quot;&gt;&lt;img src=&quot;/analcancerinfo/images/acs99.jpg&quot; align=right&gt;This website is the creation of a team of highly dedicated clinicians and scientists at the UCSF Comprehensive Cancer Center.  The group, led by Dr. Joel Palefsky, Professor of Medicine at UCSF, is devoted to performing research to promote awareness of and screening for AIN and anal cancer, identify the causes of AIN and anal cancer, and develop new and better therapies for these diseases.  Through their activities at the Anal Neoplasia Clinic of the UCSF Comprehensive Cancer Center, they provide state of the art care for men and women with AIN and anal cancer.  Through this website and other tools the group works to educate patients and their doctors about AIN and anal cancer.  As you navigate through this website, we welcome your &lt;a href=&quot;mailto:Fred.Fishman@ucsf.edu&quot;&gt;comments and feedback&lt;/a&gt;.&lt;/p&gt;
			&lt;/div&gt;

			&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/99bbcc&#45;bottomleft&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;img src=&quot;/sites/infectiousdiseases.ucsf.edu/files/images/common/99bbcc&#45;bottomright&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;&lt;br clear=all&gt;&lt;p&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/p2.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/p2.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/p2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/p2.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/providers.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/providers.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;The following physicians and nurse practitioners have indicated an interest in being listed as providers of high&#45;resolution anoscopy (HRA).  We are happy to offer this list as a resource.  However, a listing here does not constitute endorsement, recommendation, or favoring of any provider's expertise or level of education by The Regents of the University of California nor by its officers, agents or employees.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;We encourage you to contact them directly to ask questions that would help you to feel comfortable with the services provided.  It is typical to inquire about someone's specific training in a new technique as well as how many procedures have been done.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The list is organized alphabetically by country and by state within the United States.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;We hope that this information will help you to be better able to participate with your health care providers in making informed decisions about your care.  It is not a substitute for appropriate professional medical treatment or diagnosis.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Never disregard professional medical advice or delay in seeking it because of something you have read on this site.  Except where explicitly stated otherwise, it is not intended as specific medical advice.  Neither The Regents nor its officers, agents, or employees assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or medical procedure described.&lt;/p&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;hr color=#B33700 size=1px width=75%&gt;&lt;br&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
HRA Providers ./id/x/providers.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/providers.html~</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;The following physicians and nurse practitioners have indicated an interest in being listed as providers of high&#45;resolution anoscopy (HRA).  We are happy to offer this list as a resource.  However, a listing here does not constitute endorsement, recommendation, or favoring of any provider's expertise or level of education by The Regents of the University of California nor by its officers, agents or employees.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;We encourage you to contact them directly to ask questions that would help you to feel comfortable with the services provided.  It is typical to inquire about someone's specific training in a new technique as well as how many procedures have been done.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The list is organized alphabetically by country and by state within the United States.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;We hope that this information will help you to be better able to participate with your health care providers in making informed decisions about your care.  It is not a substitute for appropriate professional medical treatment or diagnosis.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Never disregard professional medical advice or delay in seeking it because of something you have read on this site.  Except where explicitly stated otherwise, it is not intended as specific medical advice.  Neither The Regents nor its officers, agents, or employees assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or medical procedure described.&lt;/p&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;hr color=#B33700 size=1px width=75%&gt;&lt;br&gt;

					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/x/admin/contacts.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/contacts.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/x/admin/contacts.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/contacts.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/x/admin/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/index.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./id/x/admin/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/index.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Log In ./id/x/admin/login.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/login.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Log In ./id/x/admin/login.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/login.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
results.html ./id/x/admin/results.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/results.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
results.html~ ./id/x/admin/results.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/results.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
success.html ./id/x/admin/success.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/success.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
success.html~ ./id/x/admin/success.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/admin/success.html~</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Diagnosis ./id/x/cancer/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/cancer/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;incidence&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How Common is Anal Cancer?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The incidence (number of new cases) of anal cancer in the population continues to increase.  In contrast, the incidence of cervical cancer has steadily declined over the last 40 years.  According to data from the American Cancer Society, 3,990 cases of anal cancer are estimated to occur in 2005 including 1,750 men and 2,240 women, and 620 persons will die due to anal cancer.  This is in comparison to 10,370 new cases of cervical cancer estimated to occur in 2005.  Anal cancer is relatively uncommon in the general population: the rate for invasive anal cancer in men during the period 1994&#45;2000 was 1.59/100,000 person&#45;years and 1.84/100,000 person&#45;years in women and the rate has increased from the period 1973&#45;1979 when the rates were 0.97 for men and 1.27 for women.  Even more dramatic increases have been reported in San Francisco, where the incidence of anal cancer has increased in men aged 40 to 64 from 3.7 in 1973&#45;1978 to 20.6 per 100,000 in 1996&#45;1999.  This likely reflects the large proportion of men who have sex with men (MSM) and the large number of HIV&#45;positive men living in San Francisco, because similar increases were not demonstrated in any other counties in California.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Prior to the AIDS epidemic in 1982, the incidence of anal cancer in MSM was estimated to be between 12.5 and 36.9 per 100,000.  The exact incidence of anal cancer in HIV&#45;positive MSM is difficult to determine, but appears to be higher than in HIV&#45;negative MSM.  A study that matched data from cancer registries with AIDS data showed an incidence rate of invasive anal cancer in HIV&#45;positive MSM of 23.9/100,000 person years.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;In that same report, the relative risks (the increase in cancers in AIDS patients compared with an age&#45;matched sample of the general population) for anogenital cancers for persons who were less than 30 at the age of onset of AIDS were 6.1 (confidence interval 2.6&#45;12.0) for cervical cancer, 37.3 (7.7&#45;108.8) for vulvar/vaginal cancer, 134.3 (16.3&#45;484.8) for anal cancer in women, and 162.7 (103.1&#45;244.0) for men.  For subjects of all ages the relative risks were 5.4 (3.9&#45;7.2) for cervical cancer, 5.8 (3.0&#45;10.2) for vulvar/vaginal cancer, 6.8 (2.7&#45;14.0) for anal cancer in women, and 37.9 (33.0&#45;43.4) for anal cancer in men.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;A study published from Denmark looking at men and women in registered homosexual partnerships showed an increased relative risk among MSM of 31.2 (8.4&#45;79.8) for invasive anal cancer and 3 of the 4 cases were in HIV&#45;positive men.  More recently data from the Chelsea and Westminster Hospital in London determined the incidence of invasive anal cancer in 8,640 individuals followed in their clinic.  The overall incidence was 60/100,000 (40&#45;89) patient&#45;years compared with 0.52/100,000 (0.27&#45;0.78) in an age and gender matched segment of the population.  In the pre&#45;HAART (highly active antiretroviral therapy) era from 1984&#45;1995 the rate was 35/100,000 (15&#45;72), which increased to 92 (52&#45;149) in the post&#45;HAART era from 1996&#45;2003, although the increase was not statistically significant.  In a study from France in which patients treated for anal condyloma were followed from 1993 to 2002, 7 of 199 (3.5%) developed invasive anal cancer including 6 that were HIV&#45;positive.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;It is clear that patients who are HIV&#45;positive are at increased risk to develop anal cancer, as are HIV&#45;negative MSM and women with a history of anal intercourse (although the association is less for women).  Other groups at risk include patients who are chronically immunosuppressed as a result of taking medications to treat autoimmune disorders and other illnesses, organ transplant recipients, women with a history of vulvar HSIL or vulvar cancer and possibly women with a history of cervical HSIL and cervical cancer.  We recommend that people at increased risk have regular and careful digital rectal examinations (DRE) and in areas where high&#45;resolution anoscopy (HRA) is available, that they be screened with anorectal cytology on a regular basis.  Patients with any symptoms or abnormalities suspicious for cancer should be referred to clinicians experienced in managing anorectal problems for assessment and biopsy.&lt;/p&gt;

			&lt;a name=&quot;symptoms&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What Symptoms do Patients with Anal Cancer Have and How are They Diagnosed?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Patients with invasive anal cancer present with a wide variety of symptoms, but at the earliest stage of cancer patients often have no symptoms, which means they are not aware in any way that they have a cancer.  The most common symptom reported is pain or localized tenderness, which can be present constantly or only with bowel movements or receptive sex.  Some patients experience bleeding with bowel movements or following sex that is different from their normal pattern.  Some will feel a lump or hard area on the outside of the anal area that appears to be increasing in size.  As tumors grow and begin to invade the sphincter muscle, pain is common and often patients experience a sense of fullness and a constant need to evacuate.  If you are at risk of anal cancer and you begin to develop symptoms, then you should be examined promptly.  Our patients are all provided with the warning signs of anal cancer and urged to contact us immediately if they begin to develop any symptoms.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Generally, when patients have symptoms related to anal cancer, almost always something can be felt by inserting a finger into the anus.  Too often, the possibility of cancer is overlooked and symptomatic patients are told that it must be their hemorrhoids and not examined with a simple digital rectal examination (DRE).  Sometimes patients are embarrassed and don't let their providers know they are having symptoms.  Even in patients with no symptoms, something abnormal is usually felt with a DRE.  Since many will have no symptoms, it is important for patients at risk to be examined regularly with DRE.  If a mass, a thickening, an area of hardness, a lump, an area of localized tenderness or an ulcer is found, then the patient must be referred to clinicians experienced in managing anorectal problems who can evaluate and biopsy the suspicious areas.  Every time we examine a patient we are searching for the presence of any of these signs or symptoms, which are highly suggestive of a diagnosis of invasive cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Another way in which cancers are found is during routine HRA.  The areas that appear the most worrisome or possibly suggestive of cancer are assessed and biopsied as patients are examined.  We tend to biopsy ulcerated areas, thickened areas, and lesions containing abnormal vessels and occasionally, the biopsy will show superficially invasive or early cancer.  It is unusual not to be able to feel something abnormal that correlates with the abnormality seen through the microscope, but the goal is to evaluate and to periodically biopsy the most abnormal appearing area seen during an exam.  We do this because it is important to assess microscopically the severity of AIN and to rule out the possibility of invasion, which sometimes is occult or not visually obvious even to the experienced eye.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Some patients are diagnosed incidentally when they have anal surgery for treatment of presumably benign processes such as removal of hemorrhoids or treatment of fissures (a tear in the lining of the anus that is often quite painful) and fistulas (an abnormal connection between the inside of the anus and the outside skin, often associated with infection or abscesses), or occasionally incidental cancers are noted during surgery to remove warts.  Most of these diagnoses occur in procedures not assisted by HRA and it is highly likely that if HRA had been performed, the characteristic signs of HSIL would have been noted.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;HRA is an evolving and powerful technique that is not widely available at the present time, because only a limited number of clinicians have been trained to perform it.  It is an important way of assessing patients who have been serendipitously diagnosed with cancer during surgery for benign processes or in whom perianal cancers have been diagnosed and excised (cut out).  The treatment of anal cancer will be discussed in detail below, but there is a tendency among some physicians to feel that incidentally noted superficially invasive cancers have been thoroughly treated by removing the hemorrhoid, wart or obvious external lesion.  While that treatment may be sufficient, based on our experience it is imperative that patients be examined internally with HRA to look for other areas at risk, and in most cases other areas of HSIL will be found during HRA.  The use of vinegar and magnification makes lesions visible that without HRA would be missed.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Invasive anal cancer can only be conclusively diagnosed by biopsy of a suspicious lesion.  Patients who have symptoms or abnormalities felt on DRE that are suggestive of cancer should be biopsied.  If the index of suspicion is high and an exam done in the clinic is not adequate or does not confirm the diagnosis, then patients should be examined in the operating room under anesthesia by a clinician experienced in managing anorectal problems.  Patients being followed for their anal HSIL will occasionally be diagnosed with invasive cancer during routine biopsies, but usually some abnormality can be felt.  Patients incidentally diagnosed with early or superficially invasive cancers during surgery for benign conditions should be followed up with HRA.&lt;/p&gt;

			&lt;a name=&quot;next_steps&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Once a Diagnosis af Anal Cancer is Made, What Needs to be Done?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Invasive anal cancer is curable in a great number of patients, particularly when it is diagnosed early and tumors are small.  Anal canal cancers are most commonly treated with a combination of chemotherapy and radiation, which will be discussed in further detail below but can be expected to cause the tumors to completely regress in 80 to 90% of patients.  Once a diagnosis of cancer is made from any site, one of the first steps done prior to determining how the cancer should be treated is to determine whether it is localized or has spread or metastasized either to nearby lymph nodes or to distant organs, a process known as staging a cancer.  The American Joint Committee on Cancer has created a formal staging system for most cancers that is based on 3 criteria: T or tumor size and an assessment of invasion of nearby organs, N or whether or not the cancer has spread to local lymph nodes, and M, which denotes the absence or presence of metastases to distant organs.  The stage of a cancer is based on determining the T, N, and M for each tumor, which is then used to guide treatment and also provide an idea of the probability that the cancer can be cured or how effective the treatment is likely to be.&lt;/p&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Staging ./id/x/cancer/staging.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/cancer/staging.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;staging&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Staging of Anal Cancer&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Primary tumor (T):&lt;/b&gt;&lt;/p&gt;

																											&lt;table border=0 style=&quot;margin&#45;left:12px&quot; cellpadding=3&gt;
																		&lt;/table&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Distant metastasis (M):&lt;/b&gt;&lt;/p&gt;
															&lt;table border=0 style=&quot;margin&#45;left:12px&quot; cellpadding=3&gt;






						&lt;/table&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Based on the AJCC Cancer Staging Manual, 6th edition (2002) published by Springer&#45;Verlag, New York.&lt;p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The size of the tumor is usually measured by DRE.  Typically following a diagnosis, patients will have CAT scans of the chest, abdomen, and pelvis to stage their cancer.  A CAT scan is a common x&#45;ray procedure that in comparison to common x&#45;rays of bones provides images of the internal organs and other structures such as blood vessels and lymph nodes.  Prior to imaging, patients usually drink a barium&#45;like solution to outline the contents of the gastrointestinal tract, barium is also inserted through a tube in the rectum, and contrast dye is injected intravenously to distinguish the vascular structures.  This test is commonly done to assess the inguinal and pelvic lymph nodes and presence or absence of distant metastases in the liver and lungs.  In some cases, an MRI of the pelvis is done, which is a different type of imaging that uses a large magnetic coil and may be helpful in detecting spread to nearby organs.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Another test that is becoming more commonly used to stage anal cancers is an endoanal ultrasound.  This is a probe approximately the size of an anoscope that can be inserted into the anus and rectum and uses sound waves like SONAR to generate images.  It is very sensitive at detecting perirectal lymph nodes and involvement of neighboring organs.  Ultrasound also provides a good estimation of the depth of invasion of the tumor, whether it is limited to the submucosa (tissue immediately beneath the lining of the anus) or penetrates the sphincter muscle.  A modified staging system based on ultrasound findings has been proposed: a uT1 tumor is confined to the submucosa, a uTa lesion only invades the internal anal sphincter, a uTb lesion invades the external sphincter, a uT3 invades through the sphincter muscles into the perianal tissue, and a uT4 tumor invades neighboring structures.&lt;/p&gt;


			&lt;a name=&quot;significance&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What is the Significance Oof the Stage of Anal Cancer?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Earlier stage cancers such as stage I and II are more likely to be cured than more advanced stages with larger tumors and cancers that have spread to local lymph nodes.  With the use of radiation and chemotherapy, known as combined modality therapy (CMT), even some patients with spread to the lymph nodes will have good results.  Using combined modality therapy, the anal sphincter can be preserved in a majority of patients with acceptable side effects and toxicity and very low treatment&#45;related deaths.  Recognized adverse prognostic factors include tumors located in the anal canal as opposed to anal margin or perianal skin cancers, locally advanced tumors including tumors greater than 5 cm (T3), tumors of any size that invade adjacent organ such as the vagina, urethra, or bladder (T4), lymph node involvement, and probably being HIV&#45;positive, particularly for patients with CD4 lymphocyte counts under 200.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The goal of CMT is to eradicate the tumor and still preserve the anus.  Many patients achieve good results and don't require a colostomy (a surgical procedure in which the large intestine is brought out through a hole in the lower abdomen known as a stoma and covered with a plastic bag).  The effectiveness of treatment is often evaluated by a term known as colostomy&#45;free survival, which means the percentage of patients treated with CMT who never required a colostomy.  Overall survival is another way of evaluating the effectiveness and refers to the percentage of patients treated who survived the treatment and did not die for other reasons, such as advanced HIV infection or an automobile accident or heart attack for example.  Sometimes this is reported as the percentage of people treated who are alive 5 years after treatment, which is known as 5&#45;year survival.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Up to 90% of patients present with local disease without distant metastases.  In cases where the therapy is not completely effective, the cancer may return or grow back in the original site, which is known as a local recurrence and the percentage of patients treated who recur locally is known as the local failure rate.  Most local recurrences tend to occur within the first 2 years after completing therapy.  When local recurrences occur after CMT, then an operation known as an abdominoperineal resection (APR) with placement of a permanent colostomy is performed and approximately 50% of patients will be cured with this additional operation.&lt;/p&gt;


			&lt;a name=&quot;outcome&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Outcome According to T and N Stage with Combined Modality Therapy&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Local failure rate according to T stage:&lt;/b&gt;&lt;/p&gt;
																		&lt;table border=0 style=&quot;margin&#45;left:12px&quot; cellpadding=3&gt;

															&lt;/table&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;5&#45;year colostomy&#45;free survival rate according to T stage:&lt;/b&gt;&lt;/p&gt;
																		include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Treatment ./id/x/cancer/treatment.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/cancer/treatment.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;combined&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Why Are Radiation and Chemotherapy Given Together?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Prior to the 1970s, the standard treatment for anal cancer was an APR with colostomy, which is a large operation known as an abdominoperineal resection (APR).  During an APR the anus and lower rectum and the skin around the anus is surgically removed. The lower end of the colon is brought out through a hole in the lower abdominal wall to create a permanent colostomy.  In 1974, Nigro published preliminary results, which showed that when patients were treated prior to surgery with chemotherapy consisting of mitomycin and 5&#45;fluorouracil (5&#45;FU) combined with a relatively low dose of radiation of 30 Gray (Gy and 1 Gy=100 rad) that the tumor was effectively eliminated in most surgical specimens.  Additional studies confirmed the success of this approach of using combined modality therapy with higher doses of radiation and without surgery.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Several general principles emerge.  Higher doses of radiation may achieve better control.  It is better to treat patients continuously for 6 to 8 weeks than to take a break in the middle of therapy.  Combining chemotherapy and radiation produces a better outcome than radiation alone.  Overall survival is similar, perhaps due to the ability of APR to render those patients who recur after combined modality therapy disease&#45;free.  Combination chemotherapy with mitomycin and 5&#45;FU produces better results than 5&#45;FU alone and patients treated with the combination had a complete response of 74&#45;90%, local control in 54&#45;73%, colostomy&#45;free survival in 66&#45;70%, disease&#45;free survival in 53&#45;77%, and 58&#45;89% overall survival.  There is another chemotherapy drug known as cisplatinum, which is being investigated in combination with 5&#45;FU and radiation to see if it is better than mitomycin.&lt;/p&gt;

			&lt;a name=&quot;all_combined&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Do All Anal Cancers Need to be Treated with Radiation and Chemotherapy?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The standard of care for treatment of invasive anal cancer is radiation and chemotherapy.  There are several situations, however, when combined modality therapy may not be necessary.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;The most obvious is when invasive cancer is not present.  A diagnosis of carcinoma in situ is not invasive cancer.  A number of patients and some health care providers have misunderstood this concept and patients have been unnecessarily treated with radiation and chemotherapy.  This is one reason why we prefer the more accurate terms high&#45;grade squamous intraepithelial lesion (HSIL), or anal intraepithelial neoplasia (AIN) 3, or severe dysplasia to carcinoma in situ.  Patients with a diagnosis of AIN 3 must be examined carefully and biopsies of any areas suspicious for cancer biopsied, but if there is no evidence of invasive cancer then these patients could be treated using electrocautery, laser, or infrared coagulation to destroy the areas of HSIL and then followed closely.
			&lt;li class=&quot;aci&quot;&gt;Anal margin cancers or cancers of the perianal skin may not require CMT.  These types of cancers are often managed in a similar way to other skin cancers, which is by cutting them out and cauterizing the base underneath the lesion.  Small T1 and T2 tumors that are not deeply invasive into the sphincter muscle and that can be completely excised with negative margins may be treated with simple excision and electrocautery.  Patients should be referred to clinicians experienced in managing anorectal conditions, preferably using high&#45;resolution anoscopy (HRA) if it is available, for careful examinations to treat any other areas of precancerous lesions that may be present.  Many patients with anal margin tumors will also have co&#45;existent internal anal HSIL that should be treated.  It is important to evaluate the inguinal lymph nodes located in the groin area as anal margin cancers may spread to this region.  Larger T3 tumors which invade into the external sphincter muscle or that impinge on the verge or anal canal are better treated with radiation and chemotherapy.
			&lt;li class=&quot;aci&quot;&gt;Tumors that are superficially invasive that are small may also be managed with simple excision and cautery.  Superficially invasive refers to cancers that invade only a short distance beyond the basement membrane less than several millimeters.  This category of superficial invasion has not been rigorously studied or clearly defined in the medical literature for anal cancer.  Often patients with anal HSIL will have involvement of large parts of the anal canal and perianal area, which is referred to as a field effect.  This means that the entire anogenital skin or epithelium is susceptible to HPV infection and may develop precancerous lesions or HSIL.  For that reason, patients diagnosed with superficially invasive cancer must be examined carefully for other lesions and they must continue to be followed on a regular basis because they are at higher risk of developing recurrences either of HSIL or other cancers.
			&lt;li class=&quot;aci&quot;&gt;Surgical excision may be appropriate for small T1 intra&#45;anal cancers if they involve only a small part of the circumference and do not deeply invade into the internal anal sphincter muscle.  This is a controversial approach, which in a small group of patients was shown to effectively eliminate the cancer.  If excising the cancer would require removing a portion of the internal sphincter muscle then this method should be avoided because incontinence is likely.  One of the great benefits of radiation and chemotherapy is preservation of the anal sphincter and often avoiding a colostomy, so CMT is the preferred method of treatment except in highly selected patients who can be very carefully followed.
			&lt;li class=&quot;aci&quot; &gt;If patients are quite ill as a result of other medical conditions and not expected to live for more than a few months, then it may not be necessary to try and treat their anal cancers.  This is a very difficult decision that should be made after consultation with the patient's primary care provider, family and friends.  If a choice is made not to treat, then patients should have excellent control of pain, if it is present.  Often this would be a situation where hospice care would be considered and be appropriate.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;combined_given&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How Are the Chemotherapy and Radiation Given?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;When patients are diagnosed with anal cancer that cannot be treated by simple surgery, they are referred for treatment with radiation and chemotherapy.  Patients are referred to a physician who specializes in delivering radiation to patients to treat their cancers, also known as a radiation oncologist.  Patients will also see a medical oncologist, a doctor who specializes in treating cancer patients and administering chemotherapy.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;The radiation oncologist will perform a history and physical examination paying particular attention to where the cancer is located and assessing the inguinal lymph nodes.  The physician will assess the patient's overall health status for conditions that may affect the treatment, such as HIV infection.  He or she will explain the course of therapy and the expected side effects and likely outcome based on the examination and review of the CAT scans.
			&lt;li class=&quot;aci&quot;&gt;Radiation therapy means using energy called ionizing radiation or X&#45;rays to kill cancer cells and shrink tumors.  Radiation only destroys cells that are targeted by the x&#45;ray beam.  It destroys cells in the area being treated by damaging their genetic material.  When damaged, the cells can no longer divide and multiply.  Although radiation damages both cancer cells and normal cells, most normal cells are able to recover and function normally.  The goal of radiation therapy is to carefully target the abnormal tissue, sparing or limiting damage to the neighboring tissue as much as possible.  The radiation is delivered externally similar to the way a regular X&#45;ray is taken, except that the energy is much higher than a regular X&#45;ray.
			&lt;li class=&quot;aci&quot;&gt;Once a plan is devised as to how much radiation will need to be given and to what areas of the body, then treatment planning and simulation occur.  During this process the patient lies very still on an examining table while the radiation therapist uses a special X&#45;ray machine to define the treatment port or field, which is the exact place where the radiation will be aimed.  Often CAT scans are used for part of this process so the X&#45;rays can be aimed as precisely as possible at the tumor and limit the damage to healthy tissue.  The patient lies on the table often in molds or forms to limit mobility.  Then small tattoos are placed on the skin so that the X&#45;ray beam can be aligned properly and in the same way every time.  Sometimes shields are made of lead to protect the normal tissues.
			&lt;li class=&quot;aci&quot;&gt;A prescription is designed to provide a total dose of radiation and then the amount that will be given per day.  This dose previously was measured in rads in which 1 rad equals 1 centiGray (cGy) and doses are also reported in Gray (Gy).  Patients are usually treated with a dose of 1.8 Gy per day for 5 days in a row for a total dose of 45 Gy delivered in 25 fractions over 5 to 6 1/2 weeks.  Patients with T3, T4, or nodal involvement or T2 tumors with residual disease at the end of 45 Gy are treated with an additional 10 to 14 Gy to a reduced field at 2 Gy per day fractions.
			&lt;li class=&quot;aci&quot;&gt;The radiation is given once a day for 5 to 6 weeks.  The treatment itself takes less than a minute once the patient is properly positioned and the beam aligned.  Patients are examined weekly to assess how they are tolerating the treatment.  Patients receive supportive care in the terms of anti&#45;nausea and pain medications and attention to good skin care around the anus to limit the severity of the reaction to normal skin.
			&lt;li class=&quot;aci&quot;&gt;Typical side effects include fatigue that tends to be cumulative meaning that it gets somewhat worse towards the end of therapy, mild nausea, loss of appetite, irritation of the rectum and anal area, diarrhea, increased frequency of urination, loss of pubic hair, redness, drying, irritation, burning, and occasionally blistering and weeping of the skin around the anus.  Long&#45;term side effects which are uncommon include ulcers, obstruction of the bowel, obstruction of the ureters, and the development of fistulas or abnormal connections or tracts between the pelvic tissues.
			&lt;li class=&quot;aci&quot;&gt;Chemotherapy is given during the first few days of the radiation and in the middle of treatment.  The chemotherapy is given during the radiation because it acts as a radiation sensitizer, which means that the chemotherapy enhances the effect of the radiation.
			&lt;li class=&quot;aci&quot;&gt;Usually a special intravenous catheter is inserted to facilitate the delivery of the chemotherapy, which is usually arranged by the medical oncologist.  One type is called a PICC line and refers to a long catheter that is threaded through a vein in the arm into the large veins near the heart.  It is covered with a special dressing and can stay in place for several weeks and then is removed at the end of therapy.
			&lt;li class=&quot;aci&quot;&gt;The medical oncologist will also review all of the medical records, CAT scans, and perform a history and physical examination prior to starting the chemotherapy.  The medical oncologist works together with the radiation oncologist to ensure that the treatment is given as safely and effectively as possible.  Together they will monitor blood counts carefully and may adjust the second cycle of chemotherapy if there are excessive side effects or toxicity with the first cycle.
			&lt;li class=&quot;aci&quot;&gt;One of the most common types of chemotherapy used is a medication known as mitomycin given at a dose of 10mg/m&lt;sup&gt;&lt;small&gt;2&lt;/small&gt;&lt;/sup&gt;, which is a method used to calculate chemotherapy doses based on body surface area that is calculated as m&lt;sup&gt;&lt;small&gt;2&lt;/small&gt;&lt;/sup&gt; (square meters) of body surface area with most adults being between 1.5 and 2 m&lt;sup&gt;&lt;small&gt;2&lt;/small&gt;&lt;/sup&gt;.  The chemotherapy is given as a single intravenous injection of the first day of the radiation and then again on the 29&lt;sup&gt;&lt;small&gt;th&lt;/small&gt;&lt;/sup&gt; day of therapy.  It is given with another chemotherapy drug called 5&#45;FU or 5&#45;fluorouracil, which is given at a dose of 1,000 mg/m&lt;sup&gt;&lt;small&gt;2&lt;/small&gt;&lt;/sup&gt; as an infusion that is given continuously for the first 4 days of therapy and then repeated on the 29&lt;sup&gt;&lt;small&gt;th&lt;/small&gt;&lt;/sup&gt; day.  The 5&#45;FU is usually delivered using a pump, which can be like a small elastic balloon or like a small tape recorder.  The treatment is usually given as an outpatient.
			&lt;li class=&quot;aci&quot;&gt;Side effects of the chemotherapy may include nausea, vomiting, hair loss, mouth sores, diarrhea, and low blood counts including low white cells, red cells and/or platelets, which can be severe enough to cause bleeding, need for transfusion and to place the patient at risk for a potentially life&#45;threatening infection and rarely death.  Rarely mitomycin has been associated with kidney damage and a disorder of the blood called hemolytic anemia in which the some of the red cells burst and small clots can form in blood vessels, a condition known as microangiopathic hemolytic anemia or hemolytic uremia syndrome.
			&lt;li class=&quot;aci&quot;&gt;Most people get through the therapy fairly well and only rarely have all of the side effects mentioned.  The good news is that the treatment is usually works very well, many people are cured, and it only lasts for 6 weeks and then is finished.
			&lt;li class=&quot;aci&quot;&gt;Once therapy is finished, the side effects begin to dissipate and energy levels and appetite and blood counts return to normal and the skin heals.  Close follow up is important.  Patients are usually seen every 3 months for the first year, then every 6 months for the second year, and then every year.  If there is a recurrence, it tends to occur in the first 2 years.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;combined_effects&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What Are the Side Effects or Toxicity of Radiation and Chemotherapy?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Patients experience cumulative side effects that tend to worsen as the therapy continues.  Immediate effects include skin reactions with redness around the anus, inflammation of the skin, and occasional open sores or ulceration; inflammation and irritation of the gastrointestinal tract producing diarrhea and/or sores in the mouth; pain and inflammation of the rectum with soreness and a sense of urgency or needing to defecate; and low blood counts with possible sepsis.  Late side effects include skin reactions with formation of scar tissue; anal ulcers that can be quite deep; death of anal tissue and/or stenosis or narrowing of the anus requiring colostomy in 6 to 12% of patients; sterility and sexual dysfunction; and a small risk of treatment&#45;related leukemia, usually thought to be related to mitomycin.&lt;/p&gt;


			&lt;a name=&quot;hiv&#45;positive&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What is Treatment Like in HIV&#45;Positive Patients?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Although the outcome of treatment of anal cancer has been evaluated in HIV&#45;positive patients, most of the studies reported have included small numbers of patients.  These studies have been retrospective, which means that a group looked back over a period of time to analyze their results.  To date, no prospective studies evaluating the treatment of anal cancer in HIV&#45;positive patients has been published.  Several principles emerge from these studies.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Immune function as assessed by CD4+ lymphocyte count appears to be an indicator of how well patients will tolerate therapy.  Studies suggest that patients with a CD4+ lymphocyte count greater than 200 cells/mm&lt;sup&gt;&lt;small&gt;3&lt;/small&gt;&lt;/sup&gt; tolerate therapy better and also have a better outcome.  Patients with higher CD4+ lymphocyte counts are treated in a similar fashion as patients who are HIV&#45;negative.  Patients who have lower CD4+ lymphocyte counts (fewer than 200 cells/mm&lt;sup&gt;&lt;small&gt;3&lt;/small&gt;&lt;/sup&gt;) have had more immediate toxicity, required longer breaks or delays in therapy due to toxicity, were more likely to require hospitalization, and were more likely to require decreases in the doses of chemotherapy, all of these factors may hamper optimal therapy.  In a few studies, however, no difference in toxicity was seen based on the CD4 count at the time of beginning therapy.  In spite of having a more difficult time with therapy, many HIV&#45;positive patients have done well with therapy and the CD4 count alone should not be used to deny therapy to patients. Rather, therapy may need to be more individualized for patients who have low CD4 counts.
			&lt;li class=&quot;aci&quot;&gt;Similar to studies reported in HIV&#45;negative patients, patients with smaller T1 and T2 tumors seems to do better than patients with more advanced disease.
			&lt;li class=&quot;aci&quot;&gt;Most of these patients were treated prior to the widespread use of highly active antiretroviral therapy (HAART) and some patients with pre&#45;existing AIDS were able to achieve elimination of their tumors, but then went on to die of AIDS&#45;related complications.
			&lt;li class=&quot;aci&quot;&gt;There is some data that patients being treated with HAART appear to do better than patients not treated with HAART.
			&lt;/ol&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;The details of several of these studies appear below:&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;At UCSF between 1991 and 1997 data were reported on 17 HIV&#45;positive patients according to their CD4 count.  9 of 17 HIV&#45;positive patients with a CD4 count &gt;200 tolerated therapy better and had a better outcome compared to the 8 patients with a CD4 count &lt;200.  16 received combined modality therapy.  The 8 patients with low CD4 counts received a variety of chemotherapy drugs and only 2 received some form of mitomycin and 5&#45;FU, 1 received only radiation therapy for a T1 lesion, and the remainder were treated with either 5&#45;FU alone or 5&#45;FU and cisplatinum.  Side effects were significant in 7 of the 8 patients with low CD4 counts.  5 had a severe skin reaction known as moist desquamation (destruction of the surface of the skin with formation of blisters and drainage accompanied by pain), 2 had very low blood counts, and severe diarrhea occurred in 3.  Four patients were hospitalized for management of side effects.  Four required a colostomy, 2 for relief of symptoms and 2 for recurrent disease.  One of the two with recurrence remained free of disease 15 months later.  All patients except 1 required a break in treatment of between 1&#45;4 weeks.  Two discontinued treatment prematurely and subsequently died of AIDS.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;In contrast, all of the 9 patients who had a CD4 count &gt;200 had no evidence of disease when last evaluated, which ranged from 12 to 74 months.  All received some form of mitomycin and 5&#45;FU and radiation doses that ranged from 45 Gy to 56.3 Gy.  5 of 9 developed moist desquamation, 2 patients developed very low blood counts, 4 patients required a 2&#45;week break, and none were hospitalized or required a colostomy.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;In a study from London, however, Cleator and colleagues saw no difference in the level of side effects in the 5 of 12 HIV&#45;positive patients who had a CD4 count &lt;200 treated with combined modality therapy from 1989 to 1999.  Side effects were similar to other studies.  Most patients had diarrhea and skin reactions and half had low blood counts.  After an average follow&#45;up of almost 5 years, 8 patients were alive, 2 died of anal cancer, 1 patient died secondary to a bowel obstruction that was attributed to radiation enteritis 7 months after diagnosis, and 1 died from an AIDS&#45;related opportunistic infection 4 months after diagnosis.  Elimination of tumor was seen in 9 of 11 evaluable patients.  An additional patient who had a partial response was rendered disease free with an APR, while the other patient developed progressive cancer during therapy and died.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;From 1985 to 1999 at the University of Texas Southwestern Medical Center 14 HIV&#45;positive patients were treated.  Four patients were treated since 1998 with HAART and had only been followed for a short time of less than 6 months.  Average survival for the remaining 10 patients was 17 months, including 2 long&#45;term survivors at 5 and 8 years.  The 8 patients who died had anal cancer present at the time of their death.  Treatment consisted of radiation therapy combined with cisplatinum and 5&#45;FU.  Among the 8 patients who died: 1 had no therapy, 1 had chemotherapy alone, and 1 was treated with radiation therapy alone.  Side effects were significant and greater in patients with a CD4 count &lt;200.  Before the use of HAART, 6 of the 10 patients required a break in treatment, but only 1 of the 4 patients receiving HAART required a break.  The 4 patients treated since July 1998 with HAART have done well so far with no evidence of disease, but have not been followed for very long.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;At the George Washington University and the Veterans Administration Medical Centers in Washington, DC between 1985 and 1998, 60 HIV&#45;negative and 13 HIV&#45;positive patients were treated for invasive anal cancer.  The HIV&#45;positive patients had a worse outcome and tolerance to treatment compared to the HIV&#45;negative patients.  The HIV&#45;positive patients were younger with an average age of 42 compared with 62 in the HIV&#45;negative group and 92% were male.  In the HIV&#45;negative group only 42% were males.  80% of HIV&#45;positive patients had significant immediate side effects compared to 30% of the HIV&#45;negative group.  A greater number of HIV&#45;positive patients had late toxicity.  Elimination of the tumor was found in only 62% of the HIV&#45;positive group compared to 85% of the HIV&#45;negative patients having eradication of their cancer.  These differences were not statistically significant because of the small number of HIV&#45;positive patients.  5 of 13 (38%) HIV&#45;positive patients died of cancer with a median time of 1.4 years compared to 5.3 years for the HIV&#45;negative patients in whom 16 of 60 died of cancer (27%).&lt;/p&gt;

			&lt;a name=&quot;ucsf_hiv&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Anal Cancer Treatment at UCSF with Modifications Used for HIV&#45;Positive Patients&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;HIV&#45;positive patients with invasive anal cancer with CD4+ lymphocyte counts &gt;200 are treated with combined modality therapy similarly to patients who are not HIV&#45;infected (Richard Krieg, MD, San Francisco, CA, personal communication, September 2003).
			&lt;li class=&quot;aci&quot;&gt;More individualized approaches are used for patients with CD4 counts &lt;200.  The volumes are kept tighter, which means that the area receiving the maximum dose of radiation more closely approximates the cancer.  Preventative radiation to the lymph nodes is not given.  It may not be possible to achieve full doses.  Patients with low CD4 counts tolerate therapy poorly and have increased complication rates and a higher rate of colostomies.  Standard chemotherapy with mitomycin and 5&#45;FU is attempted, but cisplatinum is used instead of mitomycin in some cases.
			&lt;li class=&quot;aci&quot;&gt;The plan to deliver the radiation is based on the volume of residual disease remaining after the biopsy that diagnosed the cancer.  Other factors considered include the patient's functional status (level of activity and restriction of daily activities due to symptoms of disease) and CD4 count.
			&lt;li class=&quot;aci&quot;&gt;Patients who have only microscopic disease remaining are treated with 50 Gy to the primary tumor area.
			&lt;li class=&quot;aci&quot;&gt;Those with disease that can be felt or seen that measures less than 3 cm and who respond well with no disease remaining at the end of treatment receive approximately 54 Gy to the primary tumor area.
			&lt;li class=&quot;aci&quot;&gt;Patients with more advanced tumors and those with disease that persists at the end of treatment receive 60 Gy in recognition of what may be a dose&#45;response relationship.
			&lt;li class=&quot;aci&quot;&gt;Inguinal and pelvic nodes are included in the field although field size may be adjusted in patients who have low CD4 counts and no evidence of nodal disease.  Doses in the range of 36 Gy are delivered to prophylactic nodal areas.  Only the inguinal nodes are treated in patients who have perianal or anal margin lesions that do not extend above the dentate line.
			&lt;li class=&quot;aci&quot;&gt;Similar to other centers, shrinking fields are used and conformal radiotherapy is not used because of the possibility of geographic miss of the tumor until more data on efficacy are available.
			&lt;li class=&quot;aci&quot;&gt;In a few patients who have presented with concurrent abscesses or fistulae, initial chemotherapy with cisplatinum and 5&#45;FU has been used with some success to shrink the tumor prior to delivering the radiation, which is followed by standard combined modality therapy.
			&lt;li class=&quot;aci&quot;&gt;The goal is for patients to receive as much of their planned course of therapy in as timely a fashion as possible without delays.  All HIV&#45;positive patients are followed very carefully with great attention to skin care, supportive care including the use of appropriate narcotics for pain control, and close monitoring of blood counts with no planned interruptions in therapy.  Interruptions are considered only when necessary due to excessive toxicity.
			&lt;li class=&quot;aci&quot;&gt;Once therapy is completed patients are followed with careful digital examination and avoidance of unnecessary biopsies.  When patients develop progressive disease by digital rectal examination or documented by CAT scan or MRI they are examined under anesthesia with biopsies of suspicious masses in order to document recurrence pathologically.  The majority of recurrences occur within the first 2 years, and patients with recurrences documented on biopsy are referred for APR.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;recur&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What Treatment is Available if the Cancer Recurs?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;If the cancer returns locally and has not spread to distant parts of the body such as the liver and lungs then it may be able to be removed with an operation known as an abdominoperineal resection (APR).  During an APR the skin and tissue around the anus along with lower part of the rectum are cut out and removed.  The end of the colon is brought out through a hole in the abdomen to create a colostomy, which is covered by a plastic bag that collects the stool.  The bag is changed daily and as needed.  This regimen is reported to effectively cure around half of patients who develop recurrences.  Patients in whom the cancer cannot be completely removed because it has invaded into adjacent structures usually do not survive for long periods of time.  Occasionally additional radiation can be given by implanting radioactive seeds and chemotherapy can be tried if metastatic disease to other organs develops, but usually this therapy is not curative.&lt;/p&gt;


			&lt;a name=&quot;conclusions&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Conclusions&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;The treatment of anal cancer is one of the success stories of modern cancer care and many patients will be cured with surgery, radiation, or a combination of radiation and chemotherapy.  However, while tolerable, the side effects of treatment can be substantial and not all patients will respond well to treatment.  Earlier diagnosis will help improve outcome and smaller tumors can be treated more effectively and with less side effects as well.  At the very least, it is our hope by providing this information about anal cancer that patients with symptoms of anal cancer will be evaluated promptly, so that if cancer is present, it will be diagnosed as early as possible.  There is little doubt that the best way to treat anal caner is to prevent it from occurring.  Patients with an increased risk of anal cancer may benefit from screening with anal cytology followed by eradication of the precursors to anal cancer, anal HSIL, if they are identified.  It is our hope that the advancement that has been seen with declining rates of cervical cancer will also translate to declining rates of anal cancer.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anatomy ./id/x/diagnosis/anatomy.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/diagnosis/anatomy.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; align=center&gt;&lt;img src=&quot;/analcancerinfo/images/anusdiagram562.jpg&quot; align=center&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;The anus is the opening to the lower gastrointestinal (GI) tract and connects to the rectum, which connects to the colon, which traveling backwards connects to the small intestine, then the stomach, then the esophagus and finally the mouth.  The anus is approximately 2 to 3 inches long and composed of skin type cells also known as squamous cells.  There are two sphincter muscles: an internal sphincter muscle, which can be felt as a muscular ring, beyond which is the rectum; and an external sphincter muscle.  The upper portion of the anus, or that part that connects to the rectum, is known as the squamocolumnar junction.  This is where the columnar or glandular epithelial cells of the rectum transition to the squamous cells of the anus.  This border is somewhat irregular and dynamic meaning that it can be seen as a fluctuating undulating edge, when viewed during high&#45;resolution anoscopy (HRA) after application of 3% acetic acid (vinegar).  There is a &quot;toothed&quot; or jagged line that corresponds to columns also known as the dentate line, which can be seen with the naked eye and is just below the squamocolumnar junction or towards the outside.  This is followed by the anal canal, which leads to the anal verge, which is the junction on the outside of the anus of hair&#45;bearing and non hair&#45;bearing skin, similar to the junction of the lip of the mouth with the skin of the face.  Beyond the verge traveling outwards for 2 inches is the perianal skin, which is also referred to as the anal margin.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;The squamocolumnar junction is the area most commonly affected by HPV and where many of the lesions are likely to arise.  Historically a distinction has been made between anal canal or intra&#45;anal cancers (cancers located within or inside of the anus) and anal margin or perianal cancers, which are thought to behave much more like true skin cancers.  One of the problems in evaluating the medical literature is that these areas have not been clearly defined and often patients and health care providers confuse terms.&lt;/p&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Examination ./id/x/diagnosis/examination.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/diagnosis/examination.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;examination&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How is the Anus Examined?&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;The easiest and best way to examine the anus is to insert a lubricated finger into the anus and carefully feel for abnormalities.  This is called a digital rectal examination (DRE) and requires no investment in expensive equipment or any special training.  It is available to every patient that sees a health care provider.  We feel that DRE is the most important part of every anal exam, because it is a very good way of detecting any abnormal growths or masses.  After DRE, health care providers may perform anoscopy if abnormalities are felt.  Anoscopy is a simple procedure that also can be performed by most health care providers.  A small plastic disposable cylindrical tube known as an anoscope is placed into the anal canal and a strong light shined inside.  The examiner then looks with the naked eye for any abnormalities that correspond to what was felt on DRE.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;Occasionally patients will have a sigmoidoscopy, which is a test in which a flexible tube is inserted higher up into the colon beyond the anus.  Sigmoidoscopy examines the lower third of the colon and rectum, whereas a colonoscopy is an exam in which a longer tube is passed through the entire large bowel to where it connects to the small intestine.  Sigmoidoscopy and colonoscopy are both tests used to screen for colorectal cancer.  As the physician is inspecting the rectum they can turn the scope backwards on itself to view the anus and occasionally visualize abnormalities.  However, these tests are much better for evaluating the colon and rectum than they are for looking at the anus.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;It has only been since the late 1980s and early 1990s that the technique known as high&#45;resolution anoscopy (HRA) was developed to examine the anus.  Physicians in England were the first to describe this technique in which a microscope is used to examine the anus after applying vinegar.  The microscope, officially called a colposcope, was first developed in the 1930s in Germany to examine the cervix for cancer and precancerous lesions.  The use of the colposcope became widespread in the 1960s as a way of evaluating abnormal cervical Pap smears by directly viewing the cervix with magnification so biopsies could be performed.  Biopsies are small pieces of tissue that are removed, fixed, sliced, stained, and placed on glass slides in order for the pathologist to examine them and make a diagnosis.  Since 1991, our group here at UCSF has pioneered and developed this technique of HRA to examine the anus and has performed HRA on over 1,000 patients who have been enrolled in various natural history studies.&lt;/p&gt;

			&lt;a name=&quot;clinic&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How Anal Exams and HRA are Done in the UCSF Anal Dysplasia Clinic&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Patients are first asked to tell us about their general health, medical history, immune status, medications, CD4+ lymphocyte count and viral load if HIV&#45;positive, sexual history, any history of anal warts, dysplasia, or any other anal problems.  We specifically ask if they have a heart valve abnormality that is severe enough to warrant taking antibiotics when they get their teeth cleaned to prevent infections from occurring on their heart valves.  It has been our recent practice to prescribe antibiotics to such patients prior to performing any biopsies.
			&lt;li class=&quot;aci&quot;&gt;Next, patients are asked to describe any anal symptoms present such as itching, discomfort, irritation, pain or difficulty with bowel movements or with receptive anal intercourse (if they have anal sex), bleeding, or any other symptoms related to their anus.
			&lt;li class=&quot;aci&quot;&gt;Patients undress and lie down on the examining table on their left side with their bottom at the end of the table and their feet resting in the stirrup.  A Dacron swab is moistened in tap water and inserted into the anus to collect a specimen for anal cytology as described above.  This must be done PRIOR to putting any lubricant into the anus because the lubricating jelly interferes with the Pap smear.
			&lt;li class=&quot;aci&quot;&gt;Then a careful DRE is performed using a combination of 2% lidocaine jelly and lubricating jelly.  If patients are symptomatic with tenderness or irritation or highly anxious and hyperresponsive, then 5% anorectal lidocaine cream such as L.M.X.5 or Lidosense is inserted gently and carefully into the anal canal for a few minutes prior to proceeding with DRE.  It is important to put patients at ease and make the exam as comfortable as possible because patients are often embarrassed and uncomfortable being examined.  Performing DRE first has several advantages: it helps to establish trust with the patient that you are not going to hurt them, topical anesthesia facilitates examination and decreases the burning effect of 3% acetic acid that is used, and most importantly, DRE allows the detection of anal masses or areas of induration or hardness (signs of cancer) in order to direct the exam to areas of concern for possible invasion.
			&lt;li class=&quot;aci&quot;&gt;The lubricated and gloved finger is swept over the entire circumference of the anal canal with attention to any areas of thickening or nodularity at the level of the internal sphincter, which corresponds to the dentate line, near the location of the squamocolumnar junction.  Internally the finger is feeling for masses, warty growths, ulcerations, or hard areas.  Finally, the finger is swept externally in a similar fashion to palpate for any suspicious areas perianally or externally including raised, thickened, hardened, ulcerated, or tender areas.
			&lt;li class=&quot;aci&quot;&gt;After DRE, the anoscope is inserted and a wooden cotton swab that is thinly wrapped with a single ply 4 x 4 cotton gauze soaked in 3% acetic acid is inserted through the anoscope and allowed to remain in the anus for 1 minute.  The swab is removed.  The anoscope is re&#45;inserted and slowly withdrawn from the rectum into the anus while looking through the binoculars of the colposcope until the anal epithelium is visualized.
			&lt;li class=&quot;aci&quot;&gt;Then the anoscope is manipulated in such a way as to visualize the entire circumference of the squamocolumnar junction, which is where the majority of HPV&#45;related lesions are located.  We have found that frequent re&#45;applications of vinegar using a wooden Q&#45;tip are helpful in making lesions appear and also in looking between the mucosal folds and hemorrhoidal cushions.  Occasionally the anoscope must be re&#45;inserted beyond the internal sphincter in order to rotate it to visualize and/or flatten out the folds.  Often during longer exams, engorgement of hemorrhoids occurs in some patients, which may complicate and make exams sub&#45;optimal.  We define an adequate exam as one in which the entire circumference of the squamocolumnar junction can be visualized and inspected.
			&lt;li class=&quot;aci&quot;&gt;Normal anal epithelium is shiny, glistening, translucent, and usually grayish pink; it is seen as an edge demarcating the rectal epithelium which is also acetowhite (appearing white after the application of vinegar) and more granular or grape&#45;like in appearance reflecting the cells of the rectum.  The actual junction is often scalloped in appearance and islands of metaplasia can be seen at or near the edge as “holes” in the squamous epithelium.  Squamous metaplasia is normal and refers to the area of change or transition where the squamous cells cover over the rectal cells.
			&lt;li class=&quot;aci&quot;&gt;The squamocolumnar junction is examined carefully for any abnormal white areas or acetowhitening, which appear as denser opaque areas.  These areas appear distinct from the normal anal tissue and acetowhitening is the first indication noted that a lesion is present.  Lesions are then evaluated for their surface characteristics such as papillae or the little finger&#45;like fronds associated with warts or changes such as micropapillae, which are simply very small papillae often characteristic of LSIL.  Texture or thickening is noted and whether or not there is ulceration (an area where the surface is eroded, denuded or missing leaving a hole similar to a sore on the skin).
			&lt;li class=&quot;aci&quot;&gt;Lesions are next evaluated for the presence of abnormal blood vessels, which are characteristic of high&#45;grade or precancerous lesions.  Some of these vascular changes are called punctation and mosaicism and usually indicate areas of HSIL.  Cancers contain very abnormal appearing blood vessels in addition to feeling thickened or hard and in some cases may be recognized by these features.
			&lt;li class=&quot;aci&quot;&gt;Once a lesion is found it can be biopsied using a forceps, which means to cut out or remove a small piece of it, which is then preserved in formalin and sent to the pathologist.  We tend to biopsy the most abnormal areas as a means of determining the severity of the disease present and ensuring that cancer is not present.  Biopsies taken in the clinic during HRA are usually quite small, measuring about the size of a half of a grain of rice (1/8 of an inch or 1 to 3 mm).  The biopsy removes the surface and underlying tissue including the basement membrane so the pathologist can determine the level of severity of the SIL and whether or not there is invasion or cancer present.
			&lt;li class=&quot;aci&quot;&gt;Biopsies are easily performed and usually quite well tolerated.  No anesthesia is required other than the topical numbing jelly unless the lesions are located close to the outside and then local anesthesia must be infiltrated prior to biopsy.  The nervous supply to the inside of the anus is similar to the nervous supply to the internal organs; pressure and stretching are usually felt, but not cutting and pinching per se, which is in contrast to the skin in which sharpness is easily felt.  Significant bleeding and infections are extremely uncommon following anal biopsy.  If brisk bleeding occurs, removing the anoscope is usually all that is needed and if that is not successful, then re&#45;insertion of the anoscope and application of Monsel’s solution (ferric subsulfate) will usually help to stop the bleeding.
			&lt;li class=&quot;aci&quot;&gt;Patients may experience mild discomfort for a few hours to a few days, but often do not feel anything.  There may be bleeding with bowel movements, which can last up to a week, but often does not occur.
			&lt;li class=&quot;aci&quot;&gt;The anal canal in women is usually shorter, which can make assessment difficult.  Obese patients and patients with very muscular buttocks can often be quite difficult to examine.
			&lt;li class=&quot;aci&quot;&gt;Once the entire circumference of the squamocolumnar junction has been examined with frequent re&#45;applications of vinegar, then the anoscope is slowly withdrawn while looking though the colposcope to evaluate the distal anal canal and mucosa close to the verge.  Lesions in this more keratinized mucosa (covered with a thicker layer of skin cells) are less common and often more difficult to characterize and require anesthesia prior to biopsy.
			&lt;li class=&quot;aci&quot;&gt;Following removal of the anoscope, the lubricating jelly is wiped off and then 3% acetic acid applied to the external anus, which is then examined carefully with the colposcope.  External lesions can be more challenging to evaluate. Such a lesion may manifest as a more subtle superficial ulceration or denuding of the surface epithelium, and in the presence of punctation should be biopsied.  External lesions can be biopsied after infiltration with lidocaine with a variety of forceps.  Bleeding is stopped by application of silver nitrate sticks and pressure.
			&lt;/ol&gt;&lt;p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Screening Principles ./id/x/diagnosis/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/diagnosis/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;The goal of cancer screening is to detect cancers at the earliest time possible when they are small, before they cause symptoms, and when they can be most easily and likely cured.  A screening test is even better if it can detect precancerous or pre&#45;invasive cells or changes, which can then be removed, preventing the development of invasive cancer.  For example, the detection and elimination of precancerous changes in the cervix has led to a steady decline in the incidence of cervical cancer in the developed world over the last 40 years.  Currently the American Cancer Society recommends guidelines for screening for breast, colorectal, prostate, and cervical cancer.  Each of these cancers has different specific tests that are done, and screening is started when people are thought to be at greatest risk of developing a certain cancer or precancerous changes.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Cervical Pap smears are performed to screen for cervical cancer or the changes that are believed to be precursors to cervical cancer.  These precursors are known as cervical high&#45;grade squamous intraepithelial lesions (HSIL), or also known as cervical intraepithelial neoplasia 2 or3 (CIN 2 or CIN 3) or moderate or severe dysplasia or sometimes, the term carcinoma in situ (CIS) is used.  These terms are used interchangeably, which can be confusing.  The technical term for a cervical Pap smear is cervical cytology; cytology means the examination of cells and in this case, it is the examination of cells from the surface of the cervix.  The test is performed by gently scraping cells off the surface of the cervix using a spatula or brush and then smearing them on a glass slide or dispersing them in a liquid medium, which is then spread onto a glass slide.  The glass slides are then stained and examined under the microscope by a pathologist.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Cervical cytology screening is recommended to begin no later than age 21 or within 3 years after a woman begins having intercourse.  Tests are performed annually until age 30, when if a woman has had 3 consecutive normal tests, she may now be screened every 2 to 3 years.  This continues until a woman reaches age 70, when if she has had 3 consecutive normal tests over a 10 year period she may choose to stop screening.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;In a similar way screening can also be performed for anal cancer and its precursors known as anal high&#45;grade squamous intraepithelial lesions (HSIL), which are also known as anal intraepithelial neoplasia 2 or 3 (AIN 2 or AIN 3) or moderate or severe dysplasia or sometimes, the term carcinoma in situ (CIS) is used. You will notice that the terms to describe cervical cancer and anal cancer precursors are very similar, and this is because in many ways the anus and cervix are very similar.  They are composed of similar types of cells that are susceptible to infection with the same types of HPV, which then in some people leads to the development of abnormal or potentially precancerous cells.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Results ./id/x/diagnosis/results.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/diagnosis/results.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;To summarize, anal cytology screening is performed in patients at risk to develop anal cancer to determine whether there are any signs of HPV&#45;related infection, particularly HSIL.  Anal cytology is a fairly good indicator of who should be examined and who might have HSIL, but it is not the best way to determine the severity of SIL nor is it the best way to diagnose invasive anal cancer.  It is our recommendation that any level of abnormal anal cytology should be followed up with further examination with DRE at a minimum and ideally, when it is available, HRA with biopsies of the most abnormal areas.  The only way to provide a sample to the pathologist adequate to make a conclusive diagnosis regarding the severity of SIL and whether or not invasion or cancer is present is by biopsy.  If someone is symptomatic with pain, bleeding or feels a mass, he or she must be examined digitally or referred to an experienced clinician who can perform a good DRE.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;Following completion of your anal exam, your provider will discuss the meaning of your results and formulate a plan for treatment, further evaluation, or for continued follow&#45;up.  With the results of anal cytology, DRE, and HRA with biopsy of any suspicious lesions we should be able to provide you with an assessment of your risk for anal cancer.  A treatment plan is based on the extent and severity of disease found factoring in whether someone has symptoms and the status of their immune system.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;A normal DRE, negative anal cytology, and no lesions seen on HRA represent a completely normal exam.  Patients should continue screening based on their immune status and their anticipated risk of exposure to HPV.  For HIV&#45;negative MSM and no prior history of anal SIL, anal cytology screening every 2 to 3 years should be adequate.  HIV&#45;positive persons should be seen annually.
			&lt;li class=&quot;aci&quot;&gt;Patients with ASC&#45;US on anal cytology and a normal DRE with no significant lesions noted on HRA who are HIV&#45;negative could be seen once a year.  HIV&#45;positive patients could be seen every 6 months.
			&lt;li class=&quot;aci&quot;&gt;Patients with ASC&#45;H on either cytology or biopsy of lesions that show atypical squamous cells suggestive of HSIL could be followed more frequently at 4 to 6 month intervals.  The natural history of ASC&#45;H is not well established, although generally we do not specifically try to treat atypia, but choose to follow patients instead.
			&lt;li class=&quot;aci&quot;&gt;Patients with LSIL on anal cytology, normal DRE and no evidence of HSIL during HRA could be followed every 6 months.  Patients with LSIL are at increased risk to progress to HSIL and should continue to be followed regularly.
			&lt;li class=&quot;aci&quot;&gt;Patients with LSIL on anal cytology who have large intra&#45;anal warts or who are symptomatic from their warts should be offered treatment.  Following treatment, patients should continue to be followed at intervals determined by their response to treatment and depending on their immune status.  Please see specific section on treatment for further information.
			&lt;li class=&quot;aci&quot;&gt;Patients with HSIL on anal cytology, a normal DRE and no lesions found on HRA should be followed more frequently, which could be at 4 month intervals.  In this case the HSIL cannot be treated unless it can be located on HRA.  It seems reasonable to follow these patients in a similar fashion to patients with untreated HSIL.
			&lt;li class=&quot;aci&quot;&gt;Patients with HSIL identified in biopsies should be treated if at all possible regardless of immune status.  Currently we think this is the best way to prevent anal cancer.  Only a small number of people with HSIL will go on to progress to invasive anal cancer, but at the present time we have no certain way of identifying who will and who will not progress.  Please see specific section on treatment for further information.
			&lt;li class=&quot;aci&quot;&gt;Patients with HSIL who cannot be treated should be followed closely and regularly.  As previously stated only a small number of people with HSIL will progress to cancer, but when progression to cancer occurs, lesions often seem to grow at a more rapid pace.  Based on our experience in several patients who had untreated HSIL who developed detectable anal cancers over a 3 to 4 month period, we recommend that patients should be seen every 4 months at a minimum.  We think this interval will permit the early detection of a cancer should it develop.  Cancers diagnosed earlier when they are smaller are more likely to be cured and often more easily cured than larger more advanced cancers.
			&lt;li class=&quot;aci&quot;&gt;Patients with exams that are suspicious for invasive anal cancer and who cannot be biopsied in clinic or in whom the exam is not adequate should be referred to an experienced surgeon for an examination under anesthesia.
			&lt;li class=&quot;aci&quot;&gt;Patients diagnosed with invasive anal cancers should be referred to providers experienced in managing this type of cancer.  For further information, please see the section on treatment of anal cancer.
			&lt;/ol&gt;&lt;p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Screening ./id/x/diagnosis/screening.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/diagnosis/screening.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;obtaining_specimen&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Obtaining an Anorectal Cytology Specimen&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;The reason to do an anal Pap smear is to look for evidence of HPV&#45;related cellular changes.  When someone becomes infected with HPV and the infection persists, the cells that are infected with HPV may not appear normal.  HPV infected cells also may divide and multiply more than normal uninfected cells.  There are also other changes that interfere with normal cellular processes at a molecular level in such a way as to allow the development of lesions or growths.  In some cases warts or condyloma grow, in other cases flat lesions occur, with thickening of the tissues and sometimes increased blood vessels, which are usually hallmarks of the precancerous kind of lesions. And in some cases with HPV, there are no visible changes seen at all.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;By obtaining a sample of cells from the anus, we can get an idea of whether HPV has caused any changes and if so, how severe these changes might be.  Most importantly, we can determine whether or not further examination is necessary.  The anal Pap smear is a blind sampling of the anal canal and similar to a cervical Pap smear, is best looked at as a general indicator of whether the cells are normal or abnormal.  If abnormal cells are present, then further examination is required to determine the exact nature of the abnormality.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;As mentioned earlier, HPV infection is the principal cause of AIN, CIN, and anal and cervical cancer.  So, why not do tests to look for HPV?  One of the reasons not to do HPV screening is that in groups of patients known to be at increased risk for anal cancer, such as HIV&#45;positive men who have sex with men (MSM) with a history of receptive anal intercourse, the likelihood of finding HPV is nearly 100%; even 60% of HIV&#45;negative MSM with a history of receptive anal intercourse have been shown to have HPV.  The point is that HPV infection is so widespread that knowing someone has HPV doesn't help discriminate who needs to be treated.  Going back to cervical cancer screening, HPV testing is only recommended for women with ASC&#45;US Pap smears and if high&#45;risk types of HPV are found then women are referred for colposcopy or examination of the cervix using a microscope.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;Remember not all people infected with HPV will have problems and we want to focus our attention on the ones in whom HPV has led to potentially precancerous changes.  The best way to do that is by sampling the cells of the anus with a Pap smear.  An anal Pap smear is performed to screen for anal HSIL (the correct terminology is to obtain a sample for anorectal cytology) in the following manner.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Patients are asked not to douche or have an enema or insert anything into their anus for 24 hours prior to an anal cytology exam.
			&lt;li class=&quot;aci&quot;&gt;Lubricants should not be used prior to obtaining a cytology sample because the lubricant may interfere with the processing and interpretation of the sample.
			&lt;li class=&quot;aci&quot;&gt;We usually obtain the sample with the patient lying on their left side, but other positions are acceptable.
			&lt;li class=&quot;aci&quot;&gt;The buttocks are retracted to visualize the anal opening and a Dacron or polyester tipped swab moistened in tap water is inserted for approximately 2 to 3 inches into the anus.  The swab can be felt to pass through the internal sphincter so the sample is obtained from the junction of the anus and rectum, which is where most of the HPV&#45;related lesions are found.  This area is slightly above the region that corresponds anatomically to the dentate line.
			&lt;li class=&quot;aci&quot;&gt;The swab is rotated 360 degrees with firm lateral pressure applied to the end of the swab, such that it is bowed slightly and then it is slowly withdrawn over a period of 15 to 30 seconds from the anus, continuing to rotate the swab in a circular fashion.  The lateral pressure ensures that the mucosal surface, rather than rectal contents are sampled.
			&lt;li class=&quot;aci&quot;&gt;The swab is either smeared directly onto a glass slide and fixed as a conventional Pap smear by placing it into alcohol, or the swab is placed in a preservative vial and vigorously agitated to disperse the cells for liquid based cytology.
			&lt;li class=&quot;aci&quot;&gt;Regardless of method used, the sample must be fixed quickly within 15 seconds in order to avoid drying artifact, which occurs easily and makes interpretation difficult.
			&lt;li class=&quot;aci&quot;&gt;The slides are stained using the Papanicolau stain, hence the term Pap smear, and then are examined by the pathologist.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;possible_results&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;What are the Possible Results from Anal Cytology and What Do They Mean?&lt;/b&gt;&lt;/p&gt;

			&lt;p style=&quot;width:530px; padding:10px;background:#fffff4;&quot;&gt;&lt;img src=&quot;/analcancerinfo/images/schematic530.gif&quot; align=center&gt;&lt;br clear=all&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;width:530px;&quot;&gt;As shown in this illustration, with increasing severity of SIL, of either the cervix or anus, the proportion of the epithelium replaced by immature cells with large nuclear&#45;cytoplasmic ratios increases.  Invasive cancer probably arises from one or more foci of high&#45;grade squamous intraepithelial lesions (HSIL), which is depicted in the drawing by epithelial cells crossing the basement membrane.  All epithelial cells sit on a basement membrane and below the basement membrane are connective tissue, blood vessels, nerves, and the muscles of the anus.  Cancer arises when abnormal HSIL cells develop additional genetic changes, which then turns them into cancer cells that have the ability to invade across the basement membrane into normal tissues.&lt;br&gt;

			&lt;span style=&quot;color:#999999;font&#45;size:10px;&quot;&gt;Adapted and used with permission of Joel Palefsky, MD&lt;/span&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Examination of an anal cytology specimen will yield one of the following results:&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Insufficient&lt;/b&gt;: not enough cells were obtained for the pathologist to evaluate to make an interpretation: a new sample should be obtained.  Some of the reasons why the specimen may have been inadequate include having an enema or sex within 24 hours prior to collecting the specimen or the swab may not have been inserted deep enough or rotated with enough pressure to dislodge cells from the lining of the anus.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Negative for intraepithelial lesions&lt;/b&gt;: the sample had an adequate number of cells to be examined and they were normal in appearance with no evidence of HPV&#45;related changes.  It is still possible to have HSIL, because the swab may not have sampled an area of HSIL if it was very small or hidden deep in a fold and sometimes the lesions just don't shed cells.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;ASC&#45;US (atypical squamous cell&#45;undetermined significance)&lt;/b&gt;: also known as atypia, which means that the cells were somewhat abnormal in appearance but not so much so as to be formally classified as a SIL.  Based on our natural history studies, we currently recommend that patients with ASC&#45;US on anal cytology be examined with a digital rectal examination (DRE) and using high&#45;resolution anoscopy (HRA).  HRA will be described below and is a more effective way of visually inspecting the anus for the presence of any lesions.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;ASC&#45;H (atypical squamous cells&#45;cannot exclude HSIL)&lt;/b&gt;: this is another form of atypia in which the cells appear more abnormal and in some ways similar to HSIL, but the changes are not definitive enough to make a diagnosis of HSIL.  Similar to the recommendations for ASC&#45;US, patients with this type of atypia should be examined with DRE and HRA and are probably more likely to have either LSIL or HSIL found.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;LSIL (low&#45;grade squamous intraepithelial lesion)&lt;/b&gt;: also known as mild dysplasia or AIN 1, these changes include anal warts, which are also known as condyloma.  As mentioned above, since cytology is not the best way to determine the exact level of abnormality, patients with LSIL on cytology should be examined with DRE and HRA to look for evidence of HSIL or anal cancer.  More than half of patients with LSIL on cytology will have HSIL found during HRA.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;HSIL (high&#45;grade squamous intraepithelial lesion)&lt;/b&gt;: often subdivided into moderate or severe dysplasia, which are also known as AIN 2 or 3.  Most patients with HSIL on anal cytology will have a lesion visible on HRA that when biopsied will also show HSIL.  As with lower grades of abnormality, patients should undergo DRE and HRA to be sure that anal cancer is not present.  Remember the swab is sampling only the cells on the surface, and as seen in the diagram, cancer develops when cells invade more deeply.  This means that these cells may not be sampled with a Pap smear.  Also since we believe that HSIL is a potentially precancerous lesion, then patients should be examined to determine how best to eliminate these areas as a means of preventing invasive anal cancer from developing.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;HSIL with features suggestive of invasion&lt;/b&gt;: the pathologist detects very abnormal cells that appear like cancer cells.  As mentioned, patients should be examined as above with a DRE and HRA with biopsies.  A biopsy is when samples of the most abnormal areas are cut out, so the pathologist can see the relationship of the cells to one another and evaluate the tissue underneath to see whether there are cells invading across the basement membrane as shown in the diagram above, which is how cancer is diagnosed.
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Squamous cell cancer (invasive anal cancer)&lt;/b&gt;: this is the type of cancer that develops in the anus and is very different from colon or rectal cancer, although many people, including some health care providers, will incorrectly use the term rectal cancer for anal cancer.  The anus is the opening to the rectum and is composed of skin type cells called squamous cells, which are susceptible to HPV, which in a very small percentage of all those infected develops into cancer.  In contrast, cancers of the rectum and colon are called adenocarcinomas.  They develop from the gland&#45;like cells of the colon and rectum, which are different than the skin cells of the anus and do not become infected with HPV.  Rectal or colon cancer is a type of cancer in which an increased tendency to develop it can be inherited from your parents; there is no inherited risk for anal cancer.
			&lt;/ol&gt;&lt;p&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
AIN2/3 ./id/x/hpv/ain23.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/hpv/ain23.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;The spectrum of disease changes caused by HPV goes from AIN1 to AIN2/3 to invasive anal cancer.  Other terms for AIN2/3 include moderate or severe dysplasia and high&#45;grade squamous intraepithelial lesions (HSIL).  Unlike AIN1, many experts believe that AIN2/3 has the potential to progress to invasive cancer.  For this reason, anal screening programs are designed to find AIN2/3 and remove it before it has the chance to progress to cancer.  AIN2/3 is not as common as AIN1, and in the majority of people AIN2/3 will either stay that way or go away by itself.  Over time though, and it could be as long as several decades, AIN2/3 may progress to cancer if left untreated.  There are no data yet that tell us the proportion of AIN2/3 that will progress, nor how long it takes.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;AIN2/3 is painless but may lead to bleeding when inside the anal canal.  Outside the anal canal it may itch or bleed but again is usually painless.  AIN2/3 can be found in either HIV&#45;seronegative people or HIV&#45;seropositive people, but it tends to be more common among the HIV&#45;seropositive people and the lesions tend to be bigger (and therefore harder to treat).  Some studies have shown that given enough time, about half of HIV&#45;seropositive men with a history of receptive anal intercourse will develop AIN2/3.  That number is lower in HIV&#45;seropositive women, but still pretty high at about 25%.  There are few data on how common AIN2/3 is among HIV&#45;seronegative men and women without a history of anal intercourse but it is likely to be fairly uncommon.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer ./id/x/hpv/analcancer.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/hpv/analcancer.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; class=&quot;bluify&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;Anal cancer is a bad disease to get.  In the general population, it is a rare cancer, found in about 1 per million people every year in the United States.  But studies have shown that people in the groups referred to above are at higher risk.  Among HIV&#45;seropositive men with a history of receptive anal intercourse, the risk may be about 1 in a thousand men per year (no one really knows for sure).  The risk is about a third of that for HIV&#45;seronegative men with a history of receptive anal intercourse.  Among HIV&#45;seropositive women the risk is probably about 1 in 10,000 women per year.  Again, no one really knows for sure.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;These numbers indicate that on an individual basis, the risk of getting anal cancer is very low.  Despite that, several thousand people die every year of anal cancer in the general population, and a high proportion of these are men with a history of anal intercourse, whether HIV&#45;positive or HIV&#45;negative.  In the past, anal cancer usually occurred in people over the age of 60 years.  In the last few decades or so, though, that has changed, particularly among HIV&#45;seropositive men and women, in whom the average age of diagnosis is now in the 40's.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;One of the major unanswered questions about anal cancer is whether HIV&#45;seropositive men and women on highly active antiretroviral therapy (HAART) will be at lower risk of anal cancer due to HAART or higher risk.  HAART has lowered the risk of several other types of cancer such as Kaposi's sarcoma so it would be logical to think the same may be true of anal cancer.  On the other hand, since AIN2/3 can take many years to progress to cancer, it is possible that the increased survival time brought about by HAART may also give people the time to develop anal cancer of their AIN2/3 is not treated.  The answer is not yet in, but early data suggest that if anything the risk of anal cancer will stay the same or continue to rise among people on HAART rather than drop.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;The good news about anal cancer is that it is usually treated successfully if caught early. Most people will survive it.  The bad news is that the recommended treatment for anal cancer &#45; a combination of chemotherapy and radiation therapy&#45; causes lots of side effects that can last for years.  These can include severe anal pain (proctitis).  For this reason, many experts believe that it is better to seek and treat AIN2/3 to prevent anal cancer since the treatment can be simple, even though in most cases the AIN2/3 would not have progressed to cancer even if left untreated.  The problem is that clinicians have no way to distinguish the AIN2/3 that will progress from the ones that won't.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;See the &lt;a href=&quot;/analcancerinfo/cancer/&quot;&gt;Anal Cancer&lt;/a&gt; section for a complete discussion of this topic.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
HPV ./id/x/hpv/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/hpv/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;There are over 200 different kinds of HPV but only about 20 or so commonly infect the genital region.  HPV types 6 and 11 cause genital warts.  Since warts do not usually progress to cancer, HPV 6 and 11 are considered to be &quot;low&#45;risk of cancer&quot; HPV types.  They are also called &quot;non&#45;oncogenic,&quot; meaning non&#45;cancer&#45;causing.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;On the other hand, there are a variety of &quot;high&#45;risk,&quot; or oncogenic (cancer&#45;causing) HPV types that also infect the anal canal.  The most common of these is HPV type 16.  Other common types include HPV18, HPV31, HPV33, HPV35, and several others.  Many people have warts on their hands and feet, and these are usually caused by types 1, 2 or 4. These HPV types do not cause cancer and the good news is that they only rarely go the genital skin. Likewise, genital HPV types only rarely live in the skin of the hands and feet.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;HPV lives only in skin cells (epithelium) and no other kinds of cells, so the only way to get it from another person is through skin&#45;to&#45;skin spread.  That usually means contact between genital skin to genital skin. It is currently believed that HPV is rather easily acquired, and while wearing condoms may help some, it is by no means completely effective to prevent HPV spread.  Many people get HPV within having their first few sexual partners.  With a higher number of partners, the risk of acquiring new HPV types increases even more.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;How common is anal HPV infection?  Nearly all HIV&#45;seropositive men with a history of receptive anal intercourse have anal HPV infection.  About 60% of HIV&#45;seronegative men with a history of receptive anal intercourse have anal HPV infection, and even 60% of HIV&#45;seropositive men &lt;i&gt;without&lt;/i&gt; a history of receptive anal intercourse have anal HPV infection. One recent study showed that the prevalence of anal HPV infection stays pretty consistent at that rate from ages 20 to 60.  Very little is known about how common anal HPV infection is among HIV&#45;seronegative men without a history of receptive anal intercourse.  Many men and women also have multiple HPV types at one time.  This tends to be more common among HIV&#45;seropositive men and women, and especially among people with lower CD4+ T cell counts.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;Women are at risk of anal HPV infection too.  Most of the studies have been done on HIV&#45;seropositive women and HIV&#45;seronegative women at high risk of HIV infection either through heterosexual contact with a male with HIV infection or through injection drug use.  These studies show that about 76% of HIV&#45;seropositive women and 42% of HIV&#45;seronegative women are at high risk of HPV infection.  These figures were even more common than the rates of cervical HPV infection!  Very little is known about other populations of women but one study of HIV&#45;seropositive adolescent girls showed a 59% rate of infection.  How do women get anal HPV infection?  Some get it through anal intercourse but others may get it through spread from their vagina or vulva, or through anal insertion of fingers or toys during sex.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;What is the natural history of anal HPV infection?  We don't really know since long&#45;term studies have never been done.  What is clear though is that most people don't run into trouble from HPV infection.  Some people develop AIN due to HPV infection, but most of the cases of AIN will not progress to cancer.  In most people the AIN will go away by itself and they will not even have been aware of it.  But for some people can be a real problem.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Warts &amp; AIN1 ./id/x/hpv/warts.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/hpv/warts.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;Anal warts are a variant of AIN1. Other terms for AIN1 are mild dysplasia and low&#45;grade squamous intraepithelial lesions (LSIL).  Anal warts are the way most people become aware that they have anal HPV infection.  Anal warts are among the most common sexually acquired diseases. They are usually caused by HPV6 or HPV11 and, like AIN1, rarely if ever progress to cancer.  But, even so, nobody likes them!  They are unsightly and they can bleed or itch.  They can be found outside the opening of the anus or in the anal canal up to and including the transformation zone.  That means they don't usually go much beyond 1 or 2 inches into the anus.  Much of the time warts will go away by themselves, but they often will not.  It is not possible to tell which will go away by themselves and which need to be treated.  If left untreated, some warts will continue to grow in size and spread to other areas of the genitals; others just stay the way they are.&lt;/p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/ain.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/ain.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/cervicalcancer.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/cervicalcancer.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/conclusion.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/conclusion.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/hpv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/hpv.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Incidence ./id/x/overview/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;



			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/other.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/other.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/papsmear.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/papsmear.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/overview/populations.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/overview/populations.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Current Research &amp; Clinical Trials ./id/x/research/index-old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/research/index-old.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;bluify&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;We are a team of highly dedicated clinicians and scientists at the UCSF Comprehensive Cancer Center and the UCSF General Clinical Research Center.  The group, led by Dr. Joel Palefsky, Professor of Medicine at UCSF, is devoted to performing research that seeks to promote awareness of and screening for AIN and anal cancer, identify the causes of AIN and anal cancer, and develop new and better therapies for these diseases.&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Actively recruiting for the following clinical trials:&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;A Study to Determine the Efficacy of a Prophylactic Vaccine for HPV to Prevent Anal and Penile HPV Infection, Anogenital Warts and Dysplasia in Men who have Sex with Men (MSM)&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Study objectives:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;ol style=&quot;list&#45;style&#45;type:lower&#45;alpha&quot;&gt;
			&lt;li class=&quot;aci&quot;&gt;To demonstrate that a 3&#45;dose regimen of quadrivalent HPV (Types 6, 11, 16, 18) L1 virus&#45;like particle (VLP) vaccine, when administered at 0, 2, and 6 months, is generally well tolerated in 16&#45; to 26&#45;year&#45;old men.
			&lt;li class=&quot;aci&quot;&gt;To demonstrate that the quadrivalent HPV VLP vaccine reduces the incidence of HPV 6&#45;, 11&#45;, 16&#45;, or 18 related anogenital warts and dysplasia in 16&#45; to 26&#45;year&#45;old men who are na&amp;iuml;ve to the relevant HPV type, compared with placebo.
			&lt;/ol&gt;&lt;br&gt;

			&lt;b&gt;Who is eligible:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			MSM aged 16&#45;26 who have had receptive or insertive anal intercourse at least once, but with fewer than 5 lifetime male or female sexual partners.
			Study procedures: This is a randomized placebo controlled double&#45;blinded Phase III study that includes 9 visits over a 3&#45;year period.  Half of the subjects will be given vaccine and half will receive placebo.  At Day 1, each subject will undergo informed consent procedures.  If they agree to participate in the study, the subjects will undergo a general medical history (including a detailed sexual history) and physical examination (including a detailed inspection of the genital and peri&#45;anal regions).  Subjects with clinically diagnosed anogenital warts will not be enrolled.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Study vaccine/placebo will be administered at Day 1, Month 2, and Month 6.  Specimens will be collected for HPV testing from the penis, scrotum, and peri&#45;anal region.  External genital lesions judged to be possibly HPV&#45;related will be biopsied. Subjects will undergo a digital rectal exam, intra&#45;anal sampling for HPV and anal cytology testing at all genital examination visits.  Those who have abnormal cytology will undergo high resolution anoscopy (HRA) with biopsy of visible lesions. A 10&#45;mL blood sample will be collected at Day 1 and Months 7, 24, and 36 for detection of anti&#45;HPV antibodies. A rectal swab specimen will be collected for gonorrhea and chlamydia culture at Day 1 and Months 12, 24, 36 visits.  A serum sample will be collected from these subjects for HIV and syphilis serology testing at Day 1 and Month 12, 24, 36 visits.  If clinically indicated, subjects may be tested at any time for gonorrhea, chlamydia, hepatitis B, hepatitis C, herpes simplex, HIV, or syphilis.  Ongoing education will be provided to the subjects to increase their knowledge base regarding HPV and other health&#45;related issues.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;What if warts or dysplasia are found in the course of the study:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			If the primary care provider agrees, the study staff will treat these lesions at no cost to the subject once the necessary biopsies have been obtained. &lt;b&gt;&lt;i&gt;However, if other infections such as HIV, herpes, chlamydia, gonorrhea, hepatitis or syphilis are found, the participant will be referred to his own doctor for treatment and follow&#45;up.  The study will not cover the cost of this care.&lt;/i&gt;&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The study is being conducted at the UCSF/Mount Zion Medical Center.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Study subjects will receive $75 for their time and travel expenses in cash at the end of each of the nine visits.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Interested men should call Marya Krogstad, R.N. at (415) 353&#45;7527.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Anal dysplasia: a substudy of a large, simple trial comparing two strategies for management of anti&#45;retroviral therapy (The SMART Study)&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This is a multicenter study of the Terry Beirn Community Programs for Clinical Research on AIDS and sponsored by: The National Institute of Allergy and Infectious Diseases, Division of AIDS.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The purpose of this study is to compare the Drug Conservation (DC) and the Viral Suppression (VS) strategies of the SMART Study for the development of high&#45;grade anal dysplasia or anal cancer.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Study design:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This is a substudy of a multi&#45;center randomized trial, the SMART Study.  Patients are randomized equally by the SMART Study, 1:1 to the Drug Conservation (DC) and Viral Suppression (VS) groups.  DC is a strategy aimed at conserving drugs through episodic use of antiretroviral treatment for the minimum time to maintain CD4+ cell count &amp;ge; 250 cells/mm&lt;sup&gt;&lt;small&gt;3&lt;/small&gt;&lt;/sup&gt;, and VS is a strategy aimed at suppressing viral load as much as possible irrespective of CD4+ cell count.  Patients will be followed in this substudy until they have reached the primary substudy endpoint, or to the common closing date of the SMART Study.  The primary substudy endpoint is the time to development of high&#45;grade anal dysplasia or anal cancer.  Patients who reach the primary substudy endpoint will continue to be followed in the main SMART Study.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			A total of 560 patients will be enrolled.  This is considered sufficient to enroll 400 patients without high&#45;grade anal dysplasia or anal cancer at baseline.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Inclusion Criteria:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Signed informed consent
			&lt;li class=&quot;aci&quot;&gt;Patient will simultaneously co&#45;enroll in the SMART Study
			&lt;li class=&quot;aci&quot;&gt;Normal anal cytology result &lt;b&gt;or&lt;/b&gt;, if baseline anal cytology is abnormal, high&#45;resolution anoscopy (HRA) has been performed and specimens have been obtained (HRA cytology specimen and, if applicable, biopsy) to demonstrate that subjects do not have HSIL.
			&lt;/ol&gt;&lt;br&gt;

			&lt;b&gt;Exclusion Criteria:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Current or prior history of anal or cervical cancer (excluding baseline cytology and biopsy results)
			&lt;li class=&quot;aci&quot;&gt;A known permanent or irreversible bleeding disorder that, in the opinion of the investigator, would contraindicate any biopsy of the anal canal
			&lt;/ol&gt;&lt;br&gt;

			&lt;b&gt;Study Procedures:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Patients will be co&#45;enrolled in the substudy at the same time as in the main SMART Study.  The following data will be collected at &lt;i&gt;baseline&lt;/i&gt; (within 90 days prior to randomization) and &lt;i&gt;annually&lt;/i&gt;: anal swab for cytology and human papilloma virus (HPV) testing, cervical swab for HPV testing (for a subset of women), history of treatment for anal condyloma or dysplasia, detailed sexual history, history of sexually transmitted infections, history of anal fissures, fistulas, diarrhea, hemorrhoids, and other relevant diseases, and alcohol and recreational drug use.  If the anal cytology shows high&#45;grade squamous intraepithelial lesions (HSIL) or atypical squamous cells where HSIL cannot be ruled out (ASC&#45;H) during follow&#45;up, or any abnormality at baseline, then HRA is performed with a biopsy of visible lesions. A second specimen for anal cytology is collected before HRA, to be interpreted if HRA and biopsy do &lt;i&gt;not&lt;/i&gt; identify high&#45;grade anal dysplasia.  Additionally, if the annual anal cytology shows atypical squamous cells of undetermined significance (ASC&#45;US) or low&#45;grade squamous intraepithelial lesions (LSIL), then a follow&#45;up cytology is performed.  Depending on these cytology results, HRA and biopsy may be performed.  If anal HSIL or anal cancer is diagnosed, then the primary endpoint has been met and follow&#45;up in the anal dysplasia substudy ends, although follow&#45;up in the main SMART study continues.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Subjects with abnormal anal cytology will be evaluated in the UCSF Anal Dysplasia Clinic.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This study is designed for men and women newly enrolling in the SMART study.  Men and women interested in this study should contact Mike Jones at (415) 476&#45;9554 x 343.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Solid organ transplantation in HIV: multisite study&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This is a national multisite study sponsored by UCSF and the National Institute of Allergy and Infectious Diseases.  The goal of the study is to prospectively evaluate the safety and efficacy of solid organ transplantation in HIV&#45;positive patients.  The target number of subjects is 150 kidney transplants and 125 liver transplants.  A secondary goal is to explore the impact of post&#45;transplant immunosuppression on the host response to viral co&#45;pathogens including hepatitis b, hepatitis c, cytomegalovirus, Epstein&#45;Barr virus, human herpesviruses 6 and 8, and human papillomavirus.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Solid organ transplant recipients have an increased incidence of HPV&#45;related anogenital neoplasia as do HIV&#45; positive patients.  Therefore, HIV&#45;positive solid organ transplant recipients may be at even greater risk.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			In the HPV substudy we seek to determine the prevalence of HPV infection and anal SIL before and after transplantation.  Patients enrolled in the main transplant study have samples obtained for anal cytology and HPV testing every 3 to 6 months either at UCSF, Cedars Sinai Medical Center in Los Angeles, University of Maryland, or Mount Sinai School of Medicine and Columbia University in New York City.  Patients with any level of cytologic abnormality are referred to local clinicians experienced in HRA for further evaluation.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			For further information contact Rodney Rogers at (415) 514&#45;2194.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Collection of specimens for the ACSR&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Many scientists are interested in learning more about HPV and studying how it leads to anogenital cancer.  Patients in the Anal Dysplasia Clinic may be asked if they are willing to donate anal tissue and blood to the AIDS Clinical Specimen Resource (ACSR).  The ACSR is supported by the National Institutes of Health to collect and store tissues and send them to qualified scientists after a rigorous scientific review.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Collection of specimens for Dr. Joel Palefsky’s lab&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The ways that HPV contributes to the development of cancer are not well understood.  The goal of this study is to collect anal tissues and analyze them to understand the changes in cellular genes that may be playing a role.  Other kinds of studies are in progress as well.  Patients in the UCSF Anal Dysplasia Clinic may be asked if they are willing to donate tissue for these purposes.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Collection of specimens for molecular genetic analysis during surgery&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The ways that HPV contributes to the development of cancer are not well understood.  The goal of this study is to collect anal tissues and analyze them to understand the changes in cellular genes that may be playing a role.  Patients in the UCSF Anal Dysplasia Clinic who are undergoing surgery to treat anal neoplasia or warts may be asked if they are willing to donate tissue for this purpose.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;TOPS study: The role of HPV infection and HPV&#45;related lesions as risk factors for the acquisition of HIV infection.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This study is examining the role of HPV as a risk factor for the acquisition of HIV.  Sexually transmitted diseases (STDs) such as gonorrhea and chancroid have been shown to be cofactors for HIV acquisition.  However, very little information is available regarding the role of HPV infection and cervical or anal pre&#45;cancerous lesions as risk factors for acquiring HIV infection.  The specific aims of this study are to examine the role of anal and cervical pre&#45;cancerous lesions as cofactors for HIV acquisition, and to examine the association of HPV infection with HIV acquisition.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			TOPS is a case&#45;control study of 140 new HIV cases that will be identified over 4 years from the ongoing Options Project, an NIH&#45;funded study of women and men with primary (acquired recently) HIV infection (PHI).  The referent group will be 140 men and women referred to the Options Project because of possible PHI but found to be HIV&#45;negative.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			All participants will have samples obtained for anal HPV testing and anal cytology and have high&#45;resolution anoscopy (HRA) to assess for HPV&#45;related lesions.  Women will also undergo cervical PAP smears and colposcopy.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Self reports regarding sexual behavior, drug use, STD history and laboratory data for STDs will also be collected and included in statistical models.  If HPV&#45;associated epithelial abnormalities are risk factors for HIV infection, then identification of such lesions may improve assessment of HIV transmission risk and could direct future interventions for HIV prevention.
			&lt;/ol&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Publications from completed clinical trials:&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, Holly EA,
			Darragh T, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			High&#45;resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182&#45;9&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Efird JT, Da Costa M, Jay N, Berry JM, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV&#45;positive men who have sex with men.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			AIDS. 2005 Sep 2;19(13):1407&#45;14.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chin&#45;Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Age&#45;related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Natl Cancer Inst. 2005 Jun 15;97(12):896&#45;905.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chin&#45;Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Age&#45;Specific prevalence of anal human papillomavirus infection in HIV&#45;negative sexually active men who have sex with men: the EXPLORE study.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Infect Dis. 2004 Dec 15;190(12):2070&#45;6. Epub 2004 Nov 10.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Cranston RD, Darragh TM, Holly EA, Jay N, Berry JM, Da Costa M, Efird JT, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Self&#45;collected versus clinician&#45;collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV&#45;positive men.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915&#45;20.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Surgical treatment of high&#45;grade anal squamous intraepithelial lesions: a prospective study.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Dis Colon Rectum. 2002 Apr;45(4):453&#45;8.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Encapsulated plasmid DNA treatment for human papillomavirus 16&#45;associated anal dysplasia: a Phase I study of ZYC101.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Clin Cancer Res. 2002 May;8(5):1028&#45;37.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, Berry JM, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422&#45;8.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Prevalence and risk factors for anal squamous intraepithelial lesions in women.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Natl Cancer Inst. 2001 Jun 6;93(11):843&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV&#45;positive and HIV&#45;negative men.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):256&#45;62.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			High incidence of anal high&#45;grade squamous intra&#45;epithelial lesions among HIV&#45;positive and HIV&#45;negative homosexual and bisexual men.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			AIDS. 1998 Mar 26;12(5):495&#45;503.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Arthur SP, Jay N, Berry JM, DaCosta MM, Botts R, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Anal squamous intraepithelial lesions in HIV&#45;positive and HIV&#45;negative homosexual and bisexual men: prevalence and risk factors.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320&#45;6.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, Berry JM, Jay N, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV&#45;positive and HIV&#45;negative homosexual men.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Dis Colon Rectum. 1997 Aug;40(8):919&#45;28.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Acta Cytol. 1997 Jul&#45;Aug;41(4):1167&#45;70.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Anal cytology as a screening tool for anal squamous intraepithelial lesions.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415&#45;22.
			&lt;/ol&gt;
			&lt;br&gt;&lt;/p&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Current Research &amp; Clinical Trials ./id/x/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/research/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;We are a team of highly dedicated clinicians and scientists at the UCSF Comprehensive Cancer Center and the UCSF General Clinical Research Center.  The group, led by Dr. Joel Palefsky, Professor of Medicine at UCSF, is devoted to performing research that seeks to promote awareness of and screening for AIN and anal cancer, identify the causes of AIN and anal cancer, and develop new and better therapies for these diseases.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;&lt;b&gt;Actively recruiting for the following clinical trials:&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Phase II Study for Treatment of Anal HSIL through Use of a Chinese Herbal Topical Cream&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Study Objectives:&lt;/b&gt;&lt;br&gt;
			&lt;ol style=&quot;list&#45;style&#45;type:lower&#45;alpha;&quot;&gt;
			&lt;li class=&quot;aci&quot;&gt;To determine the safety and efficacy of a Chinese herbal topical cream for the treatment of anal HSIL in HIV&#45;positive individuals.
			&lt;li class=&quot;aci&quot;&gt;To evaluate treatment adherence and drop&#45;out rates; to obtain effect size for a Phase III trial; to test ability to maintain placebo blinding; to assess topical herb cream application methods and dosing; to obtain initial assessment of Chinese diagnoses found in HIV&#45;positive people with anal HSIL; and to conduct laboratory analysis to identify potential biologic pathways and mechanisms by which the Traditional Chinese Medicine intervention may have an effect.
			&lt;/ol&gt;&lt;br&gt;

			&lt;b&gt;Who is eligible&lt;/b&gt;:  HIV&#45;positive adults who have anal HSIL.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Study procedures&lt;/b&gt;:  This is a randomized controlled intent&#45;to&#45;treat efficacy trial comparing a topical Chinese herbal cream to a placebo cream in men and women with histologically confirmed anal high&#45;grade squamous intraepithelial lesions (HSIL) over a 60&#45;week period.  Subjects will apply the cream at home twice daily for 48 weeks, followed by a 12&#45;week follow up period.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Collection of specimens for Dr. Joel Palefsky's lab&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The ways that HPV contributes to the development of cancer are not well understood.  The goal of this study is to collect anal tissues and analyze them to understand the changes in cellular genes that may be playing a role.  Other kinds of studies are in progress as well.  Patients in the UCSF Anal Dysplasia Clinic may be asked if they are willing to donate tissue for these purposes.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;TOPS study: The role of HPV infection and HPV&#45;related lesions as risk factors for the acquisition of HIV infection.&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			This study is examining the role of HPV as a risk factor for the acquisition of HIV.  Sexually transmitted diseases (STD) such as gonorrhea and chancroid have been shown to be cofactors for HIV acquisition.  However, very little information is available regarding the role of HPV infection and cervical or anal pre&#45;cancerous lesions as risk factors for acquiring HIV infection.  The specific aims of this study are to examine the role of anal and cervical pre&#45;cancerous lesions as cofactors for HIV acquisition, and to examine the association of HPV infection with HIV acquisition.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			TOPS is a case&#45;control study of 140 new HIV cases that will be identified over 4 years from the ongoing Options Project, an NIH&#45;funded study of women and men with primary (acquired recently) HIV infection (PHI).  The referent group will be 140 men and women referred to the Options Project or seen at San Francisco City Clinic because of possible PHI but found to be HIV&#45;negative.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			All participants will have samples obtained for anal HPV testing and anal cytology and have high&#45;resolution anoscopy (HRA) to assess for HPV&#45;related lesions.  Women will also undergo cervical PAP smears and colposcopy.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			Self reports regarding sexual behavior, drug use, STD history and laboratory data for STDs will also be collected and included in statistical models.  If HPV&#45;associated epithelial abnormalities are risk factors for HIV infection, then identification of such lesions may improve assessment of HIV transmission risk and could direct future interventions for HIV prevention.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;IMPACT study: Investigating Motivations for Participation in Anal Cancer Prevention Trials&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;

			A definitive trial to establish screening and treatment recommendations for anal cancer requires the involvement of thousands of participants with specific demographic traits to be screened and observed for several years. Recruitment and retention of such a large number of people presents a number of challenges.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The IMPACT study aims to identify the motivations, barriers, incentives, and concerns related to potential participation, including the willingness of health care providers to refer eligible participants. The project will also aid in the determination of optimum design for the future definitive study, including sample size and recruitment strategies.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			The IMPACT study will conduct multiple focus groups with ethnically and geographically diverse populations in cities across the United States in an attempt to assess these aspects of future involvement in anal cancer screening trials. Information gathered from these groups and interviews with health care providers will be analyzed and used to develop a national online survey for collecting further data relevant to preparation of the larger study. Our &lt;a href=&quot;http://www.surveygizmo.com&quot;&gt;online surveys&lt;/a&gt; are powered by SurveyGizmo.

			&lt;/ol&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;&lt;b&gt;Publications from completed clinical trials:&lt;/b&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, Holly EA, Darragh T, Palefsky JM.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			High&#45;resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182&#45;9&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Efird JT, Da Costa M, Jay N, Berry JM, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV&#45;positive men who have sex with men.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			AIDS. 2005 Sep 2;19(13):1407&#45;14. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chin&#45;Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Age&#45;related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Natl Cancer Inst. 2005 Jun 15;97(12):896&#45;905. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chin&#45;Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Age&#45;Specific prevalence of anal human papillomavirus infection in HIV&#45;negative sexually active men who have sex with men: the EXPLORE study.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Infect Dis. 2004 Dec 15;190(12):2070&#45;6. Epub 2004 Nov 10. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Cranston RD, Darragh TM, Holly EA, Jay N, Berry JM, Da Costa M, Efird JT, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Self&#45;collected versus clinician&#45;collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV&#45;positive men.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915&#45;20. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Surgical treatment of high&#45;grade anal squamous intraepithelial lesions: a prospective study.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			Dis Colon Rectum. 2002 Apr;45(4):453&#45;8. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Encapsulated plasmid DNA treatment for human papillomavirus 16&#45;associated anal dysplasia: a Phase I study of ZYC101.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			Clin Cancer Res. 2002 May;8(5):1028&#45;37. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, Berry JM, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422&#45;8. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Prevalence and risk factors for anal squamous intraepithelial lesions in women.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Natl Cancer Inst. 2001 Jun 6;93(11):843&#45;9. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV&#45;positive and HIV&#45;negative men.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):256&#45;62. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			High incidence of anal high&#45;grade squamous intra&#45;epithelial lesions among HIV&#45;positive and HIV&#45;negative homosexual and bisexual men.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			AIDS. 1998 Mar 26;12(5):495&#45;503. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Ralston ML, Arthur SP, Jay N, Berry JM, DaCosta MM, Botts R, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Anal squamous intraepithelial lesions in HIV&#45;positive and HIV&#45;negative homosexual and bisexual men: prevalence and risk factors.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320&#45;6. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, Berry JM, Jay N, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV&#45;positive and HIV&#45;negative homosexual men.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314&#45;9. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			Dis Colon Rectum. 1997 Aug;40(8):919&#45;28. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA, Palefsky JM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			Acta Cytol. 1997 Jul&#45;Aug;41(4):1167&#45;70. &lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			Anal cytology as a screening tool for anal squamous intraepithelial lesions.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415&#45;22.
			&lt;/ol&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Anal Cancer Info -  ./id/x/research/trials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/research/trials.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Treatment of HGAIN ./id/x/treatment/hgain.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/hgain.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;The primary purpose of treating anal HGAIN is to prevent the progression of these lesions to cancer. Although most of these will not progress to cancer, based on the success with decreased rates in cervical cancer associated with treatment of the cervical precancer HSIL lesions, we believe that anal HGAIN should be treated when possible. We do not have any way to determine which HGAIN is more likely to progress to a cancer. It is also important to treat any HGAIN that is suspicious for anal cancer, or is symptomatic and causing problems such as bleeding or irritation.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;HGAIN can occur inside or outside the anal canal around the anal opening, which is called the perianal region or perianus. Perianal HGAIN is often called Bowen's disease and is often treated by dermatologists.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;Like warts, the goal of treatment is to eradicate the HGAIN. HGAIN can only be successfully treated if it can be seen. &lt;a href=&quot;/analcancerinfo/diagnosis/examination.html&quot;&gt;Many of these lesions can only be diagnosed and seen with the aid of a colposcope or other magnification&lt;/a&gt;.  The magnification and lighting of the colposcope along with the application of acetic acid (vinegar) allows for even very small lesions to be seen which would otherwise be invisible to the naked eye. Although lesions can recur, any lesion that is successfully ablated will be gone and therefore cannot progress to a cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;Internal HGAIN will be best treated with the aid of the colposcope to determine the complete extent of the disease. External disease should be evaluated to determine whether or not it extends internally to the anus, and also towards the vulva in women. Sometimes perianal (external) HGAIN can be treated at the same procedure for vulvar HSIL or warts. Depending on the type of procedure, this may be done as a joint procedure with your proctologist, dermatologist, or gynecologist.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;HGAIN can be treated surgically or with office&#45;based therapies. Some patient&#45;applied therapies have been used for treatment of external anal HGAIN but have not been studied in treatment trials.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;There are circumstances in which HGAIN cannot be treated. Sometimes the amount of disease is so extensive that it would require ablating the entire anal canal. Sometimes the patient is not physically able to handle an extensive procedure. We will usually attempt to remove even extensive HGAIN in several procedures if possible. But in people for whom the disease keeps recurring despite treatment, careful and frequent monitoring of the HGAIN with Pap smear, HRA and careful digital rectal exams every 3&#45;4 months to be certain that cancer is not developing may be the best course of action.&lt;/p&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Treatment of Non-Cancerous HPV ./id/x/treatment/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/index.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;Treatment of anal HPV&#45;associated disease depends on the diagnosis, location, and size or amount of disease.  Most clinicians treat grossly evident genital warts, or those that can be seen with the naked eye. Treatment of cervical, vaginal, and vulvar high&#45;grade squamous intraepithelial lesions (HSIL), the precancerous lesions, is routine in clinical practice. There are also common clinical practices for treatment and follow&#45;up of non&#45;warty cervical, vaginal, and vulvar low&#45;grade squamous intraepithelial lesions (LSIL), the benign lesions.  However, there are no current standards of care for non&#45;warty anal low&#45;grade (LG) or the precancerous high&#45;grade anal intraepithelial lesions (HGAIN). There are arguments both in favor and against treatment of anal warts, LGAIN and HGAIN disease.  Because LGAIN (including warts) is benign, and usually regresses on its own, it may be unnecessary to treat.  However, many patients and clinicians prefer to remove warts rather than waiting for them to go away on their own. Treatment of HGAIN may be unnecessary because most HGAIN does not progress to cancer, and much of it also regresses without treatment, nor it been proven to be the definitive cancer precursor lesion. However, it is also argued that since some HSIL does progress to cancer, the prevention of cancer overrides these concerns. In our practice we accept the limitations of current knowledge, and hypothesize that treatment of the precancerous lesions (HSIL) will result in a decreased incidence of anal cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There is considerable overlap in the treatment of warts, LGAIN and HGAIN. However, there are principles for treatment that are specific to each, and the way each type presents or looks may be somewhat different. Therefore treatment guidelines will be presented first, followed by a description of the treatments that may be relevant to either warts, LGAIN or HGAIN.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment of anal warts, LGAIN or HGAIN can take a long time and may require many visits over several months. It will also require long&#45;term follow up to be certain that the disease has not recurred and to evaluate for any new developments. It is common, especially in people who are immune&#45;compromised, to have ongoing HPV and to develop HGAIN within a few years of developing LGAIN or warts. &lt;a href=&quot;/analcancerinfo/diagnosis/screening.html&quot;&gt;As such continued evaluation is recommended&lt;/a&gt;. It is important for patients to work with their providers in developing both a treatment and follow&#45;up plan.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;One aspect of treatment which is in the hands of the person being treated is smoking. Tobacco has been implicated in the development of all HPV disease, although the evidence is sometimes confused by other risk factors. In practice, we strongly believe that people who smoke are harder to treat successfully, and that smoking cessation can contribute to faster treatment and less recurrence. In addition to the cancer producing elements of tobacco, it also suppresses the immune system which contributes to the development and persistence of HPV and its associated diseases. Treating your warts or HSIL may be the excuse you were looking for to quit smoking now! Every local community and hospital has many programs to help you quit. There are also many web&#45;based programs.&lt;/p&gt;

			&lt;ul&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.lungusa.org&quot; target=&quot;_blank&quot;&gt;American Lung Association&lt;/a&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.cancer.org&quot; target=&quot;_blank&quot;&gt;American Cancer Society&lt;/a&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.smokenders.com&quot; target=&quot;_blank&quot;&gt;Smokenders&lt;/a&gt;
			&lt;/ul&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Efficacy of Treatment&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There has been very little published which evaluates the efficacy of treatments for anal or perianal HGAIN disease. A small prospective study of surgical intervention for HGAIN showed it to be effective in HIV negative men (n=8) but 23 of 29 HIV seropositive men had persistence or recurrence of HSIL&lt;sup&gt;&lt;a href=&quot;references.html#1&quot;&gt;1&lt;/a&gt;&lt;/sup&gt;. Laser therapy has been used intra&#45;operatively for both perianal HSIL&lt;sup&gt;&lt;a href=&quot;references.html#2&quot;&gt;2&lt;/a&gt;&lt;/sup&gt; and internally&lt;sup&gt;&lt;a href=&quot;references.html#3&quot;&gt;3&lt;/a&gt;,&lt;a href=&quot;references.html#4&quot;&gt;4&lt;/a&gt;&lt;/sup&gt;. Efficacy (measured by recurrence) ranged from 20&#45;91% depending on the location, level of disease and type of treatment. None of these were randomized controlled studies.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Several small non&#45;randomized studies indicate that imiquimod has reduced anal, perianal or vulvar HSIL&lt;sup&gt;&lt;a href=&quot;references.html#5&quot;&gt;5&lt;/a&gt;&lt;/sup&gt;. Imiquimod has been used to decrease lesions in size and number so that surgical ablation is possible&lt;sup&gt;&lt;a href=&quot;references.html#6&quot;&gt;6&lt;/a&gt;&lt;/sup&gt; and in preventing recurrence of condyloma post&#45;surgery&lt;sup&gt;&lt;a href=&quot;references.html#7&quot;&gt;7&lt;/a&gt;&lt;/sup&gt;. But imiquimod currently is approved solely for treatment of external genital warts and using it internally or for treatment of HSIL is off&#45;label.  Another topical agent, Efudex TM (5% fluorouracil cream, also known as 5fU) has been reported as effective when used on the peri&#45;anus&lt;sup&gt;&lt;a href=&quot;references.html#8&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;  and intra&#45;anally&lt;sup&gt;&lt;a href=&quot;references.html#9&quot;&gt;9&lt;/a&gt;&lt;/sup&gt; for HGAIN.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Efudex&amp;trade; has been used intra&#45;vaginally to treat both HSIL and LSIL. As a primary treatment (comparing daily Efudex&amp;trade; for six weeks vs. biweekly for up to 10 weeks), 71% had complete or partial response&lt;sup&gt;&lt;a href=&quot;references.html#10&quot;&gt;10&lt;/a&gt;&lt;/sup&gt;.  Intra&#45;vaginal application of Efudex TM following surgical ablation has been shown to reduce recurrences in women treated for cervical HSIL (28% versus 47%)&lt;sup&gt;&lt;a href=&quot;references.html#11&quot;&gt;11&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment efficacy is determined by successful regression of lesions and to a lesser extent, the length of time the patient remains free of disease post&#45;treatment. However, the paucity of efficacy studies, and specifically randomized placebo designed studies, hinders our ability to manage anal LGAIN and HGAIN.&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Treatment Guidelines for Anal Warts, LGAIN and HGAIN&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;It is important to understand that in treatment of any HPV&#45;associated disease, the underlying cause itself is not treated. In other words the HPV virus, which causes the problem, cannot be treated. Only the disease that the HPV causes, i.e., warts or lesions, either LGAIN or HGAIN, can be treated. Some treatments may affect the amount of HPV that the body sheds but we do not currently have any treatments that can rid the body of the HPV.  However, in most cases we can effectively treat anything that the HPV causes.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;A careful examination will determine whether or not the warts or lesions are located inside the anus, outside (or perianal), or both. Although some lesions will be clinically apparent without any special equipment, many lesions will only be seen with the aid of magnification, lighting and the application of acetic acid (vinegar). This exam can be done with a colposcope, a microscope that was specially designed to provide magnification and lighting for cervical exams but has been shown to be just as valuable in examining the anus and surrounding areas. &lt;a href=&quot;/analcancerinfo/diagnosis/examination.html&quot;&gt;This exam is now called High&#45;Resolution Anoscopy (HRA)&lt;/a&gt;. The examination will determine what lesions need to be treated. Sometimes only HGAIN will be treated in order to minimize the amount of treatment needed. Areas of HGAIN can be located using HRA and diagnosis of any lesions so identified can be confirmed by biopsy.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;HPV only affects squamous epithelium, which includes the anus and perianal areas, as well as the cervix, vagina and vulva in women. or penis in men. HPV does not extend beyond the anus into the colon. The colon is a different tissue type, which is not infected by HPV. Therefore it is not necessary to have a colonoscopy in order to determine if warts are further inside the colon.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment of warts, LGAIN or HGAIN can be a long and frustrating process. This is especially true in the primary outbreak of warts. It takes the immune system time to &quot;figure out&quot; how to cope with this new virus. Once the immune system has learned to control the virus, there are generally few recurrences for most people. This means the HPV will be latent and will not cause any outbreaks unless the immune system stops suppressing it. This can happen if you become immune&#45;compromised (for example, becoming HIV positive, or needing steroid therapy for asthma or auto&#45;immune diseases such as Lupus, or following an organ transplant). There are times when it will not be possible or desirable to treat the lesions. Untreated, these lesions may regress on their own, may persist unchanged, or may increase in size and quantity. This cannot be predicted by any factors.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Not everyone will respond to every type of treatment and it may take several types of treatment before there is finally a response. This can take many months. People who are immune&#45;compromised from HIV or other reasons, may have frequent recurrences of warts and HSIL. In some cases, the lesions will never be completely eradicated.  However, whatever is treated will be gone and that lesion cannot progress to cancer. So even treatment that is not 100% effective may still help prevent progression to cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Once it is determined whether the patient has LGAIN (which includes warts), HGAIN, or both, as well as the location and extent of the lesions, a treatment plan will be suggested which may include a single type of treatment or a combination of treatments. The goal of treatment will be to ablate (get rid of) all the lesions that can be seen. Once this is accomplished, the clinician will determine a follow&#45;up plan to look for recurrences or just to be certain that the patient remains healthy and free of any further disease.&lt;/p&gt;&lt;br&gt;



			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Treatment of Non-Cancerous HPV ./id/x/treatment/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/index.html~</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;i&gt;Note: this page is under review&lt;/i&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;&quot;&gt;Treatment of anal HPV&#45;associated disease depends on the diagnosis, location, and size or amount of disease.  Most clinicians treat grossly evident genital warts, or those that can be seen with the naked eye. However, despite the fact that treatment of cervical, vaginal, and vulvar HSIL is routine in clinical practice and that there are common clinical practices for treatment and follow up of non&#45;warty cervical, vaginal, and vulvar LSIL as well, there are no current standards of care for non&#45;warty anal LSIL or HSIL.	There are arguments both in favor and against treatment of anal warts, LSIL and HSIL disease.  Because LSIL (including warts) is benign, and usually regresses on its own, it may be unnecessary to treat.  However, many patients and clinicians prefer to remove warts rather than waiting for them to go away on their own. Treatment of HSIL may be unnecessary because most HSIL does not progress to cancer, and much of it also regresses without treatment, nor it been proven to be the definitive cancer precursor lesion. However, it is also argued that since some HSIL does progress to cancer, the prevention of cancer overrides these concerns. In our practice we accept the limitations of current knowledge, and hypothesize that treatment of the precancerous lesions (HSIL) will result in a decreased incidence of anal cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There is considerable overlap in the treatment of warts, LSIL and HSIL. However, there are principles for treatment that are specific to each, and the way each looks may be somewhat different. Therefore treatment guidelines will be presented first, followed by a description of the treatments that may be relevant to either warts, LSIL or HSIL.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment of anal warts, LSIL or HSIL can take a long time and may require many visits over several months. It will also require long&#45;term follow up to be certain that the disease has not recurred and to evaluate for any new developments. It is common, especially in people who are immune&#45;compromised, to have ongoing HPV and to develop HSIL within a few years of developing LSIL or warts. As such continued evaluation is recommended. It is important for patients to work with their providers in developing both a treatment and follow up plan.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;One aspect of treatment which is in the hands of the person being treated is smoking. Tobacco has been implicated in the development of all HPV disease, although the evidence is sometimes confused by other risk factors. In practice, we strongly believe that people who smoke are harder to treat successfully, and that smoking cessation can contribute to faster treatment and less recurrence. In addition to the cancer producing elements of tobacco, it also suppresses the immune system which contributes to the development and persistence of HPV and its associated diseases. Treating your warts or HSIL may be the excuse you were looking for to quit smoking now! Every local community and hospital has many programs to help you quit. There are also many web&#45;based programs.&lt;/p&gt;

			&lt;ul&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.lungusa.org&quot; target=&quot;_blank&quot;&gt;American Lung Association&lt;/a&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.cancer.org&quot; target=&quot;_blank&quot;&gt;American Cancer Society&lt;/a&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;a href=&quot;http://www.smokenders.com&quot; target=&quot;_blank&quot;&gt;Smokenders&lt;/a&gt;
			&lt;/ul&gt;&lt;p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Efficacy of Treatment&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There has been very little published which evaluates the efficacy of treatments for anal or perianal HSIL disease. A small prospective study of surgical intervention for HSIL showed it to be effective in HIV negative men (n=8) but 23 of 29 HIV seropositive men had persistence or recurrence of HSIL (Chang02). Laser therapy has been used intra&#45;operatively for both perianal HSIL (Marchesa97) and internally (Brittain94, Bandieramonte93).  Efficacy (measured by recurrence) ranged from 20&#45;91% depending on the location, level of disease and type of treatment. None of these were randomized controlled studies.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Several small non&#45;randomized studies indicate that imiquimod has reduced anal, perianal or vulvar HSIL (Jayne, Kreuter, Pehoushek, Gutzmer02). Imiquimod has been used to decrease lesions in size and number so that surgical ablation is possible (Heinzerling) and in preventing recurrence of condyloma post&#45;surgery (Kaspari). But imiquimod currently is approved solely for treatment of external genital warts and using it internally or for treatment of HSIL is off&#45;label.  Another topical agent, Efudex&amp;trade; (5% fluorouracil cream, also known as 5fU) has been reported as effective when used intra&#45;anally for SIL (colorectal surgery) and application of Efudex&amp;trade; following surgical ablation has been shown to reduce recurrences in cervical disease (Karen). &lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Efudex&amp;trade; has been used intra&#45;vaginally to treat both HSIL and LSIL. It reduced recurrence of disease in HIV seropositive women treated with Efudex&amp;trade; following standard ablative therapy (28% vs. 47%) (Maiman 99). As a primary treatment (comparing daily Efudex&amp;trade; for six weeks vs. biweekly for up to 10 weeks), 71% had complete or partial response (Krebs 90). There were no published reports of Efudex&amp;trade; intra&#45;anally or perianally.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment efficacy is determined by successful regression of lesions and to a lesser extent, the length of time the patient remains free of disease post&#45;treatment. However, the paucity of efficacy studies, and specifically randomized placebo designed studies, hinders our ability to manage anal HPV.&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Treatment Guidelines for Anal Warts, LSIL and HSIL&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;It is important to understand that in treatment of any HPV&#45;associated disease, the underlying cause itself is not treated. In other words the HPV virus, which causes the problem, cannot be treated. Only the disease that the HPV causes, i.e., warts or lesions, either LSIL or HSIL, can be treated. Some treatments may affect the amount of HPV that the body sheds but we do not currently have any treatments that can rid the body of the HPV.  However, in most cases we can effectively treat anything that the HPV causes.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;A careful examination will determine whether or not the warts or lesions are located inside the anus, outside (or perianal), or both. Although some lesions will be clinically apparent without any special equipment, some lesions will only be seen with the aid of magnification, lighting and the application of acetic acid (vinegar). This exam can be done with a colposcope, a microscope that was specially designed to provide magnification and lighting for cervical exams but has been shown to be just as valuable in examining the anus and surrounding areas. This exam is now called High Resolution Anoscopy (HRA). The examination will determine what lesions need to be treated. Sometimes only HSIL will be treated in order to minimize the amount of treatment needed. Areas of HSIL can be located using HRA and diagnosis of any lesions so identified can be confirmed by biopsy.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;HPV only affects squamous epithelium, which includes the anus and perianal areas, as well as the cervix, vagina and vulva in women or penis in men. HPV does not extend beyond the anus into the colon. The colon is a different tissue type, which is not infected by HPV. Therefore it is not necessary to have a colonoscopy in order to determine if warts are further inside the colon.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment of warts, LSIL or HSIL can be a long and frustrating process. This is especially true in the primary outbreak of warts. It takes the immune system time to &quot;figure out&quot; how to cope with this new virus. Once the immune system has learned how to control the virus, there are generally few recurrences for most people. There are times when it will not be possible or desirable to treat the lesions. Untreated, these lesions may regress on their own, may persist unchanged, or may increase in size and quantity. This cannot be predicted by any factors.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Not everyone will respond to every type of treatment and it may take several types of treatment before there is finally a response. This can take many months. People who are immune&#45;compromised from HIV or other reasons, may have frequent recurrences of warts and HSIL. In some cases, the lesions will never be completely eradicated.  However, whatever is treated will be gone and that lesion cannot progress to cancer. So even treatment that is not 100% effective may still help prevent progression to cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Once it is determined whether the patient has LSIL (which includes warts), HSIL, or both, as well as the location and extent of the lesions, a treatment plan will be suggested which may include a single type of treatment or a combination. The goal of treatment will be to ablate (get rid of) all the lesions that can be seen. Once this is accomplished, the clinician will determine a follow up plan to look for recurrences or just to be certain that the patient remains healthy and free of any further disease.&lt;/p&gt;&lt;br&gt;



			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Treatment of LGAIN &amp; Warts ./id/x/treatment/lgain.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/lgain.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;margin&#45;top:12px;&quot;&gt;LGAIN is a category of HPV disease that includes both warts and mild dysplasia.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Usually warts will be diagnosed as &quot;warts,&quot; but sometimes the diagnosis will be LGAIN and so it is important to understand that warts are simply a type of LGAIN. Mild dysplasia is sometimes called anal intraepithelial neoplasia (AIN) I. All of these are considered benign. This means that they are not cancerous or precancerous, and are very unlikely to progress to cancer.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There are two types of warts &amp;mdash; raised warts and flat warts. When these are located externally, near the anal opening, they may be felt as new fleshy bumps. Warts can be any size. They can be firm to the touch but are not usually hard. Flat warts may be felt as rough, like sandpaper. Warts may be itchy. Of course all of this is subjective. There are many normal changes that may &quot;feel&quot; this way, and warts should always be diagnosed by a clinician.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There are several reasons to treat anal warts even though they are benign and not considered a precursor to anal cancer:&lt;/p&gt;

			&lt;ul&gt;
			&lt;li class=&quot;aci&quot;&gt;HGAIN may be present in the same location and treatment of the warts may treat these as well.
			&lt;li class=&quot;aci&quot;&gt;Sometimes warts are extensive and it may be difficult to thoroughly evaluate for HGAIN or cancer; treatment of the warts allows for more complete evaluation.
			&lt;li class=&quot;aci&quot;&gt;Warts frequently bleed causing discomfort and may provide a means of infection for other sexually transmitted diseases.
			&lt;li class=&quot;aci&quot;&gt;Warts are rarely painful but they can be obstructive, create difficulties with personal hygiene, and may be itchy.
			&lt;li class=&quot;aci&quot;&gt;Finally, it may be embarrassing or otherwise psychologically traumatic.
			&lt;/ul&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;It is commonly believed that not treating warts will create a &quot;field&#45;effect&quot; allowing more warts to develop. This belief is based on the difficulty in eradicating the &quot;primary outbreak&quot; of warts, the first time warts develop. Treatment of the primary outbreak of warts can be a long, frustrating experience and it may take many months to eradicate the warts as new warts may continue to occur until the immune system has learned to cope with the underlying cause &amp;mdash; the HPV. Because of this experience many patients believe that in a subsequent outbreak of warts, if they do not treat a single discrete wart or small cluster that this will proliferate into another large outbreak of warts again. This is rarely the case; warts, like herpes, often reoccur in singular limited outbreaks.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;In our practice we recommend treatment for anal warts if they are obstructive, if they obscure our ability to completely examine the rest of the anal canal, if they are causing any symptoms, or if the patient prefers to have them removed.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Treatment protocols for genital warts are fairly standard. There is no therapy for warts that works reliably for everyone. Response rates can be as low as 30% and as high as 80%.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;There are both clinician&#45; and patient&#45;applied therapies. Clinician&#45;applied therapies include those which can be done in the office or outpatient surgery. Patient&#45;applied therapies are those which the patient can do at home. In either case, the goal of treatment is ablation or eradication of the warts. The decision to use a clinician&#45;applied therapy versus a patient&#45;applied therapy depends on many factors including location, the presentation of the warts, and the ability of the patient to complete the treatment.&lt;/p&gt;

			&lt;table border=0 style=&quot;margin:12px;&quot; cellpadding=6&gt;
			&lt;tr valign=top style=&quot;background:#EEEEEE&quot;&gt;&lt;th class=&quot;aci&quot;&gt;Location&lt;/th&gt;&lt;td class=&quot;aci&quot;&gt;Internal warts can only be treated by a clinician. There are currently no approved patient&#45;applied treatments for internal anal warts although sometimes Aldara&amp;trade; (5% imiquimod) or Efudex&amp;trade; has been prescribed. Neither has been evaluated for safety or efficacy in treating internal anal warts.&lt;/td&gt;&lt;/tr&gt;
			&lt;tr valign=top style=&quot;background:#CBDEEC&quot;&gt;&lt;th class=&quot;aci&quot;&gt;Presentation/Amount&lt;/th&gt;&lt;td class=&quot;aci&quot;&gt;Clinician&#45;applied therapies may be recommended if the warts are too extensive for adequate home therapy; or if it would be difficult for someone to apply the treatment without help. At times a home&#45;based therapy is best applied for an initial outbreak even if it is diffuse and extensive. If only a few warts are present, they may be adequately treated by either an office&#45; or home&#45;based therapy.&lt;/td&gt;&lt;/tr&gt;
			&lt;tr valign=top style=&quot;background:#EEEEEE&quot;&gt;&lt;th class=&quot;aci&quot;&gt;Response to Therapy&lt;/th&gt;&lt;td class=&quot;aci&quot;&gt;The type of treatment will be changed if the warts do not respond to one type of therapy. For example, a patient&#45;applied treatment may be tried first, but if the response is not adequate a clinician&#45;applied treatment will be tried.&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
References ./id/x/treatment/references.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/references.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;ol&gt;
			&lt;a name=&quot;1&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML.  Surgical treatment of high&#45;grade anal squamous intraepithelial lesions: a prospective study.  Dis Colon Rectum. 2002 Apr;45(4):453&#45;8.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;2&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Dis Colon Rectum. 1997 Nov;40(11):1286&#45;93.  Perianal Bowen's disease: a clinicopathologic study of 47 patients.  Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;3&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Brittain PC, Carlson JW, Hawley&#45;Bowland C.  Laser ablation of squamous cell carcinoma in situ of the anal canal.  A case report. J Reprod Med.1994 Nov;39(11):913&#45;4.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;4&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Bandieramonte G, Bono A, Zurrida S, Bartoli C, de Palo G Eur J Cancer.  Laser surgery for small perianal neoplasms. 29A(11):1528&#45;31, 1993&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;5&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;J Reprod Med. 2002 May;47(5):395&#45;8.  Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod.  Jayne CJ, Kaufman RH.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;6&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Dermatology. 2003;207(1):119&#45;22.  Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation.  Heinzerling LM, Kempf W, Kamarashev J, Hafner J, Nestle FO.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;7&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP.  Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma.  Br J Dermatol. 2002 Oct;147(4):757&#45;9. PubMed PMID: 12366425.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;8&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Graham BD, Jetmore AB, Foote JE, Arnold LK.  Topical 5&#45;fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum. 2005 Mar;48(3):444&#45;50.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;9&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;ADD efudex abstract HPV 2009 conference &#45; Jay&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;10&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;1: Krebs HB.  Treatment of extensive vulvar condylomata acuminata with topical 5&#45;fluorouracil.  South Med J. 1990 Jul;83(7):761&#45;4. PubMed PMID: 2371597.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;11&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Maiman M, Watts DH, Andersen J, Clax P, Merino M, Kendall MA.  Vaginal 5&#45;fluorouracil for high&#45;grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial.  Obstet Gynecol. 1999 Dec;94(6):954&#45;61.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;12&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol. 1985 Nov 1;153(5):545&#45;50.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;13&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Petersen CS [Local anesthesia in CO2 laser treatment of disseminated therapy&#45;resistant condylomata] Ugeskr Laeger.  1993 Jun 14;155(24):1861&#45;4.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;14&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Pehoushek J, Smith KJ.  Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV&#45;1&#45;positive man. Arch Dermatol.  2001 Jan;137(1):14&#45;6.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;15&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP.  Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma.  Br J Dermatol. 2002 Oct;147(4):757&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;16&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J, Altmeyer P, Pfister H, Kreuter A.  Imiquimod treatment of anal intraepithelial neoplasia in HIV&#45;positive men.  Arch Dermatol. 2006 Nov;142(11):1438&#45;44.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;17&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Bringel PJ, de Andrade Arruda R. 5&#45;fluorouracil cream 5% in the treatment of intraurethral condylomata acuminata. Br J Urol. 1982 Jun;54(3):295.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;18&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Cardamakis E, Relakis K, Ginopoulos P, Korantzis A, Metalinos K, Stathopoulos E, Papathanasiou Z, Michopoulos J, Mantouvalos H, Kotoulas IG, Tzingounis V.  Treatment of penile intraepithelial neoplasia (PIN) with interferon alpha&#45;2a, CO2 laser (vaporization) and 5&#45;fluorouracil 5% (5&#45;FU). Eur J Gynaecol Oncol.  1997;18(5):410&#45;3&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;19&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Krebs HB.  Treatment of vaginal condylomata acuminata by weekly topical application of 5&#45;fluorouracil. Obstet Gynecol. 1987 Jul;70(1):68&#45;71. PubMed PMID:3601270.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;20&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Kirwan P, Naftalin NJ.  Topical 5&#45;fluorouracil in the treatment of vaginal
			intraepithelial neoplasia.  Br J Obstet Gynaecol.  1985 Mar;92(3):287&#45;91.  PubMed
			PMID: 3978059.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;21&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Ferenczy A.  Comparison of 5&#45;fluorouracil and CO2 laser for treatment of
			vaginal condylomata.  Obstet Gynecol. 1984 Dec;64(6):773&#45;8.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;22&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Pride GL. Treatment of large lower genital tract condylomata acuminata with
			topical 5&#45;fluorouracil. J Reprod Med. 1990 Apr;35(4):384&#45;7.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;23&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Bell MC, Crowley&#45;Nowick P, Bradlow HL, Sepkovic DW, Schmidt&#45;Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat&#45;Herrera EA, Mathis JM.  Placebo&#45;controlled
			trial of indole&#45;3&#45;carbinol in the treatment of CIN. Gynecol Oncol. 2000 Aug;78(2):123&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;24&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D,
			Vanden Houte K, Reynders M, Snoeck R, Bossens M.  Topical treatment of CIN 2+ by
			Cidofovir: results of a phase II, double&#45;blind, prospective, placebo&#45;controlled study.  Gynecol Oncol. 2009 Oct;115(1):69&#45;74. Epub 2009 Aug 3. PubMed PMID:19647859.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;25&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Coremans G, Snoeck R.  Cidofovir: clinical experience and future perspectives
			on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV&#45;associated anal lesions.  Expert Opin Pharmacother.  2009 Jun;10(8):1343&#45;52. Review. PubMed PMID: 19463071.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;26&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Orlando G, Fasolo MM, Beretta R, Signori R, Adriani B, Zanchetta N, Cargnel A.
			Intralesional or topical Cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV&#45;1&#45;infected patients. AIDS. 1999 Oct 1;13(14):1978&#45;80.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;27&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Sex Transm Dis. 2001 Jun;28(6):343&#45;6.  Efficacy and tolerability of topical 1% Cidofovir cream for the treatment of external anogenital warts in HIV&#45;infected persons.
			Matteelli A, Beltrame A, Graifemberghi S, Forleo MA, Gulletta M, Ciravolo G,
			Tedoldi S, Casalini C, Carosi G.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;28&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A.  Combined surgery and
			Cidofovir is an effective treatment for genital warts in HIV&#45;infected patients.  AIDS. 2002 Feb 15;16(3):447&#45;50.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;29&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Transplantation. 2002 Feb 27;73(4):661&#45;2.  Topical use of Cidofovir induced acute renal failure.  Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Bellenger P, Morel P, Gluckman E, Lebb&amp;eacute; C.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;30&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Med Virol. 2001 Jun;64(2):195&#45;8.  Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with Cidofovir.  Koonsaeng S, Verschraegen C, Freedman R, Bossens M, Kudelka A, Kavanagh J,
			Sittisomwong T, DeClercq E, Snoeck R.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;31&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A
			prospective, randomized trial. Dis Colon Rectum. 1994 Dec;37(12):1255&#45;9
			TCA:&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;32&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of
			primary anogenital warts: a randomised observer blind placebo controlled study.
			Genitourin Med. 1991 Aug;67(4):297&#45;302. PubMed PMID: 1916791; PubMed Central
			PMCID: PMC1194704.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;33&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Int J Gynaecol Obstet. 1995 May;49(2):171&#45;4.  Interferon as an adjuvant treatment for genital condyloma acuminatum.  Klutke JJ, Bergman A.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;34&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Scholefield JH. Treatment of grade III anal intraepithelial neoplasia with
			photodynamic therapy: report of a case. Dis Colon Rectum, 2003; 46(11):1555&#45;1559.
			Tech Coloproctol. 2004 Nov;8(3):200.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;35&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Arch Surg. 2004 Mar;139(3):259&#45;61.  Photodynamic therapy for carcinoma in situ of the anus.  Webber J, Fromm D.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;36&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Hamdan KA, Tait IS, Nadeau V, Padgett M, Carey F, Steele RJ.  Treatment of
			grade III anal intraepithelial neoplasia with photodynamic therapy: report of a
			case.  Dis Colon Rectum. 2003 Nov;46(11):1555&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;37&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C.  Evaluation of
			different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2)
			laser vaporization, photodynamic therapy, excision and vulvectomy.  Gynecol Oncol.
			2006 Feb;100(2):271&#45;5. Epub 2005 Sep 16. PubMed PMID: 16169064.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;38&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U, Wyss P.  Photodynamic
			therapy of vulvar intraepithelial neoplasia III using topically applied 5&#45;aminolevulinic acid.  Gynecol Oncol. 2001 Jan;80(1):62&#45;6. PubMed PMID: 11136571.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;39&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Wierrani F, Kubin A, Jindra R, Henry M, Gharehbaghi K, Grin W, S&amp;ouml;ltz&#45;Sz&amp;ouml;tz J,
			Alth G, Gr&amp;uuml;nberger W.  5&#45;aminolevulinic acid&#45;mediated photodynamic therapy of
			intraepithelial neoplasia and human papillomavirus of the uterine cervix&#45;&#45;a new
			experimental approach.  Cancer Detect Prev. 1999;23(4):351&#45;5.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;40&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J,
			Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. Encapsulated
			plasmid DNA treatment for human papillomavirus 16&#45;associated anal dysplasia: a
			Phase I study of ZYC101.  Clin Cancer Res. 2002 May;8(5):1028&#45;37.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;a name=&quot;41&quot;&gt;&lt;/a&gt;&lt;li class=&quot;aci&quot;&gt;Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY.  A trial of SGN&#45;00101 (HspE7) to treat high&#45;grade anal intraepithelial neoplasia in
			HIV&#45;positive individuals.  AIDS. 2006 May 12;20(8):1151&#45;5.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;References for Therapies for Treatment of Warts, LGAIN, HGAIN&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;Trichloroacetic acid (TCA):&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;1998 guidelines for treatment of sexually transmitted diseases.  Centers for Disease Control and Prevention.  MMWR Recomm Rep 47:1&#45;111, 1998.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Godley MJ, Bradbeer CS, Gellan M, Thin RN.  Cryotherapy compared with trichloroacetic acid in treating genital warts.  Genitourin Med 63:390&#45;2, 1987.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Abdullah AN, Walzman M, Wade A.  Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid.  Sex Transm Dis 20:344&#45;5, 1993.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Singh JC, Kuohung V, Palefsky JM.  Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV&#45;positive and HIV&#45;negative men who have sex with men.  J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474&#45;9.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;Cryotherapy:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Simmons PD, Langlet F, Thin RN.  Cryotherapy versus electrocautery in the treatment of genital warts.  Br J Vener Dis 57:273&#45;4, 1981.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Stone KM, Becker TM, Hadgu A, Kraus SJ.  Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation.  Genitourin Med 66:16&#45;9, 1990.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Clinical Proceedings of the Association of Reproductive Health Professionals Monograph on Human Papillomavirus (HPV) and Cervical Cancer March 2001.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Clinical Proceedings of the Association of Reproductive Health Professionals Monograph on Human Papillomavirus (HPV) and Cervical Cancer March 2001.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;Infrared Coagulation:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;A retrospective clinical study of the treatment of high&#45;grade anal dysplasia by infrared coagulation in a population of HIV&#45;positive men who have sex with men.  Cranston RD, Hirschowitz SL, Cortina G, Moe AA.  Int J STD AIDS. 2008 Feb;19(2):118&#45;20.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Infrared coagulator ablation of high&#45;grade anal squamous intraepithelial lesions in HIV&#45;negative males who have sex with males.  Goldstone SE, Hundert JS, Huyett JW.  Dis Colon Rectum. 2007 May;50(5):565&#45;75.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;Laser Therapy:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Bandieramonte G, Bono A, Zurrida S, Bartoli C, de Palo G Eur J Cancer. Laser surgery for small perianal neoplasms 29A(11):1528&#45;31, 1993.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol. 1985 Nov 1;153(5):545&#45;50.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Petersen CS [Local anesthesia in CO2 laser treatment of disseminated therapy&#45;resistant condylomata] Ugeskr Laeger. 1993 Jun 14;155(24):1861&#45;4.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;Aldara&amp;trade;:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Clinical Proceedings of the Association of Reproductive Health Professionals Monograph on Human Papillomavirus (HPV) and Cervical Cancer March 2001.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Edwards L, Ferenczy A, Eron L, et al.  Self&#45;administered topical 5% imiquimod cream for external anogenital warts.  HPV Study Group. Human PapillomaVirus. Arch Dermatol 134:25&#45;30, 1998.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Edwards L.  Imiquimod in clinical practice.  J Am Acad Dermatol 43:S12&#45;7, 2000.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;

			&lt;p class=&quot;aci&quot;&gt;Podofilox/Podophyllin:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Clinical Proceedings of the Association of Reproductive Health Professionals Monograph on Human Papillomavirus (HPV) and Cervical Cancer March 2001.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Maw RD. Treatment of anogenital warts. Dermatol Clin 16:829&#45;34, xv, 1998.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;Von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A; European Course on HPV Associated Pathology (ECHPV); European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization.  Int J STD AIDS. 2001	Oct;12 Suppl 3:40&#45;7.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;/ol&gt;&lt;br&gt;



			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Surgery ./id/x/treatment/surgery.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/surgery.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px; margin&#45;top:12px;color:#990000;&quot;&gt;&lt;b&gt;&lt;i&gt;Note: this section is under review&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Surgical Management of LSIL, HSIL, and Anal Cancer&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;What we mean by surgery is the need to perform a more in&#45;depth examination or treatment that is best performed while someone is anesthetized or very heavily sedated in the operating room.  How do we decide if surgery is necessary?  In a general way, patients are referred for surgical treatment of their AIN whenever they can't be adequately or comfortably treated in the office or if larger and multiple biopsies are needed because of a concern that cancer might be present.  Although biopsies are easily performed in the clinic during HRA, these samples tend to be quite small.  If someone has a larger lesion that either should be completely removed or a large piece of it removed because it is suspicious for cancer, then it is best to do that in the operating room.  Several scenarios are described below indicating situations where treatment in the operating room would be preferred.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Patients who are symptomatic from their AIN with either itching, irritation, pain, discomfort, painful bowel movements, frequent bleeding after bowel movements or receptive intercourse, or uncomfortable receptive intercourse are often treated for AIN surgically.  If the disease is too extensive to be treated in the office or if there is a high level of concern regarding a possible cancer, then patients are probably best treated in the operating room.  In spite of the significant amount of pain and discomfort associated with anal surgery, virtually all patients who were operated on because of symptoms have improvement in their symptoms once they recover from the acute effects of surgery.
			&lt;li class=&quot;aci&quot;&gt;Patients who have a lot of intra&#45;anal warts or warts that are bulky in size or involve nearly the entire circumference of the anal canal and/or the warts extend out to the perianal skin are probably best treated in the operating room.  Remember, lesions located externally on the perianal skin can be quite sensitive and require injection of local anesthesia prior to cutting or burning.  If there are just a few small areas, then these can be treated in&#45;office, but once larger areas of the perianal skin are involved, it is usually better to treat patients in the operating room.
			&lt;li class=&quot;aci&quot;&gt;As above, patients with more extensive disease, which means a larger portion of the circumference of the anus involved by AIN may be better treated in the operating room.  Generally when treating someone for LSIL or HSIL, the goal is to destroy and remove as much of the abnormal tissue as possible.  Based on treating cervical dysplasia, when only part of a lesion is removed, the likelihood of a recurrence is very high.  So if the disease seems too extensive to be treated at one sitting in the office, then patients are often referred for surgery.
			&lt;li class=&quot;aci&quot;&gt;Patients who have HSIL which has recurred after office&#45;based treatment such as infrared coagulation within a relatively short period of time, are referred for surgery as another way of treating their HSIL.  One of the reasons that AIN recurs may be because it was incompletely treated and a more comprehensive approach in the operating room guided by HRA may improve outcome.  On the other hand, for some patients HSIL seems to recur in spite of whatever we do.  However, it is reasonable to try to decrease the burden of HSIL in the operating room at least once.  If it recurs quickly and to such a degree that it can't be managed in the office, then it may be more reasonable to follow the patient closely until better treatments become available.
			&lt;li class=&quot;aci&quot;&gt;For some patients, anal exams are very difficult and uncomfortable and they cannot tolerate having the anoscope inside them for very long.  Occasionally patients will have pain or discomfort because of lesions that are tender.  If an exam is too painful or uncomfortable, then it is best to examine patients under anesthesia.  Pain and focal tenderness are often warning signs that suggest cancer, and it is important to examine patients thoroughly and carefully to determine whether or not cancer is present, or if some other more benign process might be causing the pain, such as a fissure or fistula.
			&lt;li class=&quot;aci&quot;&gt;For some patients, anal exams aren't physically uncomfortable but produce a great deal of anxiety and emotional distress.  Sometimes this emotional distress is due to previous physically traumatic experiences such as examinations or treatment or assault.  Some people just don't like medical procedures of any kind including drawing blood.  These patients may benefit from mild sedation with drugs such as Ativan (lorazepam, a Valium&#45;like drug), but may require anesthesia in order to be examined properly.
			&lt;li class=&quot;aci&quot;&gt;Any time there is a strong suspicion of cancer that cannot be eliminated by a biopsy in the clinic, patients should be examined in the operating room by a surgeon experienced in managing anorectal problems.  Under anesthesia, not only is the patient sedated and relaxed, but the sphincter muscle is also relaxed and dilated, which allows better exposure and provides a better opportunity to visualize any abnormalities and, as mentioned above, to take larger specimens if necessary.
			&lt;li class=&quot;aci&quot;&gt;Occasionally women will have coexistent cervical or vulvar HSIL that requires laser treatment, which is performed under general anesthesia in the operating room.  If women also have anal HSIL, then we try to do one procedure to treat both areas simultaneously, which facilitates recovery and avoids having two separate operations.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;surgery_ucsf&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How Anal Surgery Is Done at UCSF&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;Since 1995, we have collaborated closely with the colorectal surgeons at UCSF and developed the technique of using high&#45;resolution anoscopy (HRA) to facilitate the diagnosis and treatment of AIN in the operating room.  We have successfully operated on over 500 patients.  Surgery is usually done on an outpatient basis in the Ambulatory Surgery Center, and patients go home the same day.  Our approach is detailed below.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;Patients are seen by an anesthesiologist in the Prepare Clinic a day or two prior to the surgery.  The anesthesiologist evaluates patients to be sure it is medically safe to give them anesthesia.
			&lt;li class=&quot;aci&quot;&gt;Patients are instructed not to eat or drink anything after midnight on the night prior to surgery including chewing gum or eating candy.  Essential medications may be taken with a sip of water, but this should be cleared in advance with anesthesia and the patient's primary care provider.
			&lt;li class=&quot;aci&quot;&gt;Patients are instructed to do a simple enema on the morning of the surgery before leaving the house.  Someone who will be responsible for transporting them home must accompany them.
			&lt;li class=&quot;aci&quot;&gt;Once patients arrive in the surgery center they undress and put on a hospital gown and the nurse starts an IV.  The procedure is explained in detail and any questions answered and then the consent signed.
			&lt;li class=&quot;aci&quot;&gt;The anesthesiologist comes in and discusses the plans for anesthesia and any concerns that the patient may have.  Most of the cases are done using heavy sedation followed by deep injections of a local anesthetic around the anus to block the nerves that supply the anus.  Occasionally if patients have very extensive disease, the anesthesiologist will place a spinal or epidural block, which is a way of putting a local anesthetic around the nerves of the spinal cord at the base of the spine to deaden the lower half of the body.  Rarely in some cases, patients are given general anesthesia, in which a tube is placed in the patient's throat in order to breathe for the patient while they are put to sleep.
			&lt;li class=&quot;aci&quot;&gt;The patient is wheeled into the operating room and is asked to transfer from the stretcher to the operating table.  Patients are treated lying on their stomach with a bolster or cushion underneath the hipbones and the table is flexed so the buttocks are placed upward and accessible to be examined and treated.
			&lt;li class=&quot;aci&quot;&gt;Once the patient is in position, the anesthesiologist begins to sedate the patient.  The hair around the anus is shaved.  Each buttock is taped to the operating table to open and separate the buttocks exposing the anus.  The anus is prepped with surgical antiseptic scrub and then sterilely draped.
			&lt;li class=&quot;aci&quot;&gt;When the patient is very heavily sedated, the surgeon injects a long acting local anesthetic, usually Marcaine, beneath the skin surrounding the anus and then deeply into the muscles of the pelvis surrounding the anus.  Patients are heavily sedated so they don't have to be awake or experience these injections.  This is called a perianal block and is a very effective way of numbing the anus prior to operating on it.  The sphincter muscles are temporarily deadened so they relax permitting a better view of the anal canal than can be obtained in the clinic.
			&lt;li class=&quot;aci&quot;&gt;A digital exam is performed feeling for any suspicious masses or areas of induration or hardness that would suggest the presence of cancer.  The perianal area is examined in a similar fashion.
			&lt;li class=&quot;aci&quot;&gt;A gauze pad is soaked in 5% acetic acid and placed inside the anal canal.  An operating microscope is brought over the buttocks, usually with a video camera attached to a monitor.  The gauze is removed and the surgeon inserts an anal retractor and then with the other hand pulls the inside of the anus out a bit in order to permit it to be examined with the microscope.  HRA is performed examining the entire anus carefully looking for any lesions.
			&lt;li class=&quot;aci&quot;&gt;Areas suspicious for cancer are biopsied by cutting around and beneath the areas and then the specimen is preserved in formalin.  Electrocautery is used to stop the bleeding, which produces a burn.  Warts, LSIL and HSIL are also destroyed using electrocautery.  The tissue is debrided or scraped off to ensure that the entire thickness of the lesion is treated.  The operating microscope is used to guide biopsy of the most abnormal appearing areas and to target destruction of all of the abnormal areas.  Small pieces of uninvolved anal skin are left as &quot;bridges&quot; to facilitate healing and to avoid anal stenosis (scarring or narrowing of the anus).
			&lt;li class=&quot;aci&quot;&gt;Our goal is to remove as much of the abnormal areas as possible.  If someone has a lesion that is highly suggestive of invasive cancer, then the exam is limited to obtaining adequate biopsies of this area to ensure the diagnosis.  We do not usually try to extensively treat the remaining areas of AIN because patients who have invasive cancer usually require treatment with a combination of radiation and chemotherapy.
			&lt;li class=&quot;aci&quot;&gt;Once the exam is completed, necessary biopsies taken and all areas of visible AIN destroyed, the surgeon ensures that there are no areas of bleeding and the case is finished.
			&lt;li class=&quot;aci&quot;&gt;A topical cream is applied to the anus that is often used to treat burn patients (Silvadene Cream/silver sulfadiazene) and a gauze dressing is applied to the outside.  Patients are awakened and transfer to the stretcher and then go to the recovery room.  Once the anesthesia wears off and patients are alert and able to urinate, they are discharged home.
			&lt;/ol&gt;&lt;p&gt;

			&lt;a name=&quot;recovery&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;How To Cope or Recover After Anal Surgery&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px&quot;&gt;As you can see from the description above, anal surgery can be very extensive, but often is necessary to establish a diagnosis of anal cancer or to ensure that anal cancer is not present.  Even with HRA it is not always possible to distinguish HSIL from superficially invasive anal cancer, which is why it is important to do biopsies whenever there is a suspicious lesion.  Sometimes the only way to obtain an adequate specimen is in the operating room.  Our goal is to try and treat patients early enough when they don't have large volumes of disease so they can be treated in the office, which is a much easier process.  Please see the section on office&#45;based treatment.  We usually advise patients that they we will need 2 to 3 weeks to recover from anal surgery before being able to return to work.  This is a similar recovery period to a hemorrhoidectomy, which can be even harder than recovering from surgery for treatment of AIN.  Based on our experience we recommend the following as the best way to recover from anal surgery.&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;The most important thing you can do to facilitate your recovery is to keep your bowels soft and moving and AVOID CONSTIPATION at all costs.
			&lt;li class=&quot;aci&quot;&gt;In the week prior to the surgery begin taking stool softeners such as Colace or Docusate and adding a fiber supplement to your daily routine such as Benefiber, Citrucel, Metamucil or a similar product.  The goal is to have soft but formed stools.
			&lt;li class=&quot;aci&quot;&gt;Stay well hydrated and drink lots of fluids including juices and Gatorade.  Your colon helps to maintain water balance in your body and if you get dehydrated this can cause constipation and hard stools.
			&lt;li class=&quot;aci&quot;&gt;By now you have probably realized that most of the pain and discomfort that people have after this kind of surgery is related to bowel movements.
			&lt;li class=&quot;aci&quot;&gt;You must continue to eat.  Fasting to avoid having bowel movements does not work well as people find they end up feeling constipated after a few days and then strain to go to the bathroom, which is painful and can help to cause fissures.
			&lt;li class=&quot;aci&quot;&gt;Eat a regular diet and avoid foods that are constipating; only you as an individual know what those foods are.  Eat plenty of fresh fruits and vegetables.  Avoid excessively hot and spicy foods that might burn on the way out.
			&lt;li class=&quot;aci&quot;&gt;As mentioned, most of the discomfort and pain that people experience is related to bowel movements and is directly due to spasm or cramping of the sphincter muscle, which is irritated because of the raw areas that were burned.  The best way to get immediate pain relief is to SOAK IN HOT WATER immersing your pelvis as opposed to just taking a &quot;sitz bath&quot; while sitting on the toilet.  We recommend that you soak 6 to 8 TIMES PER DAY.  Immediately after a bowel movement, you should soak.  Soaking helps people to heal better and more quickly, often provides immediate relief of anal pain even when pain medications aren't helping, improves the blood supply to the area, and keeps it clean.
			&lt;li class=&quot;aci&quot;&gt;SOAK IN HOT WATER 6 TO 8 TIMES PER DAY!
			&lt;li class=&quot;aci&quot;&gt;Pain control is very important.  Be sure to discuss this with your health care provider and let them know what medications work best for you.  If you can take medications like ibuprofen or Advil or naprosyn or Aleve, these can be very helpful in decreasing the pain and inflammation and you should take them around the clock at times you are not taking your other pain medication.  They are also not constipating.
			&lt;li class=&quot;aci&quot;&gt;Usually we prescribe extra strength Vicodin or hydrocodone, also known as Lortab, but some people require Percocet or oxycodone.  It's important to realize that all of these pain medications contain acetaminophen or Tylenol and that patients should not take more than 4 grams per day, otherwise liver toxicity can occur.  This translates to no more than eight (8) 500 mg tablets in a day.  Patients with underlying liver disease such as chronic hepatitis should probably stay below this dose.  Do not take extra Tylenol with these pain medications, but you can take Advil or Aleve.
			&lt;li class=&quot;aci&quot;&gt;All pain medications containing narcotics are constipating, so if you find that you are requiring a lot of pain pills, then you may need to take more fiber or stool softeners.  Again the goal is to avoid constipation at all costs.  If you haven't had a bowel movement in 2 or 3 days, then consider taking a laxative such as milk of magnesia.
			&lt;li class=&quot;aci&quot;&gt;We also recommend that you apply topical numbing jelly to help ease the pain and decrease the need for narcotics, which can be done every 2 hours as needed.  The most potent is called 5% anorectal lidocaine cream and goes by the trade names of Ela&#45;Max&#45;5, now known as L.M.X.5, which can be purchased over the counter and does not require a prescription.  Unfortunately it is quite expensive at retail pharmacies such as Walgreens and similar stores selling for $80 to $100 for a 35 gram tube.  Lidosense 5 is a new product that has similar effectiveness and may be cheaper.  5% Lidocaine ointment is another option and retails for about $20 for a 35 gram tube and works reasonably well, although the LMX seems to be more potent and longer lasting.  It can be purchased online for about $50 or less at &lt;a href=&quot;www.texaselectrolysissupply.com&quot; target=&quot;_blank&quot;&gt;www.texaselectrolysissupply.com&lt;/a&gt;.  Insurance often does not cover the cost of the numbing jelly.
			&lt;li class=&quot;aci&quot;&gt;Unless patients have an allergy to sulfa drugs, they are sent home with a tube of Silvadene cream.  This can be applied after bathing and is used to help decrease symptoms, because it is used for burn patients. If you find you would rather put the numbing jelly on and are not getting any relief from the Silvadene, then it's OK not to use it.  Some people find as they begin to get farther away from the surgery and begin to heal but still have external wounds that are slow to heal, that applying Desitin, zinc oxide, or Dr. Smith's butt ointment (&lt;a href=&quot;www.doctorsmith.com&quot; target=&quot;_blank&quot;&gt;www.doctorsmith.com&lt;/a&gt;) can be helpful.
			&lt;li class=&quot;aci&quot;&gt;It is normal to have bleeding and oozing after surgery and often it occurs with bowel movements.  Do not be frightened about this and realize that a few drops of blood will turn the toilet bowel red.  If you are continuously passing blood clots or dripping large amounts of blood that doesn't stop with rest and simple pressure, call your physician.  Rarely after surgery patients will have bleeding that is significant enough to require a trip back to the operating room on an emergency basis, but this is very uncommon.
			&lt;li class=&quot;aci&quot;&gt;If you had a lot of external disease treated, then you are more likely to have oozing and bleeding.  Some people find that wearing feminine panty liners in their underwear can be helpful and cut down on the amount of laundry that needs to be done.
			&lt;li class=&quot;aci&quot;&gt;Infection is very uncommon, but if you develop a fever greater than 101.5 degrees Fahrenheit, then call you physician.  Occasionally in people who are prone to herpes outbreaks and are not receiving suppressive medication such as acyclovir or Valtrex, a herpes outbreak can be precipitated by the surgery.  If this happens, it often occurs 5 to 7 days following the surgery and is recognized by the fact that just when things started to feel better, they suddenly begin to feel worse.
			&lt;li class=&quot;aci&quot;&gt;Activity should be as tolerated, but we recommend that you take it easy for the first week or so depending on how you are feeling.  You need time to allow your body to heal.  You also need to be close to your bathtub to be able to soak.  It's probably a good idea to avoid putting yourself in situations where you will have to stand or walk or sit for extended periods of time.  As you begin to heal and the pain abates, you can begin to resume your normal activities.  Heavy exercise in which you increase your intra&#45;abdominal pressure such as heavy sit ups, squats and leg lifts should probably be avoided for several weeks because of the possibility of causing spontaneous bleeding by aggravating your hemorrhoids.
			&lt;li class=&quot;aci&quot;&gt;The good news is everyone gets better; it just takes time.  Sometime between 7 and 14 days, things begin to turn around and improve.  That's a good sign that you will continue to get better on a daily basis, but don't push it too hard or too fast.  Some people do amazingly well and have almost no pain and discomfort.  Some people take little to no pain medications.  Recovery is a very individual experience and seems to be somewhat different for everyone, but always happens.
			&lt;li class=&quot;aci&quot;&gt;We usually recommend that patients return to be examined 2 to 3 months following the surgery.  This is ample time to allow healing and allow people to be examined without causing significant pain or discomfort.  Continued follow&#45;up is very important and you should continue to be monitored on a regular basis, because the AIN can and frequently does recur.  Frequent monitoring may catch it at a time when it can be treated in the office avoiding another operation.
			&lt;li class=&quot;aci&quot;&gt;If you have anal sex, we also recommend that you wait 2 to 3 months before resuming receptive anal intercourse.  It is important to start slowly, because scar tissue does not stretch as well or as quickly as normal skin and is more prone to tear creating a fissure.
			&lt;/ol&gt;&lt;p&gt;&lt;br&gt;

			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
	<node>
		<Fname>
Therapies for Treatment of Warts, LGAIN, HGAIN ./id/x/treatment/therapies.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./id/x/treatment/therapies.html</Path>
		<FileBody>

			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;

			&lt;a name=&quot;office&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Office&#45;based Therapies&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Trichloracetic acid (TCA) 80&#45;90% Solution.&lt;/b&gt; This is an acid that works by destroying the wart on contact.  It is applied to the wart with a cotton tip applicator. Very small lesions can be treated using the wooden tip of the applicator. The surrounding skin should be covered with a barrier cream or gel to protect healthy skin from any spills or drips.  TCA will burn with the initial application but discomfort is usually short&#45;term. It will cause a burning sensation, and the wart will eventually fall off, sometimes leaving an ulceration. TCA can be used for internal or external warts.  It usually requires several treatments. External warts can be treated weekly but internally warts should be treated 2&#45;3 weeks apart in order to allow healing of the anal mucosa.  If a wart is not successfully treated by the fourth application, an alternative method should be found.  Thick, large lesions may be difficult to treat with TCA because the acid may not penetrate to treat the entire wart. A similar agent, bichloroacetic acid or BCA, is also used.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indication:&lt;/b&gt; Internal or external, warts, LSIL and HSIL, limited disease.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Cryotherapy.&lt;/b&gt; External warts can also be treated by freezing with liquid nitrogen, nitrous oxide, or carbon dioxide. Liquid nitrogen is applied by spraying or direct contact with a swab; nitrous oxide is connected to a closed cryo&#45;system and applied with a probe to produce an iceball. The freezing causes necrosis of the wart. This may also cause mild irritation, and may be uncomfortable during the process. Discomfort can be reduced by applying lidocaine spray or gel prior to freezing.  Cryotherapy causes the wart to fall off within a few days and may leave a shallow ulceration, which generally heals without scarring.  It may require several applications. These treatments can be 1&#45;2 weeks apart. Like TCA, the lesion must be completely treated.  If the warts have not been successfully treated by the fourth application, an alternative method should be sought.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indication:&lt;/b&gt; External warts, LGAIN or HGAIN. Limited disease. Safe during pregnancy.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			A combination of cryotherapy and TCA can sometimes produce more rapid clearance of the warts. However, the double application can cause more severe discomfort than either alone.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Podophyllin&lt;/b&gt; is an extract from the podophyllum plant. It can be prepared as a 10% &#45; 25% tincture.  It causes the warts to erode approximately 3&#45;5 days after treatment. It is applied to the external warts and must be washed off four hours later. There are several problems associated with podophyllin including low efficacy, potential for toxicity and it may be carcinogenic. It is therefore no longer recommended.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indication:&lt;/b&gt; External warts; should not exceed 3&#45;4 treatments. Should not be used in pregnancy.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Electrocautery.&lt;/b&gt; Lesions can be treated by application of an electric needle to cauterize or burn the warts. Local anesthesia should be used. Small lesions can be treated in a clinic setting, but larger and more extensive lesions usually require &lt;a href=&quot;/analcancerinfo/treatment/surgery.html&quot;&gt;treatment in an outpatient surgery setting&lt;/a&gt;. The cauterization destroys the warts or lesions. Bleeding and discomfort following the procedure is common and can last for several days or weeks depending on the extent of treatment. However, the warts and lesions are more completely treated in one application and generally do not require multiple treatments. Even so, warts may recur with electrocautery as with any treatment modality.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; Internal or external warts, LGAIN, HGAIN. Safe during pregnancy. Office procedure limited to the tolerance of the patient; treats more extensive disease than what can be treated by TCA, less extensive than disease requiring outpatient surgery.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Infrared Coagulation (IRC):&lt;/b&gt; IRC was developed for the treatment of external anal warts, hemorrhoids and tattoo removals. More recently it has been shown to be an effective treatment for internal anal HGAIN and warts. The treatment involves the application of a heat&#45;guided probe directly to the lesions. The heat is at a lower range compared to laser or electric cauterization. It does not burn the lesions but rather destroys the tissue, similar to a sunburn blister, which can than be removed. It can be done as an office therapy with minimal discomfort both during and after the procedure. Patients are anesthetized pre&#45;treatment with lidocaine gel followed by the injection of 1% lidocaine into the areas to be treated. The treatment can take up to an hour (or more if very extensive) but post&#45;treatment recovery is brief and there are none of the risks of surgical intervention. Following treatment there is frequently bleeding with bowel movements for up to 2&#45;3 weeks.  Post&#45;procedure pain may require medication for 1&#45;3 days but for most patients it is minimal although noticeable and most of the pain is associated with bowel movements. The pain can be minimized by frequent soaking in hot water, especially following bowel movements. Care should be taken to increase fluids at this time to avoid constipation.  Although the procedure takes longer than the application of TCA, the lesions are usually completely treated in one procedure. Extensive disease may require an additional treatment. We generally schedule a follow&#45;up exam three months following the procedure. If there is too much to treat in one session, we complete the treatment with an additional procedure two to three months later.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; Internal and external LGAIN and HGAIN; can effectively treat more extensive areas (50&#45;70% circumference of the anal canal or perianus) but may require 2 treatments if extensive.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Laser Therapy:&lt;/b&gt; Clinicians trained in laser therapy can apply this technique for perianal disease as well. There are also case reports of laser therapy for intra&#45;anal lesions and it has become a more common practice in some offices. It appeared to be effective in some studies,&lt;sup&gt;&lt;a href=&quot;references.html#4&quot;&gt;4&lt;/a&gt;,&lt;a href=&quot;references.html#12&quot;&gt;12&lt;/a&gt;,&lt;a href=&quot;references.html#13&quot;&gt;13&lt;/a&gt;&lt;/sup&gt; but there were significant recurrences of the group treated with laser in another study2. More extensive treatments, or those done in conjunction with ablation of cervical, vaginal or vulvar warts, are often done in an operating room. It is done in conjunction with the colposcope for guidance in finding the areas to treat. Laser treats the lesions by destroying them with the heat from the laser light. The laser controls the depth of treatment, which can help minimize scarring. Extensive treatments can be painful and can be managed with hydrocodone/acetaminophen.  The pain may be minimal for the first few days since the nerve endings may be burnt initially, but can last for 2&#45;3 weeks.  Soaking in warm water especially following bowel movements will be soothing and can facilitate healing. It can take up to two months for the area to heal completely.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; Warts, LGAIN or HGAIN, more commonly used for external disease but internal disease can be treated as well.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;/ol&gt;

			&lt;a name=&quot;patient&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Patient&#45;applied Therapies&lt;/b&gt;&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Aldara&amp;trade;&lt;/b&gt; (5% imiquimod cream). This is an immune response modulating treatment, which acts to produce a local interferon response. This stimulates the immune system to recruit immune cells to the area and causes the warts to regress.  It is applied to the warts and rubbed in 3x/weekly at bedtime and rinsed off in the morning. The treatment continues for 12&#45;16 weeks. Local irritation is expected and is a sign that the treatment is working. It can take 3&#45;4 weeks for the treatment to start working. Occasionally the reaction is severe and the cream should be stopped until the inflammation goes away, or reduced to twice weekly. It is sometimes used post&#45;operatively to prevent recurrence of warts. Once the warts are clear, it may be used continuously 2x/week to prevent recurrences.  It has been used experimentally intra&#45;anally&lt;sup&gt;&lt;a href=&quot;references.html#14&quot;&gt;14&lt;/a&gt;&lt;/sup&gt;. One study showed it reduced recurrences of anal warts following surgery&lt;sup&gt;&lt;a href=&quot;references.html#15&quot;&gt;15&lt;/a&gt;&lt;/sup&gt; and was also effective as a primary treatment for anal HGAIN&lt;sup&gt;&lt;a href=&quot;references.html#16&quot;&gt;16&lt;/a&gt;&lt;/sup&gt;.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; External anal warts, especially primary outbreaks. The patient must be able to adequately reach the affected areas. Patients should be shown how to apply the cream correctly in the office. Safety in pregnancy is not established. Safety for internal disease is not established.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Condylox&amp;trade;&lt;/b&gt; (.15% podophyllotoxin cream) or &lt;b&gt;Podofilox&amp;trade;&lt;/b&gt; (.5% podophyllotoxin gel, solution, or cream). These are purified extracts of the podophyllum plant. They are applied twice daily for three consecutive days, followed by 4&#45;7 days without treatment.  The treatment can be repeated for 4 to 8  cycles. Warts that have not responded after 4 treatments should be treated with an alternative treatment. The treatment can cause burning, tenderness, and swelling and the warts will erode after a few days. If the discomfort is severe the treatment should be stopped.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; External anal warts. The patient must be able to adequately reach the affected areas. Patients should be shown how to apply the gel correctly in the office. Safety in pregnancy is not established. Safety for internal disease is not established.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Veregen 15% ointment.&lt;/b&gt; Approved by the FDA for treatment of external genital warts in 2006. It is a purified green tea extract mixed in an inert ointment. It is applied three times daily (does not need to be 8 hours apart) to affected areas for up to 16 weeks. A different treatment should be used if the warts have had no response within 4 weeks. The ointment may first cause the warts to increase in size, they will then ulcerate and disappear. Most people report some discomfort, it should be tolerable and if not a different therapy should be used. Soaking in warm water or applying lidocaine gel can help with the discomfort.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; External anal warts. Should not be used in pregnancy. Safety for immune&#45;compromised individuals has not been established.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Efudex&amp;trade; 5% cream&lt;/b&gt; has been suggested for treatment of anal warts but has not been studied. It is occasionally used for treatment of anal warts that are confluent with vulvar warts, and when all other therapies have failed. For a therapy that has been available for several decades it is surprising how little research has been published regarding its efficacy. Several studies reported its use alone or adjunctively in the treatment of intra&#45;urethral, penile, and vulvar warts&lt;sup&gt;&lt;a href=&quot;references.html#17&quot;&gt;17&lt;/a&gt;,&lt;a href=&quot;references.html#18&quot;&gt;18&lt;/a&gt;&lt;/sup&gt; . It was effective in treatment of women with extensive vulvar condyloma in two studies evaluating different treatment regimens&lt;sup&gt;&lt;a href=&quot;references.html#10&quot;&gt;10&lt;/a&gt;,&lt;a href=&quot;references.html#19&quot;&gt;19&lt;/a&gt;&lt;/sup&gt; . Several small studies of women with vaginal or vulvar intraepithelial neoplasia showed efficacy rates of 41% to 91%&lt;sup&gt;&lt;a href=&quot;references.html#10&quot;&gt;10&lt;/a&gt;,&lt;a href=&quot;references.html#20&quot;&gt;20&lt;/a&gt;,&lt;a href=&quot;references.html#21&quot;&gt;21&lt;/a&gt;,&lt;a href=&quot;references.html#22&quot;&gt;22&lt;/a&gt;&lt;/sup&gt; . It was also shown to prevent recurrence of cervical SIL in HIV&#45;seropositive woman following laser treatment&lt;sup&gt;&lt;a href=&quot;references.html#11&quot;&gt;11&lt;/a&gt;&lt;/sup&gt;.  A small non&#45;randomized trial showed improvement in 10 of 11 patients using the cream BID for perianal HGAIN&lt;sup&gt;&lt;a href=&quot;references.html#8&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;. When used intravaginally patients are taught to carefully protect the normal vulvar mucosa from burns with Efudex&amp;trade; as it can cause ulcerations of normal skin, and careful follow&#45;up is recommended. When used externally, a thin layer is put on the areas of treatment with generally little adverse effects seen.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;b&gt;Indications:&lt;/b&gt; Unknown efficacy. Possibly for external anal warts, LGAIN or HGAIN. Unknown effects for internal disease. Used for treatment of extensive vaginal warts and vulvar warts, but no longer recommended by the CDC.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;/ol&gt;

			&lt;a name=&quot;surgery&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Out&#45;Patient Surgery&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;Patients are referred for outpatient surgery when the warts or lesions are not responsive to other treatments, for very large volume of disease, or if there is any suspicion for cancer or HGAIN that cannot be found due to the presence of large amounts of warts. Although the procedures are technically simple, the usual risks for surgery must be considered.  It also has significant post&#45;operative recuperation requiring up to two weeks of generally severe discomfort.  It also may be the best option for people who prefer to have it “over and done with” in one treatment, as well as for those who cannot tolerate a long procedure in the clinic room. There are people for whom sedation is necessary and an office procedure would not be easily tolerated. There are several techniques used in surgery, but like the clinic procedures all have the same goal – eradication of the lesions.
			Surgical fulguration involves treating the lesions with an electric needle and is the most commonly used surgical intervention.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;See the &lt;a href=&quot;surgery.html&quot;&gt;Surgery&lt;/a&gt; section for more details.&lt;/p&gt;

			&lt;a name=&quot;novel&quot;&gt;&lt;/a&gt;&lt;p class=&quot;aci&quot;&gt;&lt;b&gt;Novel Treatments&lt;/b&gt;&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;margin&#45;left:12px;&quot;&gt;There is surprisingly little that is new for treatment of anal warts and LGAIN or HGAIN. A web search reveals only a few alternative therapies.  There are homeopathic remedies, Traditional Chinese Medicine, and other alternative&#45;based therapies.  Even duct tape has been claimed to effectively treat warts. None of these have been studied in scientific controlled studies. It is also important to remember that treatment of anal warts is different than treatment of skin warts. The anus and surrounding perianal area are mucous membranes. This type of tissue is sensitive and easily absorbs chemicals. Care should be taken in using products that have not been tested for treatment of mucous membranes.&lt;/p&gt;

			&lt;p class=&quot;aci&quot; style=&quot;Margin&#45;left:12px;&quot;&gt;A few therapies which may be prove to be valuable in the future are the following:&lt;/p&gt;

			&lt;ol&gt;
			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Indole 3 carbinol (I3C)&lt;/b&gt; is found in cruciferous vegetables. It has been shown to have antiestrogen effects and to be effective in treating cancers in studies with mice. There have been only initial trials of I3C in treatment of CIN (cervical dysplasia), and the results were modestly encouraging&lt;sup&gt;&lt;a href=&quot;references.html#23&quot;&gt;23&lt;/a&gt;&lt;/sup&gt;. It has not been studied in relation to anal disease. However, it is occasionally recommended in doses of 200mg BID if tolerated, adjunctively for treating warts or HSIL when other therapies are not working or feasible.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Cidofovir&lt;/b&gt; is a cytidine nucleotide analogue that has been found to have some antiviral activity. It has been used intravenously, interlesionally, and topically on external genital warts. Topical application of a 1% gel or cream has been used in a treatment cycle of five days sequentially, repeated in two&#45;week cycles. Several small studies reported response rates between 32% &#45;76%&lt;sup&gt;&lt;a href=&quot;references.html#24&quot;&gt;24&lt;/a&gt;,&lt;a href=&quot;references.html#25&quot;&gt;25&lt;/a&gt;,&lt;a href=&quot;references.html#26&quot;&gt;26&lt;/a&gt;,&lt;a href=&quot;references.html#27&quot;&gt;27&lt;/a&gt;&lt;/sup&gt;. It has also been used in combination with surgical removal of warts&lt;sup&gt;&lt;a href=&quot;references.html#28&quot;&gt;28&lt;/a&gt;&lt;/sup&gt;. Although it was tolerated with few problems in most patients, reversible renal failure was reported in one patient with prior renal insufficiency&lt;sup&gt;&lt;a href=&quot;references.html#29&quot;&gt;29&lt;/a&gt;&lt;/sup&gt;. There are no published studies using Cidofovir for treatment of HGAIN although it has been used for treatment of vulvar intraepithelial neoplasia&lt;sup&gt;&lt;a href=&quot;references.html#30&quot;&gt;30&lt;/a&gt;&lt;/sup&gt;.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Interferon alpha 2a and 2b&lt;/b&gt; has been administered by injection into the lesions as a primary treatment or used following surgery to prevent recurrence. There was reduced recurrence compared to placebo in one study in combination with surgery&lt;sup&gt;&lt;a href=&quot;references.html#31&quot;&gt;31&lt;/a&gt;&lt;/sup&gt; but no improvement in another&lt;sup&gt;&lt;a href=&quot;references.html#32&quot;&gt;32&lt;/a&gt;&lt;/sup&gt;.  In another study there was only 6.1% recurrence in patients treated for genital warts with adjunctive interferon compared to 20.7% recurrence without interferon following either Efudex&amp;trade; or laser&lt;sup&gt;&lt;a href=&quot;references.html#33&quot;&gt;33&lt;/a&gt;&lt;/sup&gt;.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Photodynamic Therapy&lt;/b&gt; uses a photosensitizing drug such as aminolevulinic acid, which is applied systemically or topically. When light is applied to the lesion, destruction of the tissue occurs which activates immune defenses. Case reports or several small studies reported complete or partial response in patients treated for external anal LGAIN or HGAIN &lt;sup&gt;&lt;a href=&quot;references.html#34&quot;&gt;34&lt;/a&gt;,&lt;a href=&quot;references.html#35&quot;&gt;35&lt;/a&gt;,&lt;a href=&quot;references.html#36&quot;&gt;36&lt;/a&gt;&lt;/sup&gt;. Similar results were reported for treatment of vulvar disease&lt;sup&gt;&lt;a href=&quot;references.html#37&quot;&gt;37&lt;/a&gt;,&lt;a href=&quot;references.html#38&quot;&gt;38&lt;/a&gt;&lt;/sup&gt;  and it has been used for cervical disease as well&lt;sup&gt;&lt;a href=&quot;references.html#39&quot;&gt;39&lt;/a&gt;&lt;/sup&gt;.&lt;br&gt;&amp;nbsp;&lt;br&gt;

			&lt;li class=&quot;aci&quot;&gt;&lt;b&gt;Treatment Vaccines.&lt;/b&gt; There has been a lot of exciting new research into the use of vaccines either to prevent or treat HPV&#45;associated diseases including anal disease.  Prophylactic vaccines are aimed at preventing LSIL or HSIL by inducing antigens to HPV and have been developed using L1 virus&#45;like proteins (VLP).  Prophylactic vaccines are targeted at populations before exposure to the virus, similar to hepatitis vaccination. The vaccine induces virus&#45;neutralizing antibodies, which protect the host when subsequently exposed to the particular HPV strain. Therapeutic vaccines target existent HSIL or SCC for treatment usually through targeting specific proteins (E6 or E7) which have been shown to be expressed in HSIL or cancers. They intend to induce the cellular immune system to recognize and attack cells infected with HPV.  In each case the vaccine is directed against a particular viral type such as HPV 16. An ideal vaccine will be multivalent (directed against multiple HPV types) and immunize against a range of common HPV types and these are in development.  Most research has focused primarily on prevention or treatment of cervical disease with scant data regarding anal disease. Two trials of therapeutic vaccines for anal HSIL have been completed&lt;sup&gt;&lt;a href=&quot;references.html#40&quot;&gt;40&lt;/a&gt;,&lt;a href=&quot;references.html#41&quot;&gt;41&lt;/a&gt;&lt;/sup&gt;. The vaccines were tolerated without significant adverse events, but there was incomplete response and further testing is warranted. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;/ol&gt;&lt;p&gt;


			&lt;!&#45;&#45; #EndEditable &quot;Content&quot; &#45;&#45;&gt;


					</FileBody>
	</node>
</nodes>
